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  SUMMARY 
Cyclic dipeptides have been well characterized for their multitude of biological 
activities, including antimicrobial and anticancer activities. Cyclo(His-Gly) and 
cyclo(His-Ala) have also recently been shown to possess significant anticancer activity 
against a range of cell lines, despite the limitations of these two molecules with 
respect to their physicochemical properties. Low Log P results in poor cell 
permeability which can often be problematic for drugs with intracellular mechanisms 
of action. It can also results in poor biodistribution, and theoretical Log P values for 
cyclo(His-Gly) and cyclo(His-Ala) were extremely low making them ideal candidates 
for inclusion into a nanoparticulate drug delivery system. The aim of this study was 
therefore to formulate and evaluate liposome-encapsulated cyclic dipeptides that 
increase the tumour-suppressive actions of the cyclic dipeptides, while showing a 
high degree of specificity for tumour cells.  
 
While liposomes are relatively simple to prepare, inter batch variation, low 
encapsulation and poor stability are often problematic in their production and this 
has lead to very few liposomal products on the market. This study aimed at using a 
comprehensive statistical methodology in optimizing liposome formulations 
encapsulating cyclo(His-Gly) and cyclo(His-Ala). Initial screening of potential factors 
was conducted using a 25-1 fractional factorial design. This design made use of two 
levels for each of the five factors and abbreviated the design to minimize runs. 
Although not much information is provided by these types of designs, the design was 
sufficient in identifying two critical factors that would be studies further in a more 
robust design. 
 
The two factors selected, based on the screening study, were cholesterol and 
stearylamine content. These two factors were then used in designing a response 
surface methodology (RSM) design making use of a central composite rotatable 
vii 
 
design (CCRD) at five levels (-1.5, -1, 0, 1, 1.5) for each factor in order to better 
understand the design space.  
 
Various factors influenced the measured responses of encapsulation efficiency, zeta 
potential, polydispersity index, cellular uptake and leakage, but most notable were 
the adverse effects of increasing stearylamine levels on encapsulations efficiency and 
cholesterol levels on leakage for both cyclo(His-Gly) and cyclo(His-Ala) liposomes. 
Optimized formulations were derived from the data and prepared. Fair correlation 
between the predicted and measured responses was obtained.  
 
The cytotoxic activity of the encapsulated cyclic dipeptides were assessed against 
HeLa and MCF-7 cells and found to have limited improvement in activity. However, 
modification of the polyethylene glycol (PEG) grafted to the liposome surface in 
order to target folate receptors showed good benefit in significantly decreasing the 
IC50 values recorded in all cells lines tested, particularly low folate HeLa cells with the 
lowest IC50 being recorded as 0.0962 mM for folate targeted cyclo(His-Ala). 
 
The results therefore indicate that hydrophilic cyclic dipeptides are ideal candidates 
for inclusion into targeted drug delivery systems such as liposomes. 
 
Key words: Liposomes, cyclo(His-Gly), cyclo(His-Ala), cyclic dipeptides, HeLa, MCF-7, 
folate receptors, factorial design, response surface methodology (RSM), central 
composite rotatable design (CCRD). 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 BACKGROUND AND PROBLEM DEFINITION 
Of late, much interest has been placed on the biological activity of selective cyclic 
dipeptides (CDPs). In a study by Milne and colleagues (1998), it was noted that some 
of these compounds containing a tryptophan moiety showed significant tumour 
inhibition. Subsequent studies (Lucietto et al., 2006; Van der Merwe et al., 2008) 
have confirmed these results, identifying cyclic dipeptides as potential 
chemotherapeutic agents. Other studies (Graz et al., 1999; Rhee, 2004) have also 
outlined the potential therapeutic usefulness of these compounds, exhibiting effects 
such as ion channel modulation, antibacterial and even antifungal properties. In a 
recent study (Brauns et al., 2004), selected cyclic dipeptides were evaluated against a 
number of cell lines, namely MCF-7 (breast carcinoma), HeLa (cervical carcinoma) 
and HT-29 (colon carcinoma), indicating that one of the compounds tested, 
cyclo(Phe-Pro), showed inhibition of more than 50% in some cell lines, and in 
addition induced apoptosis in the HT-29 cell line. More recently, significant inhibition 
of the same cell lines was demonstrated with the histidine-containing cyclic 
dipeptides, cyclo(His-Gly) and cyclo(His-Ala) (Lucietto et al., 2006). 
 
A parameter routinely used to assess the ability of drug molecules to be absorbed 
and permeate through biological membranes to their site of action is the 
octanol/water partition coefficient or Log P. An ideal Log P for a drug molecule would 
be approximately 2, indicating that it has a slightly lipophilic character, enabling it to 
pass through lipid membranes. Drug molecules are able to pass through membranes 
through several mechanisms, but three of the primary mechanisms include passive 
diffusion (transcellular), passage through pores and junctions (paracellular) and 
transporter-mediated (active transport) as shown in Figure 1.1. Lack of active 
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transporters and large molecular weight requires that drugs are able to passively 
diffuse through cells as their primary means of absorption (Smith et al., 2006).  
 
Figure 1.1:  Routes of transport of drugs across membranes (adapted from Smith et al. 
(2006)). 
 
The line between good permeability and poor solubility is a fine one and a balance 
between the hydrophilic and lipophilic nature of drug is important as shown in Figure 
1.2 (Kerns and Di, 2008). 
 
 
Figure 1.2:  Hypothetical influence of Log P on oral bioavailability of a drug (Kerns and Di, 
2008). 
 
TRANSCELLULAR
(Passive diffusion)
PARACELLULAR
(via pores)
ACTIVE 
TRANSPORTERS
3 
 
The theoretical Log P for cyclo(His-Gly) and cyclo(His-Ala) (Section 3.1.1) were 
calculated to be  -1.093 and -1.264 respectively, which, according to Figure 1.2, 
would classify them as having poor membrane permeability. Despite this, Lucietto 
and colleagues (2006) found these compounds to possess significant antineoplastic 
activity. 
 
Log D, similar to Log P but taking pH into consideration, can evaluate the 
permeability of a substance at a physiological pH of 7.4. Table 1.1 illustrates the 
impact the Log D parameter could have on drug-like properties of a substance (Kerns 
and Di, 2008). 
 
Table 1.1:  Influence of Log D of drugs on drug-like properties such as solubility, 
permeability and metabolism (Adapted from Kerns and Di, 2008). 
Log D Impact on Drug-like Properties 
<1 
Solubility high 
Permeability low by passive transcellular diffusion 
Permeability possible via paracellular diffusion if 
MW < 200 
1 – 3  
Solubility moderate 
Permeability moderate 
Metabolism low 
3 – 5  
Solubility moderate 
Permeability high 
Metabolism moderate to high 
>5 
Solubility low 
Permeability high 
Metabolism high 
 
 
Physicochemical properties of these molecules indicate limitations with respect to 
their solubility in biological solutions as well as limited cell permeation (Prasad, 
1995). The potential tumour suppressive properties as well as the physicochemical 
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limitations of this group of molecules make them ideal test candidates in the 
development of a targeted liposomal drug delivery system. 
 
Liposomes can be characterized as colloidal particles comprising mainly of 
phospholipids and cholesterol. They form spherical vesicles consisting of a 
phospholipid bilayer, much like that of normal cell membranes (Malam et al., 2009). 
These particles have a myriad of possibilities with respect to pharmaceutical 
applications due to their variation in composition, size and structure (Endruschat and 
Henschke, 2000). Incorporation of many different types of therapeutic molecules 
such as simple organic drug compounds as well as protein-based and gene 
therapeutics aim to enhance their actions through the attainment of a number of 
goals, including the enhancement of their pharmacokinetics, decreased metabolic 
degradation and improved targeting, thereby enhancing their efficacy and decreasing 
potential side effects (Vemuri and Rhodes, 1995). 
 
The properties of the liposomes can be vastly altered by changing the composition of 
the phospholipids, improving their pharmacokinetics. For instance, the incorporation 
of polyethylene glycol (PEG) modified lipids in the synthesis of liposomes has been 
shown to decrease antibody-mediated elimination of these particles, hence 
increasing circulation time of the liposomes (Li et al., 2002). The production of 
liposomes can take many routes, resulting in a final product that shows significantly 
different characteristics with respect to vesicle size, number of bilayers and their 
morphology, bilayer characteristics and surface charge characteristics. A few basic 
methodologies for liposome production include thin-film hydration of a lipid layer to 
form multilamellar vesicles, extrusion techniques to form large unilamellar vesicles, 
preparation by sonication to form small unilamellar vesicles as well as the formation 
of giant unilamellar vesicles through reverse-phase evaporation. Most of these 
methods are described as being laboratory bench scale production methods, 
however, scale-up to production scale is possible for most methodologies 
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(Drummond et al., 1999; Endruschat and Henschke, 2000; Agarwal et al., 2001; 
Malam et al., 2009). These liposomal particles may vary considerably with respect to 
the degree of drug encapsulation, stability, drug release, interaction with target sites 
and circulation time (Vemuri and Rhodes, 1995). These variations in properties are 
cause for concern in the pharmaceutical industry where standardization is essential. 
It would therefore seem logical to apply some sort of statistical methodology, such as 
experimental design in order to better optimize formulations while gaining a deeper 
understanding of the parameters that may affect their properties. 
 
Another major advancement in liposome technology has been the development of 
immunoliposomes that contain surface monoclonal antibodies (mAb) specific to 
proteins over expressed in the target cell. Examples of such proteins include HER2, 
an oncogene that is found to be over expressed in tumour cells. Efforts have shown 
that the incorporation of anti-HER2 mAb fragments into the lipid bilayer of sterically 
stabilized liposomes (forming immunoliposomes) has shown selective uptake by 
tumour cells (Park et al., 2001). This concept of sterically stabilized, long circulating 
immunoliposomes that are specific to their site of action may prove extremely 
beneficial in the treatment of malignancies, where current therapeutic options result 
in severe debilitating side effects. Besides tethering antibodies to liposomes, any 
molecule that can target proteins that are over expressed in tumour cells could prove 
beneficial. One such molecule is folic acid, as folate receptors are often found to be 
over expressed in tumours and this approach has been used in assisting with the 
targeting of liposomes (Lee and Low, 1995; Gabizon et al., 1999; Lu and Low, 2003). 
 
1.1 AIMS AND OBJECTIVES 
1.1.1 Aim of the study 
The aim of this study was therefore to formulate and evaluate liposome-
encapsulated cyclic dipeptides that increase the tumour-suppressive actions of the 
cyclic dipeptides, while showing a high degree of specificity for tumour cells. 
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1.1.2 Objectives 
With the aim in mind the following objectives were identified: 
- To identify CDPs with significant antineoplastic potential for inclusion in the 
study. 
- To characterize these CDPs with respect to their physicochemical properties, 
in particular, those that may influence permeability or stability.  
- To develop a stable liposomal formulation by determining critical formulation 
parameters and using these parameters in an experimental design in order to 
optimize the formulation 
- To develop an appropriate method for quantifying the degree of CDP 
encapsulation. 
- To establish the degree by which the prepared liposomes are taken up into 
cultured tumour cells. 
- To determine, in vitro, the variation in biological response, if any, that occurs 
between free and  encapsulated CDPs with respect to antineoplastic activity. 
- To develop a targeting strategy for the liposomal CDPs specific for tumour 
cells.  
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CHAPTER 2: LITERATURE REVIEW 
 
 
2.1 CYCLIC DIPEPTIDES 
2.1.1 Introduction 
Cyclic dipeptides that are cyclisized head-to-tail are also known as 2,5-
diketopiperazines (DKPs) and are one of the most abundant peptide derivatives 
found in nature. From the time the first cyclic dipeptide was synthesized in 1888 until 
the mid-1900’s, most interest was focused on their physicochemical properties 
instead of their potential biological activity (Prasad, 1995). The reason for this initial 
focus on physicochemical properties varies, but includes, amongst others, their 
conformational rigidity as well as their resistance to proteolysis (Martins and 
Carvalho, 2007).  
 
Recently, however, more research is emerging on the biological potential of these 
compounds, which ranges from antifungal and antibacterial activity to anticoagulant 
activity (Prasad, 1995; Lucietto et al., 2006; Martins and Carvalho, 2007; Van der 
Merwe et al., 2008). Apart from this, a number of endogenous 2,5-diketopiperazines 
have been isolated from bacteria, plants and fungi as well as mammalian cells 
(Prasad, 1995; Daniels et al., 2004; Guimarães et al., 2010). What is of even further 
interest is the ability of some of these endogenous cyclic dipeptides to inhibit or 
potentiate quorum sensing, bacteria’s ability to communicate with each other, which 
may ultimately affect bacterial virulence (Holden et al., 1999; Pesci, 2000). 
 
As cyclic dipeptides comprise both L- and D-isomers of amino acids, the numbers of 
possibilities, although mathematically finite, are practically limitless. Apart from the 
conventional cyclic dipeptides consisting of two amino acids (L or D), substitution of 
the amino acid side chains with a variety of molecules such as halogens, further 
expands the possibilities of this group of compounds. 
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2.1.2 Sources, synthesis and physicochemical properties of cyclic dipeptides 
Several natural sources of cyclic dipeptides have been identified, with plants, 
bacteria, fungi and animal tissues all being sources for these compounds (Prasad, 
1995). Several examples of DKPs have been isolated from bacteria (Prasad, 1995), 
with some even being shown to be involved with quorum sensing (Pesci, 2000).  
 
DKPs have been isolated from bacteria in sea sponges such as Bacillus and 
Staphylococcus spp, with examples including cyclo(Gly-Leu), cyclo(Pro-Tyr) and 
cyclo(D-Pro-Tyr) as well as hydroxylated derivatives of cyclo(Pro-Leu) and cyclo(Pro-
Phe) (De Rosa et al., 2003). The function of the DKPs in bacteria has been postulated 
to be as quorum sensing signals that either promote or inhibit bacterial 
communication (Holden et al., 1999). Apart from quorum sensing, there have also 
been many other micororganisms that have been shown to produce cyclic dipeptides 
with antimicrobial and antifungal activity. Some of these include Lactobacillus 
plantarum that have been shown to produce cyclo(Phe-Pro) and cyclo(Phe-OH-Pro) 
(Ström et al., 2002), which have also been found to be produced by other bacteria 
such as Pediococcus pentosaceus, Lactobacillus sakei and Lactobacillus coryniformis 
(Magnusson et al., 2003). There is a myriad of research that suggests bacterial 
sources of DKPs, some of which are listed in Table 2.1 below. 
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Table 2.1:  Natural sources of DKPs (Updated from Prasad, 1995) 
Source Common Name DKPs isolated Reference 
Ircinia variabilis Bacterium 
cyclo(cis-4-OH-D-Pro-Leu) 
cyclo(trans-4-OH-Pro-Leu) 
cyclo(trans-4-OH-Pro-Phe) 
cyclo(Gly-Leu) 
cyclo(Pro-Tyr) 
cyclo(D-Pro-Tyr) 
cyclo(cis-4-OH-D-Pro-Phe) 
1 
Lactobacillus 
plantarum 
Bacterium 
cyclo(Phe-Pro) 
cyclo(Phe-trans-4-OH-Pro) 
2 
Rosellinia necatrix Fungus 
Cyclo(Pro-Leu) 
Cyclo(Pro-Val) 
Cyclo(Pro-Phe) 
3 
Aspergillus fumigatus Fungus Cyclo(Pro-Leu) 3 
Aspergillus ochraceus Fungus Cyclo(Pro-Val) 3 
Aspergillus niger Black mould Cyclo(Ala-Leu) 3 
Penicillium 
brevicompactum 
Mould Cyclo(Trp-Pro) 3 
Sponge-associated 
Pseudomonas 
aeruginosa 
Bacterium 
Cyclo(Pro-Val) 
Cyclo(Pro-Leu) 
Cyclo(Pro-Ile) 
Cyclo(Pro-Met) 
Cyclo(Pro-Phe) 
Cyclo(Pro-Tyr) 
4 
1
(De Rosa et al., 2003), 
2
(Ström et al., 2002), 
3
(Prasad, 1995), 
4
(Jayatilake et al., 1996). 
 
 
In terms of synthesis, there have been many methods proposed for synthetic 
pathways including both solid- and liquid-phase synthesis (Martins and Carvalho, 
2007). Several groups have reported on the successful solid-phase synthesis of DKPs 
using a variety of polystyrene resins (Szardenings et al., 1997; Wang et al., 2002; Guo 
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et al., 2004) with yields ranging from 8% to as high as 85%. Figure 2.1 illustrates the 
general procedure for solid-phase synthesis of diketopiperazines. The first step is 
creating a reactive group on the resin that will bond the unprotected carboxyl group 
of the primary amino acid (AA’), which is generally achieved through the bonding of a 
reactive phenacyl ester (Pac-O). Following de-protection of the AA’ amine group, 
addition of the secondary amino acid (AA”) facilitates formation of a peptide bond 
between the two amino acids. De-protection of the AA” amine group and uncoupling 
from the Pac-O results in formation of the DKP product (Martins and Carvalho, 2007). 
 
 
Figure 2.1:  General procedure for solid phase synthesis of DKPs. (i) BrCH2COBr, AlCl3, 
nitrobenzene/DCM (1:1); (ii) Boc-AA’OH, Et3N, DMF; (iii) 3.5 N HCl/HOAc; (iv) 
Boc-AA”–OH, HOBt, DCC, NMM, DMF; (v) 10% DIEA/EtOAc; (vi) 5% Et3N/THF–
H2O (8:1) (Martins and Carvalho, 2007). 
 
Several authors have criticized the use of solid-phase synthesis for the formation of 
2,5-diketopiperazines, in part, due to the fact that this synthetic procedure has what 
some call many ‘worthless’ steps involving cleavage reactions from the solid-phase 
resins, which some feel are only justified when producing more than one or two 
peptide bonds (Campo et al., 2009) as is the case with more complex peptides. Other 
shortcomings include problems experienced with scale-up of these reactions, which 
are generally not done due to cost implications (Tullberg et al., 2006).  
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In contrast to solid-phase synthesis, solution-phase synthesis is relatively less 
expensive, but produces yields that are not independent of the amino acids used to 
form the DKP (Tullberg et al., 2006). Several strategies exist for the formation of 
DKPs in solution in terms of the synthetic starting points and are outlined in Figure 
2.2 and discussed in more detail below. Apart from the starting materials, several 
other strategies exist in improving synthetic procedures in order to decrease cost, 
improve yields or simply avoid environmental harm, through the use of microwave 
assisted synthesis (Campo et al., 2009), phase-transfer synthesis (O'Reilly et al., 
2009) and using a more environmentally friendly, ‘green’ approach, by avoiding the 
use of solvents or catalysts (Thajudeen et al., 2010).  
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Figure 2.2:  Different synthetic strategies for the formation of 2,5-diketopiperazines. (a) 
Intramolecular cyclization of the N1-C2 bond from the linear dipeptide, (b) 
Intramolecular cyclization of the N1-C6 bond, (c) Tandem formation of the N1–
C2 and C3–N4 bonds, (d) Tandem formation of the N1–C2 and N4–C5 from two α-
amino esters, (e) Tandem formation of the N1–C2 and N1–C6 bonds allowing the 
introduction of N1 substituents from primary amine reactants (Dinsmore and 
Beshore, 2002). 
 
 
Many studies have reported on the intramolecular cyclization of linear dipeptides 
through deprotection of the terminal amine and carboxyl groups and formation of 
the N1-C2 bond through a condensation reaction (Milne et al., 1998; Kanoh et al., 
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1999; Martins and Carvalho, 2007; Thajudeen et al., 2010). While some researchers 
(Kanoh et al., 1999) rely on the cyclization of already-formed linear dipeptides, 
others (Milne et al., 1998; Thajudeen et al., 2010) synthesized the linear dipeptide 
from Boc-protected amino acids and amino acid esters. This is not to be confused 
with the reaction shown in Figure 2.2 (d) above as the formation of the DKP ring 
structure in this example is by a single step, tandem formation of the N1-C6 and N4-C5 
bonds in a ‘one pot’ reaction (Dinsmore and Beshore, 2002). Another option for 
intramolecular N1-C2 bond formation is using the Ugi reaction which consists of a 
four-component reaction where a Boc-protected amino acid is reacted with a 
primary amine, a carboxylic acid and an isocyanide to form an intermediary amine 
product, which is cyclisized after Boc-deprotection (Hulme et al., 1998). 
 
Another approach to synthesis of substituted DKPs from their unsubstituted 
derivatives by either starting with piperazine-2,5-dione and di-substituting the α-
carbons through acetylation reactions to form a bis-arylidenediketopiperazine 
(Folkes et al., 2001) or by starting with iso-propyl derivatives of piperazine-2,5-dione 
and forming aromatic DKPs through benzylation reactions (Wong et al., 2008). 
 
With many reports of poor yields or complex multistep reactions , synthetic routes 
requiring fewer steps are required. In a recent study (O'Reilly et al., 2009) the 
authors presented a simple, one-step synthetic pathway using the phase transfer 
catalyst triethylbenzylammonium chloride (TEBA) to convert a chloracetamide to a 
DKP. This was facilitated by slow addition of the catalyst over 48 hours in two phases, 
an aqueous phase consisting of 50% NaOH and TEBA and an organic phase consisting 
of the reactant in dichloromethane. Good yields of between 70 and 90% were 
reported in this simple one step reaction and it was concluded by the authors that 
the low concentrations of the catalyst supplied over the phase boundary favoured 
the cyclization reaction as opposed to the polymerization reaction, which is generally 
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preferred at higher catalyst concentrations and often necessitates the need for 
protection and de-protection steps. 
 
Despite the report above showing promising results with good yields, recent years 
have seen an increase in stringency of environmental laws governing the safe use 
and disposal of catalysts and organic solvents such as dichloromethane, chloroform 
and ether used in the synthesis of DKPs. For this reason, scale-up often becomes 
problematic. In a recent study by Thajudeen and colleagues (2010), an efficient 
synthetic procedure under aqueous conditions is described that relies on autoclaving 
of the reactants at 130 C for the synthesis of a range of proline-containing cyclic 
dipeptides from their linear dipeptide counterparts. Yields presented ranged from 
70% in the case of cyclo(Ile-Pro) to as high as 92% for cyclo(Pro-Pro) in a ‘one pot’ 
reaction taking only 4 hours.  
 
While the use of organic solvents is of concern, synthetic chemists also strive 
towards reducing reaction time, while promoting yield. One method used to achieve 
this is microwave assisted synthesis, where synthetic chemists are able to reduce 
reaction time from as long as hours or days to mere minutes or even seconds while 
still ensuring high yields in a reproducible manner. Several groups have reported the 
successful synthesis of DKPs using microwave irradiation (Santagada et al., 2003; 
Tullberg et al., 2006; Campo et al., 2009; Bertamino et al., 2010). 
 
2.1.3 Structural and conformational characteristics of diketopiperazines 
The general structure of a diketopiperazine is shown in Figure 2.3 below and is 
composed of two cis peptide bonds that exhibit a large degree of conformational 
restriction (Cotrait et al., 1976).  
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Figure 2.3:  General structure of 2,5-diketopiperazines. R1 and R2 indicate substitution of 
the α-carbon. 
 
The ring structure can either be planar (particularly for unsubstituted 2,5-
piperazinedione) or in a twist-boat, boat or bowsprit-boat configuration as shown in 
Figure 2.4 (Cotrait et al., 1976). The planar conformation is most frequent, however, 
N-substitution, as is the case with proline-containing diketopiperazines, has been 
found to be present in a chair configuration as well  (Anteunis, 1978).  
 
The conformation in which the diketopiperazine ring is found, is dependent on 
several factors, including: the planarity of the cis-peptide units, chirality and 
substitution of the α-carbon (Ramanani et al., 1977). For aromatic amino acids such 
as phenylalanine and tyrosine, various forces can result in a folded conformation of 
the DKP ring, including dipole-induced dipole interactions, van der Waals forces, and 
interaction between aromatic π electrons and the polarised π system of the two 
amide groups (Ramanani et al., 1977). 
 
Both studies by Funasaki and colleagues (1993) and Yamazaki and co-workers (1991) 
have shown that the aromatic rings found in the diketopiperazines mentioned earlier 
can result in folding over of the aromatic ring onto the diketopiperazine ring, 
shielding it from interactions with receptors. In the case of di-substitution with 
aromatic amino acids, as is the case for cyclo(Phe-Phe), cyclo(Phe-Tyr) and cyclo(Tyr-
Tyr), sandwiching of the DKP ring occurs in which the benzene rings fold over on 
opposite sides shielding the DKP ring, which could result in complete steric hindrance 
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of receptor interaction reducing biological activity resulting from the DKP backbone 
(Yamazaki et al., 1991).  
 
Despite the apparent complexity of the conformation discussion above, these 
molecules are still considered as “privileged structures” in terms of their relative 
simplicity with respect to limited conformational freedom, allowing for more 
predictable receptor interaction and giving greater insight into the behaviour of 
larger, related peptides (Prasad, 1995). 
 
 
Figure 2.4:  Conformations for the diketopiperazine ring of phenylalanine-containing cyclic 
dipeptides indicating (A) planar, (B) boat, (C) bowsprit-boat and (D) twist-boat 
conformations (Adapted from Funasaki et al., 1993).  
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2.1.4 Physical stability of cyclic dipeptides 
Not much data is available on the stability of cyclic dipeptides, however, a study 
looking primarily at the formation of the diketopiperazine cyclo(Phe-Pro) in solution 
from Phe-Pro-p-nitroaniline also investigated the pH stability of the product and 
found that between pH 3 and 8, the DKP was stable, but at a pH exceeding this 
range, hydrolysis to Phe-Pro-OH occurred (Goolcharran and Borchardt, 1998).  
 
In another study by Grant (2002), where the stability of a cyclo(Trp-Trp), cyclo(Gly-
Trp) and cyclo(Gly-Gly) was assessed at various temperatures and pH, it was found 
that the naturally occurring cis-fused diketopiperazines were found to be relatively 
stable when compared to their trans-fused counterparts, but also displayed pH-
sensitive instability below pH 3 and higher than pH 9. These findings prove that 
formulation of dosage forms within a reasonable pH range would yield relatively 
stable products provided no significant drug-excipient interactions exist.  
 
2.1.5 Biological activity of cyclic dipeptides 
Several studies have shown the clinical potential of cyclic dipeptides, with a wide 
range of activities including effects on cardiovascular function and blood clotting as 
well as antitumour, antifungal, antibacterial, antihyperglycaemic while also showing 
affinities for opioid receptors, calcium channels, serotonin receptors and oxytocin 
receptors (Martins and Carvalho, 2007). 
 
2.1.5.1 Neurological effects 
Thyrotropin-releasing hormone (TRH), a hormone found in the central nervous 
system, has been thought to play a role in recovery from traumatic brain injury 
(Prakash et al., 2002). It has also been proposed that metabolism of TRH by a 
relatively abundant enzyme, pyroglutamyl aminopeptidase, yields the cyclic 
dipeptide, cyclo(His-Pro) which has also been proposed to have a neuroprotective 
action (Peterkofsky et al., 1982). Two recent studies investigated the neuroprotective 
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actions of analogues of cyclo(His-Pro), shown in Figure 2.5 below, on various models 
of neurological cell death both in vitro and in vivo (Prakash et al., 2002; Faden et al., 
2005). 
 
The earlier study by Prakash and colleagues (2002) tested two derivatives of 
cyclo(His-Pro) on an in vitro cell death model using mechanical stress applied to 
neuronal-glial co-cultures and assessing lactate dehydrogenase (LDH) activity as a 
marker for cell death. In concentrations as low as 100 nM, both agents tested 
showed approximately an 80% reduction in LDH activity in response to maitotoxin. 
Faden and co-workers (2005), also using derivatives of cyclo(His-Pro), tested these 
compounds both on in vitro and in vivo (rat) models of brain trauma. Their in vitro 
results indicated that compounds 35b and 606 (Figure 2.5) showed a dose-
dependent reduction in cell-death, measured by LDH activity. It is interesting to note 
that compound 606 is the same as compound 5 tested by Prakash, which also 
showed significant activity. In the animal model, all four compounds showed a 
reduction in lesion volume after lateral fluid percussion injury as well as an 
improvement of motor function when compared to the controls. 
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Figure 2.5:  Structures of neuroprotective cyclic dipeptides showing the structure of 
cyclo(His-Pro), from which they were derived. Structure (5) and (606) were the 
same but taken from two different research papers (Prakash et al., 2002; 
Faden et al., 2005). 
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Other studies have also shown clinical potential of proline-containing cyclic 
dipeptides as neuroprotective agents and include compounds such as a cyclo(Gly-
Pro) reducing tissue damage in rodent model of hypoxic-ischaemic brain injury (Guan 
et al., 2007). In 2010, another study, testing a similar molecule, cyclo(L-glycyl-L-2-
allylproline), showed a reduction in scopolamine-induced memory impairment when 
tested in adult rats using the Morris Water Maze tests (Guan et al., 2010). 
 
2.1.5.2 Cardiovascular activity 
Several studies have shown the potential of cyclic dipeptides as blockers of ion 
channels in cardiac myocytes, indicating that they could have beneficial 
cardiovascular activity (Oliver and Milne, 1994; Milne et al., 1998; Jamie et al., 2002a; 
McCleland et al., 2004; Kilian et al., 2005; Lucietto et al., 2006). Studies on the 
isolated, retrogradely perfused, rat heart indicated a range of activities for this group 
of compounds (Jamie et al., 2002a; Kilian et al., 2005; Lucietto et al., 2006). 
 
2.1.5.3 Hepatic effects 
The metabolism of drugs via hepatic enzymes such as the cytochrome P450 family is 
an important mechanism for biotransformation of drugs, aiding in their elimination 
from the body (Correia, 2009). Little information is available regarding the hepatic 
metabolism of diketopiperazines but in a study by Delaforge and colleagues (2001), 
the interaction of a range of cyclic dipeptides were investigated with respect to their 
interaction with and metabolism by cytochrome P450 enzymes. The study showed 
that diketopiperazines containing hydrophobic amino acid residues, such as 
phenylalanine, were extensively metabolized by cytochrome P450 3A enzymes as 
was shown with cyclo(Leu-Phe) and cyclo(Phe-Pro). This finding could limit the 
clinical effectiveness of the phenylalanine-containing cyclic dipeptides due to 
reduced circulation time as a result of rapid hepatic metabolism. 
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Another study investigating the hepatoxicity of the isomers of cyclo(Trp-Pro) in vitro 
and in vivo (Jamie et al., 2002b) showed significant increases in biological markers of 
hepatoxicity, such as lactate dehydrogenase (LDH) levels and lipid peroxidation after 
five days exposure of rats to all isomers. These findings could potentially prevent or 
greatly limit therapeutic use of these compounds unless drug delivery mechanisms 
could be employed to limit the effects of these agents outside of the target tissue. 
 
2.1.5.4 Antimicrobial activity 
The antimicrobial activity of cyclic dipeptides has been well documented (Prasad, 
1995; Milne et al., 1998; Ström et al., 2002; McCleland et al., 2004; Rhee, 2004; 
Lucietto et al., 2006; Martins and Carvalho, 2007),  and several cyclic dipeptides and 
derivatives were shown to exhibit antimicrobial activity against a range of microbes, 
including fungi, bacteria and mycobacteria. Although the antimicrobial mechanism is 
not fully understood, there have been studies that have isolated these compounds 
from fungal and bacterial sources, proposing that they play a role in intercellular 
communication by functioning as quorum sensing molecules (Holden et al., 1999). 
Previous studies screening for antibacterial activity among cyclic dipeptides have 
shown promising activity, with cyclo(Pro-Trp), cyclo(Trp-Trp), cyclo(Tyr-Pro) and 
cyclo(Phe-Pro) showing broad spectrum activity (Graz et al., 1999). Cyclo(His-Ala) and 
cyclo(His-Gly) exhibited antibacterial (mostly Gram-negative bacteria) and antifungal 
activity (Lucietto et al., 2006) and cyclo(His-Tyr) and cyclo(His-Phe) was shown to 
have excellent antifungal activity (McCleland et al., 2004). 
 
2.1.5.5 Effects on haemostasis 
One of the key events in thrombus formation and clearance is the activation of 
plasminogen to plasmin by tissue plasminogen activator, an enzyme who’s function 
is regulated by plasminogen activator inhibitor-1 (PAI-1) (Folkes et al., 2001). Over 
expression of PAI-1 has been shown to increase fibrin deposits, resulting in an 
increased risk for the development of thrombosis and arteriosclerosis (Fujii, 1997). 
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Diketopiperazines, structurally similar to cyclo(Phe-Phe) have been shown to inhibit 
PAI-1 with one derivative having fairly potent activity, with the researchers reporting 
an IC50 of as low as 0.2 M (Folkes et al., 2001). 
 
Other studies by McCleland and colleagues (2004) and Lucietto and colleagues (2006) 
also demonstrated the antithrombotic potential of this group of compounds with 
cyclo(His-Tyr), cyclo(His-Ala) and cyclo(His-Gly) showing prolonged clotting time, 
inhibition of ADP-induced platelet aggregation as well as potentiating of clot 
fibrinolysis. 
 
With many of these compounds being investigated for their anticancer activity 
(Section 2.1.5.6 below), the added benefit of having antithrombotic activity would 
greatly reduce the risk of mortality from thrombosis, which has been shown to be 4-
6 time higher in patients with tumours (Imberti et al., 2009). 
  
2.1.5.6 Anticancer activity 
Global statistics for the incidence of cancer are limited with one of the latest being 
for  2002 (Parkin et al., 2005) where it was estimated that the incidence of cancer in 
that year was 10.9 million new cases and 6.7 million deaths worldwide. The most 
recent statistics for the incidence of cancer in the United States was in 2010, where it 
was estimated that 1.53 million new cases would be diagnosed in 2010 (Jemal et al., 
2010), an increase from their estimates in 2008 of 1.44 million new cases (Jemal et 
al., 2008). Selectivity for tumour cells is one of the objectives for those developing 
new treatments for cancer as current treatment options involve cytotoxicity of both 
cancerous as well as healthy cells, leading to devastating adverse effects for the 
patient (Gu and Belury, 2005). Several reports have shown that cyclic dipeptides 
possess potential as anticancer agents, with a high degree of specificity for tumour 
cells (Graz et al., 2000; Brauns et al., 2004). Brauns and colleagues (2004) showed 
that among the selected proline-containing cyclic dipeptides tested, cyclo(Phe-Pro) 
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showed greatest promise, inhibiting the growth of three cancer cell lines, HT-29, 
MCF-7 and HeLa, in vitro. They have also proposed that this compound exhibits its 
effect through the induction of apoptosis, while showing no cytotoxic effect on cells 
representative of normal gastrointestinal mucosa (CaCo-2), indicating a high degree 
of selectivity. Other studies have also shown these compounds to possess significant 
anticancer activity, with cyclic dipeptides such as cyclo(His-Ala) and cyclo(His-Gly) 
showing inhibition of up to 80% in HT-29, MCF-7 and HeLa cell lines at concentrations 
of 100 M (Lucietto et al., 2006). The authors also noted that the solubility of these 
two compounds was higher than others in this class, potentially limiting their effects 
due to poor cell permeation as a result of their polar nature. Thus the need for 
modification of the physicochemical properties to improve permeability (which could 
ultimately result in a loss of activity) or improved means of intracellular transport 
could provide greater potency of these compounds. 
 
2.2  LIPOSOMAL DRUG DELIVERY 
Nanotechnology has vastly broadened the opportunities for drug delivery through 
the use of nanoparticles such as liposomes or micelles in the effective targeting of 
disease while limiting the adverse events experienced by free drugs (Malam et al., 
2009). With the added advantage of active targeting that can be employed during 
the formulation of liposomal drugs, an increasing number of researchers are 
reporting successful targeting using a myriad of ligands such as antibodies (Bestman-
Smith et al., 2000; Carrion et al., 2001; Xu et al., 2002; Carrion et al., 2004), proteins 
(Jones, 1995) and natural agonists of surface receptors over expressed in the target 
cells (Gabizon et al., 1999).  
 
2.2.1 Introduction to nanoparticulate drug delivery 
2.2.1.1 Nanoparticles 
Nanoparticles are those that are measured in the nanometer (nm) range and can be 
anywhere from 1 nm to a few hundred nanometers in diameter (Haley and Frenkel, 
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2008). While the methods required to control and measure the characteristics of 
these particles are complex due to their extremely small size, the major benefit of 
using nano-sized particles, amongst many others, is that they are able to pass 
through the fenestrations in vascular endothelium (Figure 2.6), allowing them to 
accumulate in tissues where these fenestrations are larger than normal, such is the 
case in inflamed tissue or tumours (Gaumet et al., 2008). 
 
 
Figure 2.6:  Mechanism of entry of nanoparticles into tissues. Most healthy tissues display 
continuous endothelial lining which prevents the accumulation of 
nanoparticles in these tissues. Diseased tissues, as is the case with 
inflammation or development of a tumour, vascular endothelium shows large 
fenestration, through which nano-sized particles are able to cross (Gaumet et 
al., 2008). 
 
 
Many different types of nanoparticles have been described in the literature, but the 
most reported with medical applications include dendrimers (Liu and Fréchet, 1999), 
micelles, nanospheres, nanocapsules, fullerenes, nanotubes and liposomes and are 
discussed in Sections 2.2.1.1.1 to 2.2.1.1.4 below (Byrne et al., 2008; Haley and 
Frenkel, 2008). 
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2.2.1.1.1 Dendrimers 
Dendrimers are polymers that branch out from a central core molecule in a tree-like 
fashion (Haley and Frenkel, 2008). Figure 2.7 gives a two-dimensional schematic 
representation of a dendrimer which shows how drugs, proteins, DNA or genes can 
be carried either adsorbed onto the surface or within the channels formed by the 
branches (Svenson, 2009). 
 
 
Figure 2.7:  Schematic representation of a G3 dendrimer, where G3 denotes the number of 
branches (or generations) from the central, core molecule. Surfaces, denoted 
by Z, can be modified to alter the surface chemistry of the particle (Svenson, 
2009). 
 
What is most beneficial with regards to dendrimers is the ability of the researcher to 
exactly control their size by manipulating the number of ‘generations’ or branches 
added to the surface. This is easily controlled through the number of polymerisation 
cycles employed and since each monomer added to the dendrimer is of a known size, 
the predicted particle size of the final product is generally close to that measured 
(Patri et al., 2005). 
 
The synthesis of these molecules was first reported by Donald Tomalia and his group 
at Dow Chemicals and the methods used followed an inward-out approach, starting 
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at the core and they referred to them aptly as starburst dendrimers (Tomalia et al., 
1985). Other researchers have developed an outward-in approach by starting at the 
outer branches and converging at a central core which they referred to as ‘cascading’ 
(Hawker and Frechet, 1990). Whether by divergent or convergent synthesis, the 
medical applications of this group of particles remains promising, with opportunities 
for gene delivery, DNA transfection, medical imaging and also importantly, targeted 
drug delivery (Liu and Fréchet, 1999). Several authors have reported the successful 
inclusion and delivery of drugs such as the cytotoxic agent doxorubicin 
(Papagiannaros et al., 2005), the anti-inflammatory ibuprofen for proposed dermal 
delivery (Kolhe et al., 2003) and the α1a receptor blocker tamsulosin (Wang et al., 
2003). 
 
2.2.1.1.2 Nanospheres and nanocapsules 
Nanospheres are porous spherical colloidal particles that are generally composed of 
synthetic polymers such as polyacrylates and are seen to be a matrix in nature, i.e. 
the drug is incorporated into the porous matrix that is formed by the polymerization 
procedure (Brigger et al., 2002). While nanospheres rely on a porous matrix, 
nanocapsules use an entrapped core usually surrounded by polymers, such as 
poloxamers and poloxamines, into which the therapeutic agent, whether it be a 
synthetic drug, protein or genetic material, is encapsulated (Moghimi et al., 2001; 
Brigger et al., 2002). While most researchers refer to a nanocapsule as being 
composed of a polymer shell, technically, liposomes may also fall into the definition 
of a nanocapsule. Figure 2.8 illustrates the fundamental structural differences 
between nanospheres and nanocapsules. 
 
While much interest has been shown in the potential of these nanoparticles to act as 
drug delivery systems by either targeting affected tissues or through sustaining 
release of the active substance, much debate has occurred around the 
biocompatibility of these polymers, with toxicity resulting from bioaccumulation 
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being a potential problem (Moghimi et al., 2001). Research regarding the 
biocompatibility of these polymers has highlighted a number of polymers, mostly 
composed of lactic- and glycolic acids, showing a good degree of biocompatibility and 
biodegradation both in vivo (Therin et al., 1992; Ali et al., 1994) and in vitro (Asano et 
al., 1993). While the possibilities with regards to the clinical applications are vast for 
these particles, research is focused on targeted delivery in cancer (Brigger et al., 
2002; Misra and Sahoo, 2010) as well as using these particles to transport drugs 
across the blood brain barrier which could be beneficial in the treatment of HIV-
related dementia (Rao et al., 2009). 
 
 
 
 
Figure 2.8:  Structural representations showing the differences between nanospheres (top) 
containing a polymeric matrix, into which therapeutic agents may be 
entrapped, and nanocapsules (below) that contain a central core that entraps 
therapeutic agents (Brigger et al., 2002). 
 
2.2.1.1.3 Fullerenes and nanotubes  
Fullerenes, typically composed of 60 carbon atoms arranged into a soccer ball-like 
structure (Figure 2.9), were originally thought to have been discovered by a 
collaborative team from Rice University in Houston and the University of Sussex and 
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was first published in Nature in 1985 (Kroto et al., 1985). Despite three of the 
researchers being awarded the Nobel Prize in Chemistry in 1991, they later published 
a paper admitting that they were, in fact, not the first to publish work on the 
molecule, giving credit to a Japanese scientist, Professor Eiji Osawa, whose paper had 
gone undiscovered by them (Curl et al., 2001). Irrespective of who made the first 
discovery, fullerenes provide a convenient means of incorporating therapeutic 
molecules for the treatment of disease (Markovic and Trajkovic, 2008). One such 
study investigated the use of immunoconjugated fullerenes, where a 
buckminsterfullerene was conjugated to a murine anti-gp240 melanoma antibody for 
the successful targeting of melanoma cells (Ashcroft et al., 2006).  The size of these 
molecules is far smaller than many other nanoparticulate systems where the average 
diameter of a fullerene is approximately 0.73 nm (Faraji and Wipf, 2009). 
 
 
 
 
Figure 2.9:  Structure of buckminsterfullerene (C60), also known as a Bucky ball which is 
composed of 60 carbon atoms arranged as a truncated icosahedron (Markovic 
and Trajkovic, 2008). 
 
 
Nanotubes, composed of a series of interlinked benzene rings with two open ends, 
have also been investigated for use as drug delivery systems and were first 
discovered in 1991 (Iijima, 1991). Although their potential usefulness has been 
extensively reported to be beneficial in the intracellular transport of genetic material 
(Pantarotto et al., 2004) and large proteins (Kam and Dai, 2005), several reports of 
their toxicity have also arisen. The data from the reports indicated an increase in 
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oxidative stress in vitro, possibly due to the iron content of the carbon nanotubes 
(Manna et al., 2005; Kagan et al., 2006). 
   
2.2.1.1.4 Micelles, solid lipid nanoparticles (SLN) and liposomes 
Micelles are spherical particles composed of amphipathic surfactants associated such 
that the hydrophilic portion associates with the aqueous environment, while the 
lipophilic ‘tails’ arrange within the core, creating a non-polar environment within the 
core, allowing for incorporation of non-polar substances within them (Haley and 
Frenkel, 2008). Micelles form when the concentration of surfactants at the surface 
exceeds what the surface can contain, known as the critical micelle concentration, 
resulting in surfactants self associating into micelles to assume the lowest possible 
energy conformation. Surfactants used in the formation of micelles include anionic 
surfactants such as sodium dodecyl sulphate, cationic surfactants such as 
cetyltrimethylammonium bromide (or cetrimide) and non-ionic surfactants such as 
sorbitan esters (Hirata et al., 1996; Florence and Attwood, 2006). One of the most 
notable pharmaceutical preparations where micelles are used to improve solubility is 
that of chloroxylenol solution BP (marketed as Dettol® in South Africa), where the 
water-insoluble disinfectant, chloroxylenol, is solubilised using alcoholic soap 
micelles (Florence and Attwood, 2006). As can be expected, the use of strongly ionic 
(cationic or anionic) surfactants poses a problem for internal use in drug delivery and 
these, as is the case for chloroxylenol micelles, are restricted for external use while 
the use for more biocompatible non-ionic polyethylene glycol co-polymer surfactants 
has shown potential for delivery of water-insoluble therapeutic agents via both the 
oral and parenteral routes (Gaucher et al., 2010). Figure 2.10 shows the formation of 
co-polymer micelles as illustrated by Torchilin (2006). 
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Figure 2.10:  Self assembly of copolymer micelles from ‘unimers’ showing the hydrophilic 
outer shell with the hydrophobic core (Torchilin, 2006). 
 
 
2.2.2 A brief history of liposomes 
Liposomes were viewed for the first time using electron microscopy by Alec Bangham 
and published in a paper with a colleague in 1964 (Bangham and Horne, 1964). What 
he had discovered was what he called spherulites or multilamellar smectic 
mesophases which later became known as multilamellar liposomes, a phrase given to 
these spherical particles by a colleague of Bangham, Gerald Weissman in 1968 
(Deamer, 2010). 
 
Some of Bangham’s first applications for these particles involved using them to study 
the properties of biological membranes, and in a paper published in 1969, he and 
two other colleagues showed that anaesthetic agents such as chloroform, ether and 
n-butanol, partitioned into lipid membranes, altering their permeability to certain 
ions, which potentially assisted in explaining their mechanism of action (Johnson and 
Bangham, 1969).  
 
While it seemed that Bangham’s original intention of his serendipitous discovery was 
to use these particles to further study the structure and functioning of biological 
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membranes, researchers began to explore liposomes as more than a biophysical tool 
and in the 1970’s research began to emerge on the use of liposomes as carriers for 
macromolecules into cells. The first reports of liposomes being used as carriers for 
drug molecules was in 1972 when a group in the United Kingdom headed by Gregory 
Gregoriadis entrapped several drugs, including penicillin and actinomycin D as well as 
enzymes such as β-fructofuranosidase, into liposomes, investigating their distribution 
in the rat (Gregoriadis and Ryman, 1972; Gregoriadis, 1973). Later, researchers found 
that targeted drug delivery using liposomes was a possibility in the treatment of 
cancer and doxorubicin became the first liposome-encapsulated anticancer agent to 
be sold in the USA (Lasic and Papahadjopoulos, 1998). 
 
2.2.3 Liposomes in drug delivery 
The past decades have seen pharmaceutical scientists striving towards more 
selective drugs or drugs that are incorporated into targeted delivery systems. Much 
interest has been shown towards liposomes as delivery systems as a multitude of 
therapeutic agents can be incorporated into their central aqueous core, including 
conventional small molecule drugs, larger protein therapeutic agents, diagnostic 
agents (such as contrast media), DNA and genetic material (Vemuri and Rhodes, 
1995; Simões et al., 2004). The fact that Bangham’s unintended discovery that 
phospholipids spontaneously form lipid bilayers and associate into vesicles (Bangham 
and Horne, 1964), making them ideal candidates for the formulation of targeted drug 
delivery, due to their relative ease of preparation. 
 
2.2.2.1 Formulation and structure of liposomes 
As has been discussed in Section 2.2.1.1.4, liposomes are composed of phospholipid 
bilayers that self-associate into vesicular structures surrounding an aqueous core 
(Figure 2.11) (Drummond et al., 1999; Haley and Frenkel, 2008). 
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Figure 2.11:  Schematic representation of the structure of a unilamellar liposome showing 
both the structure of conventional liposomes as well as surface modified 
liposomes (Drummond et al., 1999). 
 
The reason for the self-associating behaviour is as a result of the nature of the 
phospholipids that form the liposomes. Phospholipids such as phosphatidylcholine 
are amphiphilic, meaning their structure is composed of a hydrophilic head portion 
as well as a lipophilic hydrocarbon chain as a ‘tail’ (Malam et al., 2009) as shown in 
Figure 2.12. The reason they self-associate into bilayers is in order to assume a low 
energy conformation by protecting their non-polar hydrocarbon chains from the 
aqueous, polar environment while the vesicle formation is to ensure a continuous 
film, preventing the edges from being exposed to the aqueous environment, allowing 
the polar head groups to be in contact with the water (Bawarski et al., 2008). 
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Figure 2.12:  Structure of the predominant species of L-α-phosphatidylcholine showing the 
hydrophilic head group with the two hydrocarbon chains representing the 
lipophilic chain. 
 
From Figure 2.12 above, one can note that the basic amphiphilic structure of a 
phospholipid is composed of a glycerol backbone with two fatty acid side chains, 
forming the lipophilic portion, and a phosphorylated alcohol forming the hydrophilic 
portion of the molecule (Vemuri and Rhodes, 1995). The phospholipids that are most 
abundant in nature include phosphatidylcholine (or lecithin) as well as 
phosphatidylethanolamine, however, others exist that can be used in liposomes, 
their differences primarily being substituents on the phosphorylated head group and 
are shown in Table 2.2 below (Vemuri and Rhodes, 1995). 
 
The choice of phospholipid affects not only the phase transition temperature of the 
membrane, and ultimately its fluidity, but also plays a role in the stability of the 
preparation. Liposomes composed of hydrogenated variants of the common 
phospholipids such as hydrogenated soy phosphatidylcholine, can reduce the rate of 
lipid peroxidation, increasing the stability of the formulation (Brigger et al., 2002). 
Other issues surrounding the choice of phospholipid includes the surface charge of 
the hydrophilic portion of the phospholipid and studies have indicated that lipid 
membrane fusion by liposomes is increased with the use of charged lipids such as 
stearylamine or N-(1-(2,3-Dioleoyloxy)propyl)-N,N-Trimethylammoniummethyl- 
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sulfate (DOTAP) and has thus been used extensively for transfection of DNA into cells 
(Düzgüneş and Nir, 1999). 
 
Table 2.2:  Typical phospholipids, indicating head group composition. 
O O
O
-
O
P R
 
Phospholipid R-Substituent 
Phosphatidylethanolamine -CH2-CH2-NH3
+ 
Phosphatidylglycerol -CH2-CHOH-CH2OH 
Phosphatidylcholine -CH2CH2-N(CH3)3
+ 
Phosphatidylserine -CH2CH-NH2COOH 
Phosphatidylinositol 
OH
OH
OH
H
H
OH
H
H
H
OH
H
 
(Vemuri and Rhodes, 1995). 
 
Another component of liposomes includes cholesterol (Figure 2.13), a component 
frequently found in biological membranes conveying, amongst other properties, 
stability to the membrane (Nomura et al., 2005).  The result of increased stability of 
the bilayer in liposomes results in longer circulation times in vivo due to minimized 
interactions with high density lipoproteins in serum. There has also been a direct 
correlation between cholesterol content of the liposome membrane and drug 
retention within the aqueous core (Drummond et al., 1999). In an early study, the 
role of cholesterol in liposomes clearly demonstrated its ability to stabilize the 
membrane in the presence of plasma, significantly increasing the latency, or drug 
retention capabilities, both in vitro and in vivo, and further cementing its place in the 
formulation of stable liposomes (Kirby et al., 1980). The authors of this study 
indicated that a reduction in the permeability of the membrane was as a result of the 
effect cholesterol has on increasing the packing of the phospholipids in the bilayer. 
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Other authors reported that cholesterol also acts to improve membrane fluidity and 
reduce interaction with plasma proteins such as albumin, m-transferrin and 
macroglobulin in vivo (Vemuri and Rhodes, 1995). 
 
 
OH
H
H
H
 
Figure 2.13:  Structure of cholesterol 
 
 
Other additives to liposome formulations include functionalized lipids, membrane 
stabilizers and anti-oxidants. Anti-oxidants such as α-tocopherol (or vitamin E) and 
butyrated hydroxytoluene have been found to show highly beneficial properties in 
increasing the shelf-life of lipid formulations by acting as a free-radical scavenger. 
Tests have shown that ordinary egg-derived phosphatidylcholine without vitamin E, 
stored at room temperature for seven hours, resulted in oxidation double of that 
shown by the same phospholipid with vitamin E stored at 105 C for the same 
amount of time, clearly illustrating the importance of correct storage of lipids prior to 
use (Vemuri and Rhodes, 1995). 
 
2.2.2.2 Classification of liposomes 
In terms of structure, liposomes can be classified on the basis of size and lamellarity 
where there can be multilamellar vesicles (MLVs), multivesicular vesicles (MVVs), 
large unilamellar vesicles (LUVs) and small unilamellar vesicles (SUVs) (Daniels, 2001).  
Figure 2.14 shows the structure of liposomes based on size and lamellarity for MLVs, 
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SUVs and LUVs as viewed using electron microscopy while Figure 2.15 shows a 
schematic representation of the four possible configurations for liposomes. 
 
 
Figure 2.14:  Electronmicrographs (freeze-fracture) of various types of liposomes classified 
on the basis of size. (A) Large multilamellar vesicles, (B) Small unilamellar 
vesicles and (C) large unilamellar vesicles (Lasic and Papahadjopoulos, 1998). 
 
 
Figure 2.15:  Schematic representation of liposomes classified on the basis of size and 
lamellarity. SUV = small unilamellar vesicle, LUV = large unilamellar vesicle, 
MLV = large multilamellar vesicle and MVV = multivesicular vesicle (Daniels, 
2001). 
 
Many researchers have emphasized the importance of liposome size, stating that 
variation in size can influence a number of outcomes such as drug encapsulation, in 
vivo stability and the ability to reach the target site (Devine et al., 1994; Liu et al., 
1995; Drummond et al., 1999; Lian and Ho, 2001; Gaumet et al., 2008). For drug 
encapsulation, the smaller the vesicle, the smaller the aqueous volume entrapped 
relative to the lipid volume, as lipid bilayer thickness remains constant (Drummond 
A      B    C 
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et al., 1999). Therefore, it follows that larger particles should be used, within the size 
limit required for passage through fenestrations, to ensure optimal encapsulation of 
the drug. However, a number of studies have shown that larger liposomes result in 
lower circulation times in vivo (Devine et al., 1994; Liu et al., 1995). This reduction in 
circulation has been found to be as a result of recognition of the liposomes as foreign 
particles by the reticuloendothelial system (RES) and subsequent clearance by 
macrophages of the body’s immune system. The mechanism for this interaction with 
the RES was not well understood until studies done by Liu and colleagues (1995) and 
Devine and colleagues (1994) demonstrated that opsonisation of liposomes resulted 
in greater recognition by macrophages. Opsonisation involves binding of opsonin 
molecules, such as antibodies or components of the complement system, to foreign 
particulates, that can include bacteria or viruses, to facilitate recognition by 
macrophages (Nelson et al., 2008). Liu and colleagues (1995) proposed that it was 
complement proteins, in particular C3b, binding to liposomes that increased their 
elimination and not antibody-mediated phagocytosis. In their study, they 
investigated the influence of size on the rate of elimination by the RES and found 
that larger liposomes were more readily eliminated than smaller ones. Figure 2.16, 
taken from their research paper, clearly shows a linear relationship between particle 
diameter and percentage uptake by liver macrophages and they have proposed that 
the reason for this relationship is due to larger liposomes having a greater area, per 
particle, for complement binding, resulting in greater chance of recognition by 
macrophages. 
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Figure 2.16:  Effect of particle size and blood components on liver uptake of 
phosphatidylserine liposomes in saline (), 33% serum in saline(), 66% 
whole blood() or liposomes directly perfused through the liver (). 
 
However, compositionally, liposomes can be classified according to their 
phospholipid composition as well as the presence of any surface modifications. 
These include conventional liposomes, pH-sensitive liposomes, cationic liposomes, 
long circulating liposomes and immunoliposomes (Torchilin and Weissig, 2003).  
 
Conventional liposomes are composed mainly of a phospholipid bilayer that can 
include a variety of phospholipids such as phosphatidylcholine, 
phosphatidylethanolamine or phosphatidylserine along with stabilizers such as 
cholesterol and an antioxidant such as α-tocopherol (vitamin E) and they generally 
have a neutral or slightly anionic surface charge (Drummond et al., 1999).  
 
pH-sensitive liposomes are extremely beneficial in the delivery of anticancer agents 
in acidic environments such as those encountered in high-metabolizing tumour 
tissues or in endocytic vesicles, resulting in the rapid release of the liposomal 
contents at the site of action (Hafez et al., 2000). Components frequently used to 
construct pH-sensitive liposomes include pH-sensitive phospholipids such as 
dioleoylphosphatidylethanolamine (DOPE) (Simões et al., 2004) or pH-sensitive 
polymers such as N-isopropylacrylamide (NIPAM) derivatives (Roux et al., 2004), 
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however, some authors believe that the addition of large molecular weight surface 
molecules such as NIPAM, may be responsible for immune responses and toxicity 
(Drummond et al., 2000; Fonseca et al., 2005).  
 
The reason for the use of phosphatidylethanolamine-derivatives, such as DOPE, is 
due to their relatively poorly hydrated head group, when compared to 
phosphatidylcholine (PC) as shown in Figure 2.17 giving the phospholipid a more 
conical shape as opposed to PC’s more cylindrical shape due to a well hydrated head 
group. 
 
 
Figure 2.17:  Relative shapes of phosphatidylcholine (PC) (top) and 
phosphatidylethanolamine (PE) (below), showing how head group hydration 
affects the relative cross-sectional size of head group region when compared 
to the acyl chain, giving PE-derivatives more of a cone shape as opposed to the 
cylindrical shape of PC-derivatives. Adapted from Drummond et al. (2000). 
 
The result of low pH on the PE-derivatives results in the protonation of the head 
group and resultant dehydration of this region creating a cone-shaped phospholipid 
that does not support formation of a lamellar phase, but rather, non-bilayer lipid 
structures (Chernomordik, 1996) which, in the case of PE, occurs above physiological 
pH and stable liposomes composed only of PE can only be formed above pH 9 (Ellens 
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et al., 1984). Including membrane stabilizers such as mildly acidic amphiphiles which 
include oleic acid and cholesteryl hemisuccinate (CHEMS) increase the stability of the 
membrane formed by creating a more hydrated interface that supports the lamellar 
phase (Drummond et al., 2000). Reducing the pH to below physiological conditions in 
these formulations, results in protonation of the mildly acidic amphiphilic membrane 
stabilizers resulting in dehydration of the head groups and membrane fusion (Hafez 
et al., 2000). Many mechanisms have been proposed for the fusion that occurs at low 
pH, but the most prominently discussed is the ‘stalk’ theory (Chernomordik, 1996; 
Siegel and Epand, 1997; Siegel, 1999). As a result of a larger acyl chain region than 
head group region, the spontaneous curvature of bilayers is largely negative resulting 
in a high elastic force necessary to retain a flat membrane such as those that occur 
with cylindrically shape phospholipids such as PC. This high elastic force cannot be 
maintained indefinitely and upon interaction with neighbouring membranes, the 
formation of what has been described as ‘stalks’ occurs as shown in Figure 2.18 
(Chernomordik, 1996). The formation of stalks will favour transition of the lipid 
structure to an inverted hexagonal phase (HII) which ultimately results in complete 
membrane de-stabilization and release of liposome contents (Siegel, 1999). 
 
             
  A    B   C 
Figure 2.18:  Proposed mechanism for transition of phosphatidylethanolamine from the 
lamellar phase (A) to the inverted hexagonal (HII) phase (C) through the 
formation of membrane stalks (B) as a result of membrane interaction due to 
highly negative spontaneous curvatures. Modified from Siegel (1999). 
 
This concept of pH-dependent liposome de-stabilization forms the corner-stone of 
pH-mediated liposomal drug delivery, where uptake of liposomes by endocytic 
vesicles of tumour cells, exposing the liposomes to a low pH environment, as well as 
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the production of acidic by-products of highly metabolic tumours, results in release 
of liposomal contents at the desired site of action (Drummond et al., 2000). Figure 
2.19 illustrates the possible mechanism of drug release from endocytosed pH-
dependent liposomes. 
 
D
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endocytosis
Early endosome 
(pH 6.5) [2-5 minutes]
Late endosome 
(pH 5.0 - 6.0) 
[10-15 minutes]
Lysosome 
(pH 4.0-5.0) 
[30-35 minutes]
 
Figure 2.19:  Drug delivery with pH-sensitive liposomes, where once taken up into 
endosomes, one of four mechanisms of release could occur: (A) Liposome 
membrane de-stabilizes and subsequently de-stabilizes the endosomal 
membrane, releasing liposome contents into the cytosol; (B) Entrapped 
molecules are released from destabilized liposomes and diffuse into the 
cytosol; (C) Fusion of liposome membrane with endosome membrane releases 
contents into cytosol and (D) Mature endosomes develop into lysosomes and 
digest liposomes (and potentially it contents) with low pH and lysosomal 
enzymes. Recreated with modification from Simões et al. (2004). 
 
Apart from pH-sensitive liposomes being used to trigger the release of drugs in direct 
response to pH changes in biological fluids, other strategies can be used to respond 
to other chemical changes with no direct effect on pH. Such strategies include co-
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encapsulation of enzymes responsible for the conversion of biomolecules into acidic 
products that results in the de-stabilization of the membrane and, ultimately, drug 
release. One such example includes the co-encapsulation of glucose oxidase into 
insulin loaded liposomes, converting higher than normal levels of serum glucose into 
gluconic acid, raising intraliposomal pH, causing membrane de-stabilization and 
insulin release in response to the raising glucose levels (Chong-Kook et al., 1994). 
 
Early reports have shown that inclusion of cationic lipids into liposome membranes 
promotes intracellular drug delivery (Magee et al., 1974). Positively charged lipids 
such as stearylamine, dioleoyltrimethylammonium propane (DOTAP) or  
dioleyloxypropyl-trimethylammonium chloride (DOTMA) have been shown to 
increase cellular fusion and cellular uptake of encapsulated molecules (Düzgüneş and 
Nir, 1999). These cationic liposomes have also been used extensively in DNA 
transfection, known as lipofection, due to their ability to fuse with cell membrane, 
delivering the DNA molecules directly into the cell (Felgner et al., 1987; Gao and 
Huang, 1995). 
 
As has been mentioned in preceding paragraphs that uptake of liposomes by the 
reticuloendothelial systems is a major problem for ensuring adequate circulation 
time in order to promote delivery of liposomal contents to the target tissue. Apart 
from manipulating particle size, surface modification can also ‘hide’ liposomes from 
recognition particles such as opsonins. In the early 1990s several publications arose, 
describing the enhanced circulation time for liposomes with polyethylene glycol 
(PEG) of various lengths, grafted onto their surface (Blume and Cevc, 1990; Klibanov 
et al., 1990; Liu and Huang, 1990; Allen et al., 1991; Senior et al., 1991; Woodle and 
Lasic, 1992) and a research company, Liposome Technology Incorporated, licensed 
the trademark “STEALTH” in describing these long-circulating liposomes, implying 
that they evade the body’s immune system (Gabizon, 2001). The mechanism by 
which PEG reduces recognition by the opsonising proteins in plasma is proposed as 
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being as a result of local surface concentration of hydrated groups found on the PEG 
chain, reducing electrostatic and hydrophobic interaction between the liposomes 
and blood components (Lasic et al., 1991). However, with the advantage of increased 
circulation times for liposomes comprising PEG, there are several disadvantages to its 
inclusion, including a reduction in the quantity of drug encapsulated as well as a 
slight increase in the rate at which drug leaks from the vesicles. For encapsulation 
efficiency, it has been shown that concentrations of 2.5% of PEG5000 and 3.75% of 
PEG5000 can reduce the amount of encapsulated material by more than half and has 
been attributed to the fact that a reduction in the size of the interior compartment of 
the liposome occurs due to steric hindrance created by grafted PEG on the inside of 
the lipid membrane (Nicholas et al., 2000). However, without inclusion of the PEG, or 
some form of surface modification to assist in reducing RES recognition, liposomes 
will have insufficient circulation times to be of therapeutic value (Gabizon, 2001). The 
PEG moiety also provides a site for attachment of targeting molecules such as 
proteins, receptor ligands and antibodies (Allen and Moase, 1996). 
 
Immunoliposomes are as a result of surface modification of liposomes using 
antibodies and fall within the class of targeted liposomes that use active targeting to 
reach the desired site of action (Allen and Moase, 1996; Sapra and Allen, 2003). The 
antibodies used are generally those against proteins that are shown to be over 
expressed in the target cell and for tumour targeting and can include proteins such 
as HER-2 (Park et al., 2001), CD34 (Carrion et al., 2004) and transferring receptors (Xu 
et al., 2002). They can also be used to target tissues where infectious organisms are 
likely to be found, such as in HIV, where T-lymphocytes, macrophages and B 
lymphocytes all express high levels of the protein HLA-DR, which can be targeted 
with anti-HLA-DR antibodies (Bestman-Smith et al., 2000). This approach has also 
been taken in the targeting of proteins expressed in alveolar macrophages for the 
treatment of tuberculosis infection using inhaled dry-powder liposomes, reducing 
the troublesome side-effects of drugs like rifampicin, used in the long duration of 
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treatment of the infection (Vyas et al., 2004). A more detailed discussion of the 
mechanism of active targeting will be discussed in Section 2.2.2.4.2 below. 
 
2.2.2.3 Preparation of liposomes 
In terms of the preparation of liposome vesicles, many methods have been reported 
and include thin-film hydration, freeze-thawing, reverse-phase evaporation and 
ethanol injection methods (Pons et al., 1993; Vemuri and Rhodes, 1995; Torchilin and 
Weissig, 2003) and vary in terms of the final liposomes formed with respect to size, 
lamellarity and drug encapsulation.  
 
One of the most reported methods for the preparation of liposomes include the thin-
film hydration method which forms large multilamellar vesicles. This is often 
followed by an extrusion step in order to size the liposomes to the nanoscale as well 
as create a unilamellar vesicle (Torchilin and Weissig, 2003). In this method, lipids are 
generally dissolved in organic solvents such as chloroform (most widely used), 
methanol or/and ether, although recent concerns regarding the safety of these 
solvents has lead to one group developing a method of liposome preparation using 
halothane as a solvent (Ran and Yalkowsky, 2003). The removal of residual organic 
solvent is essential in ensuring adequate hydration and self-association of the lipid 
vesicles and requires extensive reduced pressure evaporation, flushing of the lipid 
film with nitrogen and/or lyophilisation (Basu and Basu, 2002). Once formed, the 
lipid film is then hydrated with either a solution of the drug to be encapsulated or a 
buffer, if the remote loading method is to be used. The hydration facilitates swelling 
of the lipid and formation of multilamellar vesicles, where each lamella is comprised 
of a phospholipid bilayer (Torchilin and Weissig, 2003). Figure 2.20 shows the basic 
scheme for the formation of liposomes from thin lipid films along with post-
hydration steps for effective sizing of liposomes.  
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Figure 2.20:  Formation of liposomes from thin lipid films during hydration (Vanniasinghe et 
al., 2009). 
 
If the drug is not loaded via passive means during the hydration step, it can be 
loaded into pre-formed liposomes using the remote loading method which relies on 
the concept of ion trapping to create a concentration gradient such that unionized 
drug diffuses into the liposome, encounters an intraliposomal pH that results in 
ionization, effectively reducing the concentration of the unionized form, promoting 
further diffusion from the extraliposomal environment (Barenholz, 2001; Zucker et 
al., 2009). The principle of ion trapping for remote loading relies on a thorough 
knowledge of the physicochemical properties of the drug being loaded and the drug 
must exist as either a weak acid or a weak base. The hydration medium of the empty 
liposomes are determined by the nature of the drug and weakly acidic drugs are 
encapsulated into liposomes with a high internal pH, most often containing calcium 
acetate, while weak bases are encapsulated into liposomes with a low internal pH, 
most often containing ammonium sulphate (Zucker et al., 2009). The concept of ion 
trapping against sulphate (for basic drugs) and acetate (for acidic drugs) gradients is 
illustrated in Figure 2.21 below. 
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Figure 2.21:  Ion trapping for the remote loading of (A) weak bases by an ammonium sulfate 
gradient or (B) weak acids by a calcium acetate gradient (B). D = drug, AcH = 
acetic acid, Ac− = Acetate (Zucker et al., 2009). 
 
Research has shown that size has been shown to greatly influence the biological 
activity of liposomes as a result of varied rates of cellular interactions or cellular 
uptake with changing particle diameter, favouring liposomes with a mean diameter 
of around 100 nm (Nagayasu et al., 1999). Simple thin-film hydration produces 
multilamellar liposomes of greater than 1000 nm (or 1 m) making the need for an 
effective size reduction technique imperative (Torchilin and Weissig, 2003). Extrusion 
appears to be the most used method of size reduction and several extrusion devices, 
both small laboratory scale devices and larger production sized equipment are 
available for this purpose, most of which use high pressure extrusion through fine 
polycarbonate membranes with pore sizes of between 50 – 400 nm (Berger et al., 
2001). The devices used on the laboratory scale produce small test batches ranging 
from a few microliters to a few milliliters which is fairly limited when it comes to in 
vivo testing and as a result, some laboratories have developed bench top equipment 
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that use a multiextrusion technique that can produce batches in excess of 500 ml 
(Endruschat and Henschke, 2000). Another method of size reduction includes 
ultrasonic treatment of large multilamellar vesicle suspension using ultrasonic baths 
or probes but often produces liposomes of an unpredictable size and low entrapped 
volume (Szoka and Papahadjopoulos, 1980). 
 
Several other methods exist for the preparation of liposomes apart from formation 
of a film from lipids dissolved in organic solvents and include the formation of large 
unilamellar vesicles via reverse-phase evaporation (Szoka and Papahadjopoulos, 
1978; Maestrelli et al., 2006) or through ethanol injection (Pons et al., 1993). 
Reverse-phase evaporation involves dissolving lipids in a small volume of organic 
solvent such as chloroform, isopropyl alcohol or methanol and dispersing this 
mixture into a solution of the drug and buffers. Under reduced pressure, the organic 
solvent is evaporated and phase-inversion results in the formation of unilamellar 
vesicles with a high volume entrapment (Szoka and Papahadjopoulos, 1978). With 
the ethanol injection method, lipids are dissolved in ethanol and injected into a 
solution of the drug at high temperature (60 – 65 C) via a thin (4-5 m) diameter 
needle at a relatively slow rate to facilitate quick evaporation of the ethanol and 
formation of vesicles (Pons et al., 1993; Justo and Moraes, 2005). 
 
2.2.2.4 Liposome targeting in drug delivery 
It has been noted that liposomes can deliver drugs to cells in several basic ways, 
either by: releasing the drug close to the cell surface and allowing the drug to diffuse 
into the cell or interact with surface receptors; fusing with cell membranes and 
releasing its contents directly into the cell; or through endocytosis (Figure 2.22) 
(Goodsell, 2004). 
 
 
 
46 
 
 
 
Figure 2.22:  Delivery of encapsulated drug to cells by (A) release of contents at cell surface, 
(B) endocytosis and (C) membrane fusion (Goodsell, 2004). 
 
However, in order for liposomes to interact with cells they are intended to target can 
be achieved through either active or passive targeting as outlined below. 
 
2.2.2.4.1 Passive targeting 
Cellular junctions in normal tissue tend to prevent the entry of certain large 
molecular weight drugs and nanoparticles. However, in inflamed tissue and 
developing tumours, the cellular junctions are poorly constructed forming larger 
fenestrations, resulting in the easy entry of particles such as liposomes. Also, as a 
result of poorly developed lymphatic networks within tumours, elimination of the 
particles is slow resulting in accumulation. This process is known as the enhanced 
permeation and retention (EPR) effect and this is why nanoparticulate drug delivery 
systems are so effective in the treatment of solid tumours (Haley and Frenkel, 2008). 
The blood-brain barrier forms one of the most impermeable barriers to drug delivery 
for the treatment of brain tumours, however, fenestrations in tumour vasculature in 
the brain, although smaller, have still been shown to accumulate nanoparticles such 
as liposomes (Drummond et al., 1999). Several studies have shown significant 
accumulation of liposomes in tumours in vitro (Siegal et al., 1995; Hobbs et al., 1998; 
Xie et al., 2005; Afergan et al., 2008). 
A     B    C 
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2.2.2.4.2 Active targeting 
The term ‘magic bullet’ was first used by bacteriologist Paul Ehrlich to describe drugs 
that have a highly specific action on only the desired cells/sites without producing 
undesirable side-effects on non-target tissues (Maruyama et al., 1999).  Surface 
modification of liposomes to include targeting moieties has been found to improve 
the selectivity and efficacy of the encapsulated drug and can be accomplished 
through using targeting moieties such as small molecules, sugar molecules, serum 
proteins and antibodies  (Drummond et al., 1999). The use of antibody fragments 
(Fab’) covalently bonded to polyethylene glycol (PEG) and incorporated into the 
liposome membrane has shown great benefits in accumulation in tumour tissue 
while bonding of the complete monoclonal antibody (mab) results in reduced 
accumulation, most likely due to recognition of the constant region (Fc) of the mab 
by compliment components in plasma and a more rapid clearance by the RES 
(Drummond et al., 1999; Maruyama et al., 1999; Chapman, 2002).  
 
The manner in which antibodies or antibody fragments are bound to the liposomal 
components (most often PEG) involves four primary mechanisms, which include 
covalent amine bonding, carbohydrate modification, disulphide bonds and non-
covalent conjugation (Ansell et al., 2000). The method most commonly employed is 
the formation of disulphide bonds between the sulphydryl groups of thiolated 
antibody fragments and a maleimide group on derivatised phospholipids or PEG-
conjugated phospholipids, which can then be incorporated into the liposomes (Ansell 
et al., 2000; Nobs et al., 2004).  Several sub-types of the four primary reactions are 
possible and a schematic representation of these is shown in Figure 2.23 below. 
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Figure 2.23:  Schematic representation of the possible covalent linkages between antibody 
ligands and phospholipid moieties which include (A) maleimide and thiol bond 
formation, (B) disulphide bond formation, (C) carboxyl to 1˚ amine linkage, (D) 
hydrazide to aldehyde linkage, and (E) cross linking between two 1˚ amines 
(Nobs et al., 2004). 
 
The effect of ligand coupling to liposomes has been shown to increase cellular uptake 
of drugs encapsulated into the liposomes, however, the ability of the liposome to 
reach the desired tissue is not necessarily influenced by the ligands found on the 
surface and the enhanced permeation and retention effect (EPRS) still plays an 
important role in ensuring efficacy and specificity of encapsulated drug in vivo 
(Drummond et al., 1999). Therefore, the pharmacokinetics and biodistribution of the 
liposome is still extremely important in ensuring that the drug reaches the desired 
site of action. The addition of antibodies, antibody fragments and proteins onto the 
surface of liposomes, albeit by grafting them to functionalized PEG lipids that should 
evade the RES, still increases the risk of recognition by the RES and a subsequent 
reduction in circulation times (Li et al., 2002). However, by carefully selecting the 
molecular weight of the PEG, its concentration and keeping the ligand concentration 
to a minimum can still provide sufficient circulation time to enable accumulation of 
liposomes into the desired site of action by passive targeting and then subsequently 
increase their action by active targeting (Marcucci and Lefoulon, 2004). 
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2.2.2.5 Clinical applications of liposomes 
The potential clinical application of liposome technology in drug delivery is vast and 
can be potentially very useful for drugs with low solubility and permeability as well as 
those with a high side effect profile (Goyal et al., 2005). Although the treatment of 
cancer has been one of the most popular applications for liposomes due to a 
reduction in the side effect profile, other applications include the treatment of 
infection by bacteria, fungi, mycobacteria and viruses, delivery of genes for gene 
therapy and the delivery of contrast media for diagnosis (Goyal et al., 2005; 
Immordino et al., 2006). 
 
In the development of formulations for the treatment of cancer, encapsulation of 
anthracyclines such as doxorubicin and duanorubicin, have been extensively 
researched and doxorubicin-loaded liposomes were the first liposome product 
available for commercial use in the United States under trade name Doxil® (Lasic and 
Papahadjopoulos, 1998; Immordino et al., 2006). Liposomal doxorubicin has 
undergone extensive clinical trials for the treatment of AIDS-related Kaposi’s 
sarcoma (KS) and was found to be more effective in treatment than the standard 
ABV (Anthracycline, Bleomycin, Vincristine) triple regimen with far lower incidence of 
the side effects associated with the use of the ABV drugs (Drummond et al., 1999). 
Duanorubicin encapsulated into liposomes has also been investigated in phase III 
clinical trials for the treatment of AIDS-related KS, and although there appeared to be 
no added advantage to using the liposomal formulation as opposed to the standard 
ABV regimen, patients experienced significantly lower incidence of adverse events, 
particularly alopecia and neuropathy (Gill et al., 1996). The use of liposomal 
doxorubicin in the treatment of paclitaxil and platinum refractory ovarian cancer was 
shown to have a good response rate in patients with limited side effects showing 
great potential in the use of liposomes in the treatment of resistant cancers (Muggia 
et al., 1997). Refractory cancers, or those that develop resistance to antineoplastic 
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agents are of particular concern, yet develop rapidly due to the administration of 
lower doses in order to avoid potentially fatal side effects of the drugs (Higgins, 
2007). In a study conducted in vivo using the mouse tumour model, doxorubicin 
liposomes were tested on both doxorubicin sensitive and resistant tumours and were 
shown to overcome the resistance displayed towards free doxorubicin (Ogawara et 
al., 2009).  A list of commercially available liposome formulations for the treatment 
of a variety of cancers is shown in Table 2.3 below. 
 
Table 2.3:  Status of liposomal products for the treatment of cancer. Adapted from 
Immordino et al. (2006) 
Product Name Encapsulated Drug Company Application Trial phase 
DaunoXome
®
  Duanorubicin Nexstar Kaposi’s sarcoma Approved 
DOXIL
®
/Caelyx
®
 Doxorubicin Sequus Kaposi’s sarcoma Approved 
Myocet
®
/Evacet
®
  Doxorubicin Elan Pharma Metastatic breast cancer Approved 
SPI-077 Cisplatin Sequus Head, neck and lung cancer Phase I/II 
Lipoplatin™  Cisplatin Regulon Inc. Several cancer types Phase II/III 
S-CKD602 Camptothecin Alza Co. Several cancer types Phase I 
Aroplatin  Oxaliplatin analogue Antigenics Inc Colorectal cancer Phase II 
Depocyt Cytaribine SkyePharma Lymphomatous meningitis Approved 
LEP-ETU Paclitaxil NeoPharm Inc Ovarian, breast and lung 
cancer 
Phase I 
LEM-ETU  Mitoxantrone NeoPharm Inc Leukemia, breast, stomach, 
liver and ovarian cancers 
Phase I 
LE-SN38 Irinotecan NeoPharm Inc advanced cancer Phase I 
MBT-0206 Paclitaxil MediGene AG Anti-angiogenic properties 
Breast cancer 
Phase I 
OSI-211  Lurtotecan Enzon Co. Ovarian, head & neck cancer Phase II 
Marqibo
®
  Vincristine Inex Pharm Non-Hodgkin’s lymphoma Phase II/III 
Atragen
®
  t-Retinoic acid Aronex Pharm Advanced renal cell cancer, 
acute pro-myelocytic leukemia 
Phase I/II 
INX-0125 Vinorelbine Inex Pharm Breast, colon and lung cancer Phase I 
INX-0076  Topotecan Inex Pharm Advanced cancer Preclinical 
Liposomal-
Annamycin
®
 
Annamycine MD Anderson CC Breast cancer Phase II 
 
The emergence of drug resistant forms of infectious microorganisms has become a 
growing problem and recent outbreaks of extremely drug resistant strains of 
tuberculosis (XDR-TB) have sparked renewed interest in developing drug delivery 
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systems that can overcome the problem of resistance (Lancet, 2006). Several reports 
have shown pre-clinical benefits in the animal model for rifampicin and isoniazid 
loaded liposomes in the treatment of mycobacterial infection (Deol and Khuller, 
1997; Dutt and Khuller, 2001; Labana et al., 2002). Liposomal amikacin has also been 
shown to be potentially beneficial in the treatment of Mycobacterium avium in the 
mouse model (de Steenwinkel et al., 2007), however, several clinical reports have 
shown that the use of liposomal amikacin in the treatment of resistant and non-
resistant strains Mycobacterium tuberculosis infection, show little benefit 
(Whitehead et al., 1998; Donald et al., 2001). The clinical case described by 
Whitehead and colleagues (1998) was of a patient with drug resistant tuberculosis, 
and despite the high dosing, and an apparent improvement in the clinical symptoms 
of the infection, the patient continued to test positive for Mycobacterium 
tuberculosis in sputum cultures for 9 months following the treatment. This could be 
of concern, however, active targeting and improved formulation could potentially 
overcome the clinical limitations of these preparations in the treatment of TB. 
 
Another group of infectious organisms that pose a particularly large problem 
clinically are fungi. While the treatment of extracellular fungal infections by causative 
organisms such as Candida albicans and Aspergillus niger can be easily achieved with 
conventional antifungal agents, intracellular fungal infections such as histoplasmosis 
and leishmaniasis require treatment with a more potent antifungal agent, usually 
amphoteracin B. While effective in the treatment of fungal infections, amphoteracin 
B has extremely problematic side-effects and the use of liposomal amphoteracin B 
(marketed as AmBisome) has shown greater effectiveness with a markedly lower side 
effect profile (Adler-Moore and Proffitt, 2002). Investigations are currently underway 
determining the potential benefits of liposome encapsulation for other antifungal 
agents such as nystatin, miconazole and ketoconazole (Goyal et al., 2005).  
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The ability of liposomes to cross lipid barriers has resulted in interest being shown 
towards dermal and transdermal drug delivery facilitated by liposomes (El Maghraby 
et al., 2008). This concept has prompted researchers to utilize liposomes in the 
effective delivery of local anaesthetics across the skin for greater therapeutic effects 
and include agents such as bupivacaine (Yu et al., 1998), lignocaine (Glavas-Dodov et 
al., 2002) and benzocaine (Mura et al., 2007; Maestrelli et al., 2010). The ability of 
liposomes to transport molecules across the skin is one of the reasons they have 
been used extensively in the cosmetic industry for the formulation of cosmetic 
products. A novel liposome formulation comprising of lipids from marine organisms, 
termed Marinosomes® by the researchers, have been shown to possess optimal 
physicochemical characteristics for the delivery of molecules to deep layers of the 
skin (Moussaoui et al., 2002). Figure 2.24 shows the proposed routes for drug 
delivery across the skin using liposomes. Five routes of drug passage were proposed 
by El Maghraby and colleagues (2008). The first involves release of encapsulated 
substances from liposomes on the surface of the skin, mostly likely incorporated into 
a topical dosage form, and subsequent diffusion of the free drug through the stratum 
corneum. The second route is as a result of the penetration enhancement effect of 
liposome components, improving the diffusion of free drug through the skin. 
Another mechanism involves adsorption of intact liposomes to the skin surface and 
subsequent diffusion of the drug from the liposomes directly into skin structures. 
Permeation of intact liposomes through the stratum corneum or through hair 
follicles and sweat glands was also proposed.   
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Figure 2.24:  Possible mechanisms for liposomal drug delivery to the skin: (A) Release of free 
drug from liposomes; (B) Penetration enhancement by liposome components;  
(C) Liposome adsorption onto stratum corneum; (D) Penetration of intact 
liposomes into skin structures; (E) Penetration through hair follicles (El 
Maghraby et al., 2008). 
 
Despite the route of entry, liposomes have been shown clinically to improve entry of 
encapsulated molecules into skin structures and for this reason, they have been used 
extensively in cosmetic products since the late 1980s, when Christian Dior introduced 
Capture®. Since then, hundreds more cosmetic products containing liposomes have 
been marketed, encapsulating moisturisers, tanning agents, vitamins, tissue 
regeneration compounds and hyaluronic acid (Lasic, 1995).  
 
Another clinically relevant application of liposomes includes the use of targeted 
liposomes to deliver contrast agents to specific sites in order to facilitate diagnostic 
imaging (Lasic, 1998). Encapsulation of gadolinium and manganese salts in either the 
aqueous core or the lipid bilayer can facilitate better MRI resolution due to more 
specific delivery of the contrast agent (Mody et al., 2009). 
 
One of the largest obstacles to the clinical use of liposomes is the unpredictable 
release rate of encapsulated drugs in vitro (Chen and Wu, 2010). Recent advances 
have resulted in the ability to accelerate release of liposomal contents post 
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administration in response to stimuli such as (1) light (Mueller et al., 2000; Paasonen 
et al., 2007; Anderson et al., 2010; Paasonen et al., 2010), (2) application of 
ultrasound vibrations (Huang and MacDonald, 2004; Chen and Wu, 2010) and (3) 
heat (Needham and Dewhirst, 2001). Light-induced release can be beneficial for 
activating release of encapsulated drugs for topical treatment in areas where light is 
able to penetrate, however, the use of varying wavelengths of laser light and 
application of that light to areas that are more penetrable by the light (such as the 
eye) could result in clinically relevant applications of photo-sensitive liposomes 
(Ebrahim et al., 2005). Two main approaches seem to be common in the 
development of light-sensitive liposomes. The first involves attachment of photo-
sensitive dyes to the PEG moieties of the liposomes that react with particular 
wavelengths of light to de-stabilize the lipid membrane (Mueller et al., 2000). These 
methods, however, rely on the chemical conversion of chromophores for the 
destabilization of the membrane and may not be completely selective. Non-selective 
degradation of the chromophores by heat, chemical or enzymatic degradation may 
result in inadvertent release of liposomal contents outside of the desired site of 
action and may also be potentially toxic to normal cell membranes (Anderson et al., 
2010). Some researchers have overcome this problem by adhering photo-sensitive 
nanoparticles, such as gold nanoparticles, that exhibit plasmon resonance and 
convert light energy into heat, facilitating membrane destabilization (Paasonen et al., 
2007). 
 
Ultrasonic treatment of affected sites to stimulate liposome membrane de-
stabilization has also been investigated (Huang and MacDonald, 2004; Chen and Wu, 
2010) and relies on the principle of cavitation for drug release. Gas bubbles are 
purposely entrapped into the liposomes and on exposure to ultrasonic vibrations, 
transient cavitation results in rapid expansion of these bubbles, followed by a sudden 
collapse and subsequent destabilization of the liposome (Schroeder et al., 2009). 
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Thermally-responsive liposomes have also shown promise in the controlled delivery 
of encapsulated substances to their respective sites of action. The phase transition 
temperature of lipids is well defined and can be altered by mixing specific 
proportions of lipids of varying chain lengths together. 1,2-dipalimitoyl-sn-glycero-3-
phosphocholine (DPPC) is an ideal lipid for temperature sensitive liposomes as its 
transition temperature of 41.5 C is slightly above normal body temperature and well 
within a tolerable range (Needham and Dewhirst, 2001). Administration of thermally 
sensitive liposomes prior to hyperthermic treatment has been shown to result in 
rapid release of liposomal contents at the site of hyperthermia only, making it ideally 
selective for the heated area (Gaber et al., 1996). One problem that could arise is 
delivering heat to deep areas of the body without overheating superficial layers. A 
proposed solution for this could be the use of a device known as the Celsion Cor that 
utilizes a technology called focused heating adaptive phased array method. This 
method relies on the use of an array of beams that alone, will not heat exposed 
tissue, but when converged, result in a significant hyperthermic effect, allowing 
clinicians to heat very specific, deep seated, areas within the body (Needham and 
Dewhirst, 2001). 
 
Yet another potentially useful application of liposome technology is to use these 
vesicles as gene transfection agents in gene therapy. Since it was first reported that 
liposomes can be used to stably transfect cells with DNA (Felgner et al., 1987), 
interest has grown regarding the use of liposomes as transfection vectors for both 
laboratory applications as well as clinically, for gene therapy. Although the use of 
cationic liposomes has been shown to encourage liposome-cell membrane fusion 
and increase the rate at which liposomal contents are delivered into cells, concern 
has been raised over the ability of liposomes, with a relatively small internal aqueous 
core, to encapsulate large DNA molecules (Lasic and Templeton, 1996). This problem 
has been easily overcome by combining negatively charged DNA molecules with 
positively charged cationic liposomes which, in turn, form DNA-liposome complexes 
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referred to as genosomes  and have been found to be highly efficient in the process 
of gene transfection (Lasic and Papahadjopoulos, 1998). Figure 2.25 illustrates a 
proposed uptake mechanism for a genosome (also known as a lipoplex). 
 
 
 
Figure 2.25:  DNA-cationic liposome complex (lipoplex/genosome). Lipoplex fusion with cell 
membrane can occur directly or via proteoglycan binding and are endocytosed.  
Maturation of endosomes could then either release DNA contents to be taken 
up by the nucleus or be degraded by endosomal enzymes (Parker et al., 2003). 
 
 
Liposomes, therefore, have immense potential for clinical use but about 20 years ago 
their usefulness was met by skepticism over what Lasic and Papahadjopoulos (1998) 
refer to as the “triple S”, namely, scale-up, stability and sterility. These problems 
have been, in most part, solved, with production batches of over 100 L being 
manufactured reproducibly with a high degree of stability in either the liquid or 
freeze-dried form. With regards to sterility, small unilamellar vesicles are easily 
sterilized through 0.2 m sterile filters and larger liposomes have been successfully 
manufactured using aseptic conditions (Lasic and Papahadjopoulos, 1998). 
Therefore, as we enter an age where over regulation of the pharmaceutical industry 
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makes the introduction of new drug compounds increasingly difficult (Jones, 2005), 
possible solutions to the health care problems we are facing may be re-formulating 
currently approved drugs into novel, highly selective, drug delivery systems such as 
liposomes. 
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CHAPTER 3:  METHODOLOGY 
 
3.1 PHYSICOCHEMICAL CHARACTERIZATION OF CYCLO(HIS-GLY) AND CYCLO(HIS-
ALA) 
3.1.1 Log P and TPSA determination 
The cyclic dipeptides cyclo(His-Gly) and cyclo(His-Ala) were obtained in their pure 
form from Bachem (Bubendorf, Switzerland). Log P for both cyclo(His-Gly) and 
cyclo(His-Ala) was determined using the standard octanol/water partitioning assay 
(Sangster, 1997). A 50% mixture of octanol in water (200 ml of each) was prepared 
and allowed to equilibrate at 25 +/- 0.2 C for 48 hours prior to testing. A volume of 5 
ml of the upper octanol phase was mixed with 5 ml of the lower water phase in a 25 
ml conical flask. According to Sangster (1997), determination of Log P using this 
method may result in concentration-dependant differences in the calculated Log P as 
an increase in solute concentration can facilitate more significant solute-solute 
interactions, potentially resulting in greater deviation from Henry’s law. Therefore 
two determinations were conducted by dissolving either 10 mg or 50 mg of the cyclic 
dipeptide in the water phase prior to combining with the octanol. All determinations 
were conducted in triplicate. The mixtures were stirred at approximately 100 rpm 
using a magnetic stirrer at 25 +/- 0.2 C for 48 hours before determining the 
concentration of the upper (octanol) and lower (aqueous) phases using UV 
spectroscopy. Temperature was maintained strictly as described above in order to 
reduce temperature-dependent differences in Log P, as significant differences have 
been noted in octanol/water partitioning with relatively small differences in 
temperature (Leo et al., 1971) and temperature was therefore maintained with a 0.2 
C tolerance throughout the incubation period using a Binder KBF240 climatic 
chamber (Binder GmbH, Tuttlingen, Germany).  
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Calibration curves were established for both cyclic dipeptides in water and octanol at 
220 nm in order to quantify the cyclic dipeptides in either the water or octanol 
phase. A stock solution of 1 mg/ml of each of the drugs was prepared in both water 
and octanol that had been equilibrated together as a 1:1 mixture at 25 C. Dilutions 
of the stock solution in either water or octanol was done as such that a 
concentration range of 1.6 g/ml to 100 g/ml was tested. A calibration curve was 
established for each compound in each solvent and the linearity determined using 
linear regression analysis with linearity being defined as a correlation coefficient (r2) 
being greater than 0.999. The calibration data used for the determination of cyclic 
dipeptide content in both solvents is shown below in Figures 3.1 to 3.4.  
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Figure 3.1:  Calibration curve for cyclo(His-Gly) in octanol (n = 3 for each point, r2 = 0.9991, 
y = 0.01661x + 0.04024). 
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Figure 3.2:  Calibration curve for cyclo(His-Gly) in water (n = 3 for each point, r2 = 0.9990, y 
= 0.01638x + 0.02271). 
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Figure 3.3:  Calibration curve for cyclo(His-Ala) in octanol (n = 3 for each point, r2 = 0.9992, 
y = 0.01167x + 0.005057). 
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Figure 3.4:  Calibration curve for cyclo(His-Ala) in water (n = 3 for each point, r2 =0.9987, y 
= 0.008175x + 0.02134). 
 
Samples removed from the equilibrated water/octanol mixtures were diluted 1:1 for 
octanol and 1:50 for water before the absorbance was read at 220 nm on a Shimadzu 
1600 spectrophotometer (Shimadzu, Tokyo, Japan). The concentrations determined 
from the linear equation of the standard curves were used to calculate the actual 
concentration in each of the phases in order to determine the Log P according to the 
equation below (Sangster, 1997): 
 
Log P = Log  
*cyclic dipep de+octanol
*cyclic dipep de+water
  
 
The log P values determined experimentally were compared with values calculated 
using the Log P function of the software package ACD/ChemSketch Version 12.01. 
Log P values calculated using this software were -1.093 for cyclo(His-Gly) and -1.264 
for cyclo(His-Ala). 
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Topological polar surface area (TPSA) is an effective calculation for the prediction of 
drug transport characteristics of molecules and is far simpler to calculate than 3-
dimension polar surface areas (3-D TPA). It is based on a list of values assigned to 
functional groups found within a molecule that when added, give a prediction of the 
ability of molecules to be transported through lipid membrane and, when used in 
conjunction with Log P, can be a effective predictor of drug bioavailability, where the 
higher the TPSA value, the lower the ability to cross biological membranes (Ertl et al., 
2000).  
Table 3.1:  Contribution of functional groups to the calculation of topological polar surface 
area (Ertl et al., 2000). 
Atom typea PSA contribution Atom typea PSA contribution  
*N+(−*)(−*)−*  3.24  [nH](:*):*  15.79  
*N+(−*) *  12.36  [n+](:*)(:*):*  4.10  
[N]#*  23.79  [n++(−*)(:*):*  3.88  
*N+(−*)( *) * b  11.68  [nH+](:*):*  14.14  
[N]( *)#* c  13.60  *O+(−*)−*  9.23  
*N+1(−*)−*−*−1d  3.01  *O+1−*−*−1d  12.53  
*NH+(−*)−*  12.03  [O] *  17.07  
*NH+1−*−*−1d  21.94  *OH+−*  20.23  
[NH] *  23.85  [O−+−*  23.06  
[NH2+−*  26.02  [o](:*):*  13.14  
[N++(−*)(−*)(−*)−*  0.00  *S+(−*)−*  25.30  
[N++(−*)(−*) *  3.01  [S] *  32.09  
[N++(−*)#* e  4.36  *S+(−*)(−*) *  19.21  
[NH++(−*)(−*)−*  4.44  *S+(−*)(−*)( *) *  8.38  
[NH++(−*) *  13.97  *SH+−*  38.80  
[NH2
++(−*)−*  16.61  [s](:*):*  28.24  
[NH2
+] *  25.59  [s]( *)(:*):*  21.70  
[NH3
++−*  27.64  *P+(−*)(−*)−*  13.59  
[n](:*):*  12.89  *P+(−*) *  34.14  
[n](:*)(:*):*  4.41  *P+(−*)(−*)(−*) *  9.81  
*n+(−*)(:*):*  4.93  *PH+(−*)(−*) *  23.47  
[n]( *)(:*):* f  8.39      
a
 An asterisk (*) stands for any non-hydrogen atom, − for a single bond, for a double bond, # for a triple bond, : for an 
aromatic bond; atomic symbol in lowercase means that the atom is part of an aromatic system.
b
 As in nitro group.
c
 Middle 
nitrogen in azide group.
d
 Atom in a three-membered ring.
e
 Nitrogen in isocyano group.
f
 As in pyridine N-oxide. 
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3.1.2 Stability at physiological pH 
The stability of solutions of cyclo(His-Gly) and cyclo(His-Ala) was investigated at 
physiological pH at various temperatures in order to predict the potential shelf life of 
liposomal suspension containing these agents. Solutions containing 1 mg/ml of either 
cyclic dipeptides were prepared in phosphate buffered saline (PBS) (pH 7.4) and 
stored under various conditions as outlined in Table 3.2 below. 1 ml samples of the 
dissolved cyclic dipeptides were prepared in triplicate for each storage condition, 
sealed and left at the various temperatures for a period of four weeks. 100 l 
samples were drawn at t = 0, 1, 2, 3 and 4 weeks and analysed for content using the 
stability-indicating HPLC method developed (Section 3.2.1.1 below). Samples were 
prepared for analysis by diluting the 100 l sample to 1 ml with PBS (pH 7.4). The 
solution was then filtered through a 0.45 m pore size hydrophilic PVDF filters 
(Millex-HV, Millipore, Billerica, USA) prior to analysis. Results were calculated as a 
mean concentration in mg/ml and graphs of concentration as a function of time (C vs 
t), reciprocal concentration as a function of time (1/C vs t) and natural logarithm of 
concentration as a function of time (lnC vs t) were constructed for each storage 
condition. The highest degree of linearity for a particular graph would be an 
indication of the reaction kinetics of the degradation of the cyclic dipeptides, where a 
linear relationship between concentration and time indicates zero order kinetics, 
between reciprocal concentration and time represents second order kinetics and 
natural logarithm and time represents first order reaction kinetics. The Arrhenius 
equation and Arrhenius plot was then used to extrapolate the results from the 
accelerated storage conditions to those likely to be used during storage (namely, 5 C 
and 25 C).  
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Table 3.2:  Stability storage protocol for the testing of cyclo(His-Gly) and cyclo(His-Ala). 
Storage Condition Sampling Interval Total Duration 
45 C 7 days 8 weeks 
60 C 7 days 4 weeks 
70 C 7 days 4 weeks 
Sonication in a sonic bath 15 minute cycles  4 cycles 
 
 
3.2  LIPOSOME PREPARATION 
3.2.1 Analytical methods 
3.2.1.1 HPLC assay of cyclo(His-Gly) and cyclo(His-Ala) 
A stability-indicating high performance liquid chromatography (HPLC) method for the 
quantification of cyclo(His-Gly) and cyclo(His-Ala) was developed on a Shimadzu 
LC2020 analytical liquid chromatography system fitted with a photodiode array (PDA) 
detector (Shimadzu, Tokyo, Japan). This method was utilized for quantification of 
both the cyclic dipeptides in liposome formulations as well as stability and 
physicochemical studies. 
 
As stated by Lucietto (2004),  one of the major challenges in the effective 
chromatographic separation of cyclo(His-Ala) and cyclo(His-Gly) was due to their 
relatively high water solubility, limiting their retention on lipophilic stationary phases 
such as C8 and C18 modified silica packings. In his study, he used a chirobiotic 
column to effectively separate these two compounds, however, the expense of this 
type of silica packing make it non-ideal in routine analysis. Therefore, in order to 
attain effective retention and separation, a stationary phase of amine-modified silica 
was used, and the pH of the mobile phase adjusted to pH 3.0 in order to keep the 
analytes in their unionized, more lipophilic, form. The stationary phase therefore 
consisted of a Luna NH2 column (with dimensions of 250 mm × 4.6 mm) with 5 m 
diameter packing (Phenomenex, Torrance, USA). The mobile phase comprised of 
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acetonitrile (65%) in 50 mM phosphate buffer (pH 3.0). A flow rate of 1.5 ml/min was 
used for analysis with an injection volume of 20 l. All samples were prepared for 
analysis in phosphate buffered saline (pH 7.4). 
 
Validation of an analytical method is essential in ensuring reliable and reproducible 
results, and in terms of quantification of analytes using HPLC, it is recommended that 
parameters such as precision, accuracy, linearity, ruggedness, limit of detection, limit 
of quantitation, selectivity and specificity are determined during the validation (Van 
Iterson, 2005). In order for the method to be used in the quantification of both cyclic 
dipeptides in formulations and in determining stability of the CDP, it was validated 
for precision, accuracy, linearity, selectivity and specificity. Ruggedness was not 
evaluated as only one analyst, instrument and column would be used during the 
study, making the need for the determination of inter-analyst and inter-instrument 
variation redundant.  
 
Precision and accuracy are often confused by analysts when performing validations 
and, in some cases, the analyst will determine both parameters together. Precision is 
the ability of an analytical method to deliver reproducible results, while accuracy is 
the ability of the method to accurately determine a concentration close to the actual 
concentration, the difference between which is illustrated in Figure 3.5 (Van Iterson, 
2005).  
 
Precision was determined by the injection of 10 samples of a solution of each of the 
CDPs in a homogenous solution. The standard deviation of the responses for each 
injection were determined and used to calculate the relative standard deviation. 
Table 3.3 displays precision data for the 10 injections indicating that the percent 
relative standard deviation for cyclo(His-Gly) (0.182%) and cyclo(His-Ala) (0.413%), 
was within acceptable limits of less than 2% (Van Iterson, 2005). 
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Figure 3.5:  Differentiation between precision and accuracy of an analytical method. The 
actual concentration in this example is 2.5 units with an acceptable range of 
2.4 – 2.6 units (Adapted from Van Iterson (2005)) 
 
 
Table 3.3:  Precision data for cyclo(His-Gly) and cyclo(His-Ala). Replicate values represent 
the response of area under the curve at a wavelength of 220 nm. 
Analyte Cyclo(His-Gly) Cyclo(His-Ala) 
Replicate 
Responses 
1759755 1762725 2008133 1981503 
1764045 1759755 1985151 1994271 
1754640 1764540 1986610 1990075 
1763715 1759425 1980043 1984968 
1763880 1764705 1983874 1983874 
Mean 
Response 
1761719 1987850 
Standard 
Deviation 
3249.611 8216.238 
%RSD 0.184% 0.413% 
 
Accuracy was determined by triplicate injections of three different concentrations 
within the linearity range. Deviation of the concentrations determined by the assay 
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and the actual values were calculated as a percentage and had to be within 2% of 
each other. Table 3.4 shows data for accuracy, indicating that no response showed 
more than a 1% deviation in terms of recovery, indicating that the method has a high 
degree of accuracy.  
 
Table 3.4:  Accuracy data for the analysis of cyclo(His-Gly) and cyclo(His-Ala). 
Actual  
[CDP]  
(mg/ml) 
Cyclo(His-Gly) Cyclo(His-Ala) 
Measured 
[CDP] (mg/ml) 
% Deviation 
Measured 
[CDP] (mg/ml) 
% Deviation 
0.1 
0.10412 0.412% 0.10107 0.107% 
0.10110 0.110% 0.09913 0.087% 
0.10213 0.213% 0.10017 0.017% 
0.25 
0.25151 0.604% 0.25223 0.892% 
0.25841 0.110% 0.25114 0.456% 
0.24974 0.213% 0.24979 0.084% 
0.5 
0.50412 0.824% 0.49564 0.872% 
0.50201 0.402% 0.49675 0.650% 
0.49874 0.252% 0.49891 0.218% 
 
Linearity was determined by the preparation of a stock solution of 0.5 mg/ml 
(defined as 100%) and dilutions of the stock solution to final concentrations of 0.375 
(75%), 0.25 (50%), 0.125 (25%), 0.06025 (12.5%) and 0.03125 mg/ml (6.25%) 
prepared in reverse osmosis (RO) water and filtered through 23 mm 0.45 m PVDF 
syringe filters (Millex-HV, Millipore, Billerica, USA). Standards were prepared in 
triplicate with triplicate injections performed for each standard. Linear regression 
analysis was conducted to determine linearity and the specification for linearity was 
defined as a correlation coefficient of greater than 0.999. The linear graphs of 
response (peak area) as a function of concentration for both cyclo(His-Gly) (Figure 
3.6) and cyclo(His-Ala) (Figure 3.7) depicted a high degree of linearity (r2 = 0.9996 
and 0.9997 respectively). 
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Figure 3.6:  Standard curve for HPLC determination of cyclo(His-Gly) (n = 3 for each point). 
r2 = 0.9996, y = 1.65×107x + 50190. 
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Figure 3.7:  Standard curve for HPLC determination of cyclo(His-Ala) (n =3 for each point). 
r2 = 0.9997, y = 1.824×107x + 71045. 
 
Another parameter that is evaluated during validation of linearity of an HPLC assay 
method is deviation of the y-intercept from zero. Many different specifications for 
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this parameter exist, but generally, the y-intercept should be less than 2% of the 50% 
response (Ahuja and Dong, 2005). In the linearity graphs, the y-intercept for 
cyclo(His-Gly) is 1.18% of the response for the 50% standard (0.25 mg/ml) and 1.53% 
for cyclo(His-Ala), indicating that deviation from zero for the y-intercept is not 
significant. 
 
Selectivity and specificity was determined by challenging the method with a variety 
of possible degradation products of the cyclic dipeptides. The following scheme 
represents the challenges used in determining specificity: 
 
a) Cyclic dipeptide dissolved in mobile phase. 
b) Linear dipeptide prepared in mobile phase. 
c) Phosphate buffered saline at pH 7.4. 
d) Cyclic dipeptide refluxed at 100 C with 1 M hydrochloric acid for 15 minutes. 
e) Cyclic dipeptide refluxed at 100 C with 1 M sodium hydroxide for 15 minutes. 
f) Cyclic dipeptide refluxed at 100 C with 1 M hydrogen peroxide for 15 
minutes. 
g) Cyclic dipeptide stored at 100 C for 48 hours. 
h) Liposome preparation containing phosphatidylcholine:cholesterol:α-
tocopherol (2:1:0.1), lysed in 10% Triton X-100. 
 
The instrument’s software, LC Solutions, was used to obtain peak purity profiles for 
the cyclic dipeptides using the PDA data, in order to determine if co-elution of 
degradants occurred with the target analyte. The following section shows the 
outcome of the selectivity and specificity determination. 
 
a) Cyclic dipeptide dissolved in mobile phase 
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The chromatogram for cyclo(His-Gly) dissolved in mobile phase (Figure 3.8) shows a 
peak with a retention at 5.3 minutes. The peak shows a good degree of symmetry 
with a peak purity index (as calculated using the PDA data) of 1.0000 (Figure 3.9). 
 
Figure 3.8:  HPLC chromatogram for cyclo(His-Gly) dissolved in mobile phase with a 
retention time of 5.3 minutes. 
 
 
Figure 3.9:  Peak purity profile calculated using PDA data (from 190 – 800 nm) for 
cyclo(His-Gly) prepared in mobile phase. Peak shown in pink and purity curve 
in black. Peak purity index = 1.00000; Single point threshold = 0.999914. 
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The chromatogram for cyclo(His-Ala) dissolved in mobile phase (Figure 3.10), shows a 
peak with a retention time of 3.17 minutes. The peak shows a good degree of 
symmetry with a peak purity index of 0.99997 (Figure 3.11). 
 
Figure 3.10:  HPLC chromatogram for cyclo(His-Ala) dissolved in mobile phase with a 
retention time of 3.17 minutes. 
 
 
Figure 3.11:  Peak purity profile calculated using PDA data (from 190 – 800 nm) for 
cyclo(His-Ala) prepared in mobile phase. Peak shown in pink and purity curve 
in black. Peak purity index = 0.99997; Single point threshold = 0.999317. 
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b) Linear dipeptide prepared in mobile phase. 
A chromatogram of the linear dipeptide, His-Gly, dissolved in mobile phase, is shown 
in Figure 3.12. Retention time for this compound is 11.48 minutes and therefore 
does not interfere with the analysis of cyclo(His-Gly). Analysis of the chromatogram 
for the linear dipeptide, His-Ala, shows elution of the peptide at 11.06 minutes and 
therefore does not interfere with the analysis of cyclo(His-Ala) (Figure 3.13). 
 
 
Figure 3.12:  HPLC chromatogram for the linear dipeptide, His-Gly dissolved in mobile phase 
with a retention time of 11.48 minutes. 
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Figure 3.13:  HPLC chromatogram for the linear dipeptide, His-Ala dissolved in mobile phase 
with a retention time of 10.89 minutes. 
 
 
c) Phosphate buffered saline at pH 7.4. 
The solvent and vehicle for most of the liposome and free CDP solutions was 
phosphate buffered saline. Therefore, in order to determine if there was no 
interference with the analysis, a 20 l injection of the buffer was analysed. Figure 
3.14 displays the chromatogram, showing no interference with either analytes. 
 
 
Figure 3.14:  HPLC chromatogram for the phosphate buffered saline. 
 
 
d) Cyclic dipeptide refluxed at 100 C with 1 M hydrochloric acid for 15 minutes. 
Significant degradation of cyclo(His-Gly) occurred due to acid-catalysed hydrolysis of 
the DKP ring to form the linear dipeptide as was the case for cyclo(His-Ala). Other 
degradation products were also present, but none of which interfered with the 
quantification of the analyte as shown in the chromatograms (Figures 3.15 and 3.16). 
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Figure 3.15:  HPLC chromatogram for cyclo(His-Gly) after undergoing acid reflux for 15 
minutes with 1 M HCl. 
 
 
Figure 3.16:  HPLC chromatogram for cyclo(His-Ala) after undergoing acid reflux for 15 
minutes with 1 M HCl. 
 
e) Cyclic dipeptide refluxed at 100 C with 1 M sodium hydroxide for 15 minutes. 
Base-catalysed breakdown for cyclo(His-Gly) was substantial, with almost complete 
breakdown after 15 minutes. No degradation products were found to interfere with 
the analyte peak (Figure 3.17), as was the case for cyclo(His-Ala) (Figure 3.18). 
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Figure 3.17:  HPLC chromatogram for cyclo(His-Gly) after undergoing alkaline reflux for 15 
minutes with 1 M NaOH. 
 
 
Figure 3.18:  HPLC chromatogram for cyclo(His-Ala) after undergoing alkaline reflux for 15 
minutes with 1 M NaOH. 
 
f) Cyclic dipeptide refluxed at 100 C with 1 M hydrogen peroxide for 15 minutes. 
Reflux of cyclo(His-Gly) with 1 M hydrogen peroxide resulted in formation of the 
linear dipeptide with few other degradation products being observed. No 
interference with the analyte peak was noted (Figure 3.19). The same was true for 
cyclo(His-Ala) (Figure 3.20). 
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Figure 3.19:  HPLC chromatogram for cyclo(His-Gly) after undergoing reflux for 15 minutes 
with 1 M hydrogen peroxide. 
 
 
Figure 3.20:  HPLC chromatogram for cyclo(His-Ala) after undergoing reflux for 15 minutes 
with 1 M hydrogen peroxide. 
 
 
g) Cyclic dipeptide stored at 100 C for 48 hours. 
Analysis of solutions of cyclo(His-Gly) that had undergone forced degradation at 100 
C for 48 hours showed no interference with analyte peaks (Figure 3.21) as was the 
case for samples of cyclo(His-Ala) (Figure 3.22). 
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Figure 3.21:  HPLC chromatogram for cyclo(His-Gly) after undergoing forced degradation at 
100 C for 48 hours.  
 
 
Figure 3.22:  HPLC chromatogram for cyclo(His-Ala) after undergoing forced degradation at 
100 C for 48 hours.  
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after the solvent front. No interference with analyte peaks was noted for either 
cyclo(His-Gly) (Figure 3.23) or cyclo(His-Ala) (Figure 3.24). 
 
 
Figure 3.23:  HPLC chromatogram for cyclo(His-Gly)-containing liposomes after undergoing 
lysis with equal parts of a solution of 10% Triton X-100. 
 
 
Figure 3.24:  HPLC chromatogram for cyclo(His-Ala)-containing liposomes after undergoing 
lysis with equal parts of a solution of 10% Triton X-100. 
 
The analytical method developed, was therefore suitable for the quantification of 
both cyclo(His-Gly) and cyclo(His-Ala) simultaneously in solution or in liposome 
formulations and showed sufficient selectivity and specificity to be used in stability 
studies. 
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3.2.1.2 Phospholipid quantification 
Several methods for quantification of phospholipids were investigated using HPLC, 
TLC and the Stewart colourimetric assay. HPLC analysis could only be conducted on 
non-hydrogenated phospholipids as the lack of double bonds in the hydrogenated 
forms prevents the detection by conventional UV absorbance. HPLC can be 
conducted on hydrogenated phospholipids through the use of an ELDS detector 
which was not feasible for this project. 
 
Quantitative TLC analysis was investigated as a means of quantification of 
phospholipids. The mobile phase consisted of chloroform:methanol:water (65:25:4) 
(Torchilin and Weissig, 2003). Standards of hydrogenated soy phosphatidylcholine 
(HSPC) were prepared in chloroform to final concentrations of 10, 5, 2.5, 1.25 and 
0.625 mg/ml by serial dilution of a stock standard that was prepared by dissolving 50 
mg of HSPC in 5 ml chloroform. Silica gel TLC plates (TLC Silica gel 60 F254, Merck, 
Darmstadt, Germany) were prepared by cutting into it 7 × 10 cm plates and drawing 
a horizontal pencil line, 1 cm from the base of the plate. 10 l of the standard 
solutions were spotted onto the line, 1.5 cm apart and allowed to air dry for 1 hour 
prior to analysis. Plates were developed in chromatography tanks, equilibrated with 
the mobile phase until the solvent front reached 1 cm from the top, removed from 
the tanks and air dried prior to staining. Plates were stained by a 1 sec immersion 
into rhodamine B stain solution and allowed to dry overnight. Scanned TLC plates 
were then analysed using Sorbfil Version 1.0 TLC visualiser software. Figure 3.25 
below shows an example of the chromatogram derived from the TLC plate.  
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Figure 3.25:  Chromatogram derived from the TLC plate using Sorbfil version 1.0 
densitometry software.  
 
The standard curve for phospholipids using this method is shown in Figure 3.26 and 
displayed a near linear relationship with a linear correlation coefficient (r2) of 0.9970. 
The y-intercept for the linear graph was 6.59% of the 50% response, which is higher 
than the recommended 2%. 
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Figure 3.26:  Standard curve for quantitative TLC determination of hydrogenated soy 
phosphatidylcholine (n = 3 for each point). r2 = 0.9970, y = 7467x + 2760. 
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Apart from the difficulty in obtaining reliable standard curve data, it was also noted 
by observation that the tail group of the phospholipid influences the size of the spot 
on the chromatogram and the use of various chain lengths (as would be necessary 
during the optimization phase) would be unlikely to produce accurate results. The 
assay for phospholipid required that quantification of the phospholipid could be 
performed that was only dependent on the head group and not the rest of the 
molecule.   
 
Of the colourimetric assays that rely on interaction with organic phosphates, the 
most extensively reported assays are the Stewart assay (Stewart, 1980) and the 
Bartlett assay (Torchilin and Weissig, 2003). Of these two, the most favoured is the 
Stewart assay, as it only quantifies organic phosphates and not inorganic phosphates 
such as those found in phosphate buffered saline (PBS), which was extensively used 
as a hydration buffer during liposome manufacture. The Stewart assay uses a dye, 
ammonium ferrothiocyanate, which is insoluble in chloroform, but when complexed 
with the phosphate portion of a phospholipid, becomes soluble in chloroform and 
partitions from the aqueous phase into the organic chloroform phase. The 
absorbance of the complex dye, with a λmax of 488 nm, is easily measured using a 
standard UV/VIS spectrometer and is far more rapid than those methods that 
measure inorganic phosphates after a lengthy digestion step (Stewart, 1980). 
 
The Stewart assay was therefore conducted as described previously (Torchilin and 
Weissig, 2003). A solution of ammonium ferrothiocyanate was prepared through the 
reaction of 27.0 g of ferric chloride with 30.4 g of ammonium thiocyanate in 1000 ml  
RO water and the solution freshly prepared on a weekly basis. In order to accurately 
quantify the phospholipids, a calibration curve was prepared using standard 
solutions of phosphatidylcholine in chloroform. A stock solution containing 0.24 
mg/ml of phosphatidylcholine was prepared in chloroform and diluted according to 
the scheme shown in Table 3.5. The assay was performed by the addition of 2.0 ml of 
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chloroform, containing a proportion of phospholipid standard, to 2.0 ml of 
ammonium ferrothiocyanate solution in a 10 ml glass test tube. The mixture was 
vortexed for 15 seconds and centrifuged at 1000 rpm for 5 minutes to separate the 
aqueous phase from the organic phase. The optical density of the lower, organic, 
layer, was read on a spectrophotometer at 485 nm. Standards were triplicated and a 
standard curve constructed. Linear regression analysis was performed, yielding a 
linear correlation coefficient (r2) of 0.9990, which was considered to be linear (Figure 
3.27). Analysis of the y-intercept to determine if the intercept was not significantly 
different from the origin, showed that the y-intercept was 0.69% of the 50% 
response, which is well below the recommended 2% (Ahuja and Dong, 2005). 
 
Table 3.5:  Standard preparation for the determination of phospholipid concentration. 
Tube 
Standard 
Volume * 
Chloroform 
Ammonium 
Ferrothiocyanate 
Phospholipid 
Concentration 
1 0.0 ml 2.0 ml 2.0 ml 0 mg/ml 
2 0.1 ml 1.9 ml 2.0 ml 0.0075 mg/ml 
3 0.2 ml 1.8 ml 2.0 ml 0.015 mg/ml 
4 0.4 ml 1.6 ml 2.0 ml 0.03 mg/ml 
5 0.6 ml 1.4 ml 2.0 ml 0.06 mg/ml 
6 0.8 ml 1.2 ml 2.0 ml 0.09 mg/ml 
7 1.0 ml 1.0 ml 2.0 ml 0.12 mg/ml 
* Standard stock solution containing 0.24 mg/ml phospholipid. 
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Figure 3.27:  Standard curve for colorimetric determination of phospholipids in liposome 
suspensions (n = 3 for each point). r2 = 0.9990, y = 10.71x - 0.00451. 
 
Liposome suspensions were analysed for phospholipid content as follows. 50 l of 
liposome suspension was added to 2 ml of chloroform and vortexed for 30 seconds 
in order to extract the phospholipid from the aqueous suspension. The assay was 
then conducted as discussed above, with the addition of 2 ml ammonium 
ferrothiocyanate, vortex mixing for a further 15 seconds and measurement of the 
absorbance of the lower organic phase at 485 nm. Concentration in the suspension 
was determined from the standard curve and multiplying the concentration of 
phospholipid in the chloroform by the dilution factor (40). 
 
3.2.1.3 Carboxyfluorescein quantification 
Carboxyfluorescein was encapsulated into liposomes as a fluorescent marker in order 
to determine the rate of leakage from liposomes as well as the rate at which 
liposomes are taken up into cells. Determining an effective concentration range at 
which to detect carboxyfluorescein by spectrofluorometric analysis is essential due 
to the self-quenching properties of carboxyfluorescein at high concentrations as a 
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result of the formation of a carboxyfluorescein dimer which is not fluorescent (Chen 
and Knutson, 1988). Therefore it was essential to establish an effective standard 
curve that defined the concentrations detectable within the linear range of the 
standard curve. 
 
5(6)-Carboxyfluorescein (CF) (>95%) (Sigma-Aldrich, St Louis, USA) was purchased as 
fluorescent grade. Several authors report the need to purify CF (Ralston et al., 1981; 
Torchilin and Weissig, 2003) due to interference of contaminants with the 
fluorescence of the compound. However, the CF used in these studies was of 
photographic grade and not pre-purified. In order to ensure purity, however, CF was 
purified through a process of re-crystallisation. This was achieved by dissolving 1 g of 
CF in 100 ml absolute ethanol and stirring at 40 C with a magnetic stirrer for 1 hour 
with 2 g activated charcoal. The warm solution was then filtered through Whatman 
no.1 filter paper and the solvent allowed to evaporate to form purified CF crystals. 
The CF was then prepared in concentrations ranging from 100 mM to 0.1 µM in 
phosphate buffered saline (pH 7.4) by serial dilution. As CF is sparingly soluble at 
acidic pH and its addition to aqueous solutions lowers pH, careful drop wise addition 
of 0.1 M NaOH while monitoring the pH allowed for complete dissolution of the CF 
and returned the pH of the buffer to 7.4. Each concentration was prepared in 
quadruplicate and the fluorescent absorption measured at an excitation of 485 nm 
and an emission of 518 nm using a Fluoroskan Ascent FL microtitre plate 
spectrofluorometer (Thermo Labsystems, Vantaa, Finland).  
 
The self-quenching nature of carboxyfluorescein was clearly noted at the higher 
concentrations and deviation from linearity was noted at concentrations higher than 
0.78 µM as shown in Figure 3.28 below.  
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Figure 3.28:  5(6)-Carboxyfluorescein spectrofluoremetric absorbance at Ex = 485 nm and 
Em = 518 nm, showing self-quenching occurring at concentrations above 100 
µM (n = 4 for each point). 
 
From the above graph, it was determined that the linear range ended at 
approximately 3.125 µM. As insufficient data points were available to determined 
statistically significant linearity in this range, a second concentration standard curve 
was constructed within this range and is shown in Figure 3.29 below. The upper and 
lower limits of detection were determined by finding the concentration range at 
which the linearity coefficient was greater than 0.999. From the data, the upper and 
lower limits of detection within the linear range were defined as 2.5 µM and 15.625 
nM respectively. All samples assayed for carboxyfluorescein had to, therefore, be 
diluted to be within this range for accurate quantification. 
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Figure 3.29:  Standard curve for the quantification of 5(6)-carboxyfluorescein. r2 = 0.9994, 
linear equation: y = 2.249x + 53.37 (n = 4 for each point). 
 
3.2.1.4 Measurement of membrane leakage 
The quantity of drug released from the liposomes was measured using 
carboxyfluorescein as an example of a hydrophilic drug. Carboxyfluorescein is ideal 
for the measurement of drug release from liposomes, as concentrations entrapped 
within the liposome core are high and result in self-quenching of the fluorescence of 
carboxyfluorescein (Torchilin and Weissig, 2003). Release rates of carboxyfluorescein 
from liposome preparations were determined as previously described (Kirby et al., 
1980). Liposomes hydrated with 100 mM carboxyfluorescein at pH 7.4 and prepared 
as described in Section 3.2.4.1 were separated from free carboxyfluorescein through 
gel filtration using Sephadex G50 (Sigma-Aldrich, St Louis, USA) hydrated in PBS pH 
7.4. The detailed process of separation of free drug from encapsulated drug using gel 
filtration is described in detail below (Section 3.1.3.5). 20 l of liposome dispersion 
separated from free carboxyfluorescein was immediately transferred to the well of a 
96 well black microtitre plate along with 50 l PBS pH 7.4 and 50 l foetal calf serum. 
The fluorescence was measured at an excitation wavelength of 485 nm and an 
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emission wavelength of 518 nm using a Fluoroskan Ascent FL microtitre plate 
spectrofluorometer (Thermo Labsystems, Vantaa, Finland). Measurements were 
taken every 30 minutes for four hours, after which, 50 l of a 10% Triton X-100 
solution in PBS was added to each well in order to digest the liposome membranes 
and release the remainder of the entrapped carboxyfluorescein. The fluorescence 
was measured once more in order to determine the total carboxyfluorescein present 
and the % carboxyfluorescein released calculated at each time point as a percentage 
of the total. 
 
3.2.1.5 Determination of encapsulation efficiency 
Separation of encapsulated drug from free drug can often be a challenge, as the size 
of the particles is too small to effectively sediment using conventional centrifugation 
(Rosier et al., 1979). In order to enable sedimentation through centrifugation, 
aggregation of particles, effectively increasing their size, and therefore increasing 
their rate of sedimentation, was the approach taken. Protamine was used as an 
aggregating agent and a solution of protamine from salmon origin (Sigma-Aldrich, St 
Louis) at a concentration of 10 mg/ml in phosphate buffered saline (PBS) (pH 7.4) 
was added in equal volume to liposome suspensions and incubated at 37 C for 15 
minutes to facilitate aggregation as previously described (Torchilin and Weissig, 
2003). On closer inspection of samples, it was noted, however, that the supernatant 
was still turbid, indicating inadequate separation of the liposomes from suspending 
medium. As the hydrating solution consisted of phosphate buffered saline at pH 7.4, 
it was investigated whether pH could possibly influence the aggregation reaction. 
Using a Malvern Zetasiser Nano ZS (Malvern Instruments Ltd., Worcestershire, UK) 
fitted with a MPT-2 autotitrator, particle size was determined as a function of pH. 
The autotitrator made use of 0.1 and 0.01 N HCl and 0.1 N NaOH to adjust the pH 
from the range of 3.0 to 9.0, making triplicate measurement of particle size at pH 1.0 
intervals. 200 l of liposome suspension, containing phosphatidylcholine, cholesterol 
and stearylamine in a molar ratio of 75:35:2, was added to 10 ml PBS and analysed 
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for particle size as a function of pH. Determinations were performed in triplicate. In 
the same manner the particle size of a mixture of 200 l liposome suspension, 200 l 
protamine (10 mg/ml) and 10 ml PBS was also analysed as a function of pH in 
triplicate. Figure 3.30 shows the results of this investigation, clearly demonstrating 
that higher pH encourages the aggregating action of protamine. 
 
 
Figure 3.30:  Influence of pH on the aggregation of particles in the absence () and 
presence () of protamine. 
 
 
Encapsulation efficiency of liposome suspensions was therefore carried out 
according to a modified protamine aggregation method (Rosier et al., 1979; Torchilin 
and Weissig, 2003). In order to determine free cyclic dipeptide in liposome 
suspensions, 50 l of suspension was added to a 1.5 ml polypropylene 
microcentrifuge tube, to which was added 50 l of protamine solution (10 mg/ml) 
and 100 l 1 mM NaOH solution. The mixture was vortex mixed for 10 seconds and 
then incubated at 37 C for 15 minutes. After incubation, 800 l PBS (pH 7.4) was 
added to the mixture and vortexed for another 15 seconds. The mixture was then 
centrifuged at 10 000 rpm for 15 minutes in a Hermle Z300 universal centrifuge 
(Hermle Labortechnik, Wehingen, Germany), fitted with a V03 1.5/2.0 ml 
microcentrifuge rotor. The supernatant was extracted and filtered through a 23 mm 
0.45 m pore size hydrophilic PVDF syringe filter (Millex-HV, Millipore, Billerica, USA) 
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into a 1.5 ml glass HPLC vial and analysed for cyclic dipeptide content using the 
validated method described above. All samples were prepared in triplicate with 
triplicate injections for each. 
 
Total concentration of cyclic dipeptide in each suspension was determined through 
liposome breakdown using the surfactant, Triton X-100. 50 l of liposome suspension 
was transferred to a 1.5 ml polypropylene microcentrifuge tube, to which was added, 
50 l of a 10% v/v solution of Triton X-100 (Sigma-Aldrich, St Louis, USA) in PBS (pH 
7.4) as well as 100 l 1 mM NaOH solution. The mixture was votex mixed for 10 
seconds and incubated at 37 C for 15 minutes to facilitate the detergency action of 
the surfactant. Liposome suspensions were inspected visually and successful lysis of 
liposomes was viewed as conversion of a turbid suspension into a clear solution. 
After incubation, 800 l PBS (pH7.4) was added to each tube and vortexed mixed for 
a further 15 seconds. Samples were filtered through a 23 mm 0.45 m pore size 
hydrophilic PVDF syringe filter (Millex-HV, Millipore, Billerica, USA) into a 1.5 ml glass 
HPLC vial and also analysed for cyclic dipeptide content using the validated method 
described above. All samples were prepared in triplicate with triplicate injections for 
each. 
 
Direct measurement of liposomal cyclic dipeptide content was also measured to 
validate the procedure described above. Liposomes were separated from free cyclic 
dipeptide using gel exclusion chromatography. SigmaPrep spin columns (Sigma-
Aldrich, St Louis, USA) were loaded with 1 ml Sephadex G50 gel exclusion media, 
equilibrated with excess PBS (pH7.4) for at least 24 hours at 25 C prior to analysis. 
Excess PBS was removed by centrifuging the columns at 5000 rpm for 5 minutes. 100 
l of liposome suspension was applied to the top of the column and centrifuged 
again at 5000 rpm for 5 minutes. The elute contained only liposomes while the free 
cyclic dipeptide was retained on the column. Validation of this procedure was 
conducted by applying a solution of cyclic dipeptide, of the same concentration as 
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the total concentration of cyclic dipeptide in the liposome suspension, to the column 
and analyzing the eluted solution using the validated HPLC assay method descried 
above. Less than 2% of cyclic dipeptide passed through the column, indicating a high 
retention ability of the column for free cyclic dipeptide. Liposome suspensions 
passed through the columns were then analysed for lipid content using the Stewart 
assay and the cyclic dipeptide measured in the same manner as for total content 
described above, using a 10% solution of Triton X-100 to lyse liposomes and 
measurement of drug content using HPLC. 
 
Encapsulation efficiency was calculated as a ratio of drug encapsulated to lipid 
content. Therefore all samples were also analysed for phospholipid content using the 
Stewart phospholipid assay described above. The ratio of drug:lipid was therefore 
calculated indirectly and directly. Indirectly encapsulation was determined by 
relating free and total cyclic dipeptide concentration with phospholipid 
concentration according to the following equation: 
 
Encapsula on E ciency ndirect =   Total   Free  /*Lipid  
 
 
Direct encapsulation was determined according to the following equation: 
 
Encapsula on E ciencyDirect =   Encapsulated  /*Lipid  
 
An average of the two calculated values was used as the encapsulation efficiency 
expressed as mg cyclic dipeptide encapsulated per mg lipid. Differences calculated 
between the indirect and direct measurements were never greater than 5%. 
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3.2.1.6 Particle size analysis and zeta potential measurement 
Particle size and zeta potential of liposomes was determined using a Malvern 
Zetasizer Nano ZS particle size analyser (Malvern Instruments GmbH, Herrenberg, 
Germany). Samples were prepared by dispersing 50 l of liposome suspension in 1 
ml phosphate buffered saline (pH 7.4) filtered through a 23 mm 0.2 m pore size 
hydrophilic PVDF syringe filter. Samples were loaded into clear, disposable, folded 
capillary cells and analysed for both particle size and zeta potential at 25 C. For 
particle size, the instrument was set to automatically determine attenuator level, 
measurement position and number of sub-runs based on correlation data and all 
measurements were performed in triplicate. 
 
Zeta potential measurements were also performed in triplicate for each sample at 25 
C and the attenuator setting and number of sub-runs was automatically determined 
by the instruments according to phase plot data. 
 
3.2.1.7 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) was used to visualize formed liposomes for 
shape and structure. A JEOL JEM 1210 transmission electron microscope (Tokyo, 
Japan) was used to record micrographs of liposomal suspensions according to the 
method adapted from Wei and Smith (1994).  
 
A 1% Agarose solution was prepared by dissolving 0.5 g agarose (Sigma Aldrich, St 
Louis, USA) in 50 ml reverse-osmosis water with gentle heat in a beaker until 
dissolved. The molten agarose gel was poured into polystyrene petri dishes and 
allowed to air dry until set. Formvar®-coated copper grids were made hydrophilic by 
glow discharge and placed on a Whatman No. 1 filter paper. One drop of the 
liposome suspension was dropped onto the grid, and once the excess liquid had 
drained off onto the filter paper, the grid was transferred to the agarose gel to 
remove excess moisture and allow for salt diffusion prior to recording of images. 
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3.2.1.8 Lipid peroxidation 
The degree of lipid peroxidation was determined according to a method modified 
from Huang and colleagues (1998) where the formation of a product of lipid 
peroxidation, malondialdehyde (MDA) is reacted with 2-thiobarbituric acid (TBA) to 
form a MDA-TBA complex that can be measured spectrophotometrically. The degree 
of peroxidation of phospholipids was investigated after the addition of a solution of 
hypochlorite to the suspensions in order to determine the degree to which the lipids 
are susceptible to degradation.  
 
Liposome suspensions all contained varying amounts of phospholipids which would 
make comparison difficult and they were therefore standardized to a uniform lipid 
content of 0.5 mg/ml through the dilution of the suspensions with PBS (pH 7.4). 100 
l of the diluted liposome suspension was added to a 1.5 ml Eppendorf tube, to 
which was added, 50 l of a solution of 1.44 mM sodium hypochlorite (NaOCl) in 145 
mM NaCl. The solution was incubated at 37 C for 1 hour before stopping the 
reaction with the addition of 450 l of a 1% phosphoric acid solution containing 0.5 
mM EDTA. 150 l of a 0.5% TBA solution was added to the tube and the mixture 
incubated at 100 C for 45 minutes. The mixture was cooled through the addition of 
750 l ice cold (4 C) n-butanol. The mixture was vortexed for 30 seconds on high 
and the upper n-butanol phase was separated from the aqueous phase by 
centrifugation at 1500 rpm for 15 minutes. The absorbance of the upper n-butanol 
phase was measured at 532 nm, using pure n-butanol as a blank. The concentration 
of the MDA-TBA complex was determined from the absorbance assuming that the 
molar extinction coefficient for this complex is 1.56 × 105 M-1.cm-1 (Huang et al., 
1998). All assays were performed in triplicate. 
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3.2.2 Liposome preparation and optimization 
3.2.2.1 Basic liposome preparation technique 
Liposomes were manufactured using the thin-film hydration method extensively 
described by others (Berger et al., 2001; Torchilin and Weissig, 2003; Mura et al., 
2007). Phospholipids with varying concentrations of cholesterol and α-tocopherol, as 
outlined in Section 3.2.2.2 below, were dissolved in 10 ml of a 9:1 mixture of 
chloroform and methanol and transferred to a 50 ml round bottomed flask. The 
solvent was then evaporated on a rotary evaporator (Büchi RE111 or R210, Büchi 
Labortechnik AG, Flawil, Switzerland) under vacuum at 50 °C for at least 3 hours. 
Remaining solvent was removed by flushing the film with nitrogen and the film kept 
under vacuum overnight. Once dried, lipid films were stored at -20 °C under nitrogen 
until hydrated. Prior to use, lipid films were inspected in terms of homogeneity and 
to ensure that no aggregates of lipids formed on the walls of the flask. 
 
Lipid films formed were hydrated at 60 °C with a solution containing cyclic dipeptide 
or 5,6-carboxyfluorescien (CF) in phosphate buffered saline at pH 7.4 in a shaking 
water bath for three hours. Once hydrated, the multilamellar liposomes formed were 
extruded 13 times through a 100 nm pore polycarbonate membrane filter 
(Nuclepore) using an extruder (Avanti Polar Lipids, Alabaster, USA). The small 
unilamellar vesicles (SUV) formed were then stored at 4 °C overnight prior to use. 
 
The number of extrusions through the filter was determined by analyzing the particle 
size every two passes to a total of 19 passes. Optimal particle size range was 
between 100 and 150 nm. The effect extrusion passes on particle size distribution is 
illustrated in Figure 3.31 while the effect on mean particle diameter and 
polydispersity index is shown graphically in Figure 3.32. Initial extrusion passes (1 to 
5 passes) shows clear bimodal distribution, and as progression of the extrusion 
process occurs, the distribution narrows. The optimum number of extrusion passes 
94 
 
was therefore defined as 15 passes through the 0.1 m pore size polycarbonate 
filter. 
 
 
 
Figure 3.31:  Influence of number of extrusion passes on particle size distribution of 
liposomes composed of phosphatidylcholine, cholesterol and stearylamine 
(69:30:1).  
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Figure 3.32:  Influence of number of extrusion passes on mean particle diameter and 
polydispersity index for liposomes composed of phosphatidylcholine, 
cholesterol and stearylamine (69:30:1). 
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Just prior to use, liposomes were separated from free drug by size exclusion 
chromatography. Sephadex G50 gel was hydrated in phosphate buffered saline for at 
least 24 hours prior to use. The barrel of a 10 ml disposable syringe was plugged with 
a small quantity of glass wool and filled with the hydrated Sephadex G50. The barrel 
was placed into a 15 ml centrifuge tube and centrifuged at 5000 rpm for 5 minutes to 
remove excess buffer. 500 µl of the liposome suspension was carefully loaded into 
the centre of the gel bed and centrifuged at 2000 rpm for a further 10 minutes. The 
elute, containing only liposomes, was retained for use in experiments. 
 
A process diagram for the preparation procedure is shown in Figure 3.33 below. 
Phosphatidylcholine
(PC)
Cholesterol
(CHOL)
α-Tocopherol
(α-TP)
Chloroform/Methanol 
9:1 (10 ml)
Rotary evaporation under 
vacuum (3 hours @ 60 °C)
Thin Lipid Film
Flushed with nitrogen to 
remove solvent traces
Drug Solution
Hydrate at 60 °C in a shaking 
water bath (3 hours)
Large Multilamellar 
Vesicles (LMV)
Extrusion 15 times through 0.1 
µm pore polycarbonate 
membrane filter (60 °C).
Small Unilamellar 
Vesicles (SUV)
Removal of free drug by gel 
filtration (Sephadex G50)
Purified SUVs
Stearylamine
(SA)
 
Figure 3.33:  Process diagram for liposome preparation. 
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3.2.2.2 Experimental Design 
Two experimental protocols were developed in order to optimize the formulation of 
the liposomes. The first screening study was developed in order to determine the 
critical formulation parameters to be used in the optimization design. 
 
A preliminary screening design was conducted using a 25-1 fractional factorial design. 
A fractional factorial design was used in order to minimize experimentation during 
the screening phase of the study as the aim was simply to determine which of the 
five parameters chosen would be manipulated during the optimization phase.  
Results from preliminary formulations as well as a search of the literature identified 
five formulation parameters that would be considered during the screening phase. 
These parameters included: degree of phospholipid hydrogenation (HSPC content), 
cholesterol content, stearylamine content (indicative of surface charge), α-
tocopherol content and PEG modified phospholipid content. Two levels for the five 
factors were set according to results of preliminary investigations and from literature 
and are outlined in Table 3.6 below. 
Table 3.6:  Formulation parameters and levels for preliminary screening of liposome 
formulations using a 25-1 fractional factorial design. 
Parameter 
Parameter 
Code 
Low Level (-1) High Level (+1) 
HSPC content X1 0% 100% 
Stearylamine content X2 0% 5% 
α-tocopherol content X3 0% 3% 
Cholesterol content  X4 20% 50% 
PEG2000-PE content X5 0% 2% 
 
The study was designed to include five replicates at the centre points in order to 
increase the statistical power of the design, and a list of 21 experimental runs was 
generated using the statistical software package, Design-Expert version 8.0.1 (Stat-
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Ease Inc., Minneapolis, USA). Table 3.7 outlines the full experimental design with 
randomized run order. 
Table 3.7:  Experimental run for screening of liposome formulations using a 25-1 fractional 
factorial design. 
Experiment Sequence 
Factors 
HSPC (%) 
Stearylamine 
(%) 
α-tocopherol 
(%) 
Cholesterol 
(%) 
PEG2000-PE (%) 
14 1 100 0 3 50 0 
10 2 100 0 0 50 2 
1 3 0 0 0 20 2 
5 4 0 0 3 20 0 
12 5 100 5 0 50 0 
8 6 100 5 3 20 0 
17 7 50 2.5 1.5 35 1 
21 8 50 2.5 1.5 35 1 
2 9 100 0 0 20 0 
20 10 50 2.5 1.5 35 1 
7 11 0 5 3 20 2 
13 12 0 0 3 50 2 
15 13 0 5 3 50 0 
16 14 100 5 3 50 2 
3 15 0 5 0 20 0 
19 16 50 2.5 1.5 35 1 
4 17 100 5 0 20 2 
18 18 50 2.5 1.5 35 1 
9 19 0 0 0 50 0 
6 20 100 0 3 20 2 
11 21 0 2.5 0 50 2 
 
 
Formulations were tested with regards to the encapsulation efficiency and 
susceptibility to lipid peroxidation as described above and the data analysed to 
determine which factors were critical to the formulation. 
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Based on the results of the screening study, two critical factors were identified that 
showed interactive effects and were selected as the two parameters to be included 
in the optimization phase. These two parameters included stearylamine content as 
well as cholesterol content. The other three factors showed similar trends in 
encapsulation and stability towards peroxidation with little to no interactive effects. 
Levels of these parameters were therefore set at either the high (+1), low (-1) or mid-
point (0) depending on their optimal responses. 
 
In order to optimize the liposome formulation, response surface methodology (RSM) 
was employed as a statistical tool for design and analysis. RSM, using a central 
composite rotatable design (CCRD) was used for the two factors, stearylamine 
content (X1) and cholesterol content (X2) which ultimately resulted in five levels for 
each factor. The design was developed such that there were two replicates at the 
four factorial points, four axial points and six replicated centre points. A graphically 
representation of a central composite design is shown in Figure 3.34, indicating how 
the factorial, axial and centre points relate to each other (Myers et al., 2009).  
 
(-1,1)
(0,0)
(1;1)
(1;-1)
(-1;-1)
(-α,0)
(α,0)
(0,-α)
(0,α)
X1
X2
 
Figure 3.34:  Schematic design space for central composite design showing how axial (red), 
factorial (blue) and centre points (yellow) relate to each other. Values in 
brackets represent coordinates (X1, X2) (Myers et al., 2009). 
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Alpha is generally accepted to be the square root of the number of factors (Anderson 
and Whitcomb, 2005), which in the case of this study, would be 1.414. In order to 
simplify the levels of each factor, an alpha value of 1.5 was chosen to define the axial 
points. A summary of the factors and their levels is shown in Table 3.8. 
 
Table 3.8:  Factors and levels for RSM design.  
Factor Name Units Type -α +α -1 +1   S 
X1 (A) Stearylamine % 
Continuous 
Numeric 
0.5 3.5 1 3 2 0.833 
X2 (B) Cholesterol Content % 
Continuous 
Numeric 
12.5 57.5 20 50 35 12.5 
α = alpha (1.5),   = mean (centre point), s = standard deviation 
 
The final design yielded a total of 18 experiments (inclusive of replicates at the 
factorial and centre points). The following design table (Table 3.8) clearly illustrates 
the factors and their levels. Quantities of stearylamine and cholesterol were 
calculated as a molar percentage of the total lipid (50 mol). 
 
Evaluation of the design was performed prior to experimentation according to a 
polynomial model. Table 3.10 displays the evaluation results for the model, with low 
predicted standard error and variance inflation factors (VIFs) close to 1. High VIFs are 
an indication of a lack of orthogonality of the design, resulting in a higher standard 
error, which is undesirable (Anderson and Whitcomb, 2005).  
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Table 3.9:  RSM design using central composite design (alpha = 1.5) 
Experiment Sequence Stearylamine (%) Cholesterol (%) 
12 1 2 57.5 
2 2 1 20 
10 3 3.5 35 
16 4 2 35 
5 5 1 50 
14 6 2 35 
9 7 0.5 35 
1 8 1 20 
7 9 3 50 
6 10 1 50 
3 11 3 20 
13 12 2 35 
17 13 2 35 
15 14 2 35 
8 15 3 50 
11 16 2 12.5 
4 17 3 20 
18 18 2 35 
 
 
Table 3.10:  Evaluation results for CCRD RSM design for optimization of liposome 
formulations. 
Term Std. Error VIF Ri
2 
A 0.282843 1.00000 0.00000 
B 0.282843 1.00000 0.00000 
AB 0.353553 1.00000 0.00000 
A2 0.326244 1.00522 0.005192 
B2 0.326244 1.00522 0.005192 
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Figure 3.35 depicts a three dimensional (3D) plot of standard error within the design 
space, showing equal variance for points equidistant from the centre, an indication 
that the design is rotatable. A final evaluation of the design was conducted using a 
fraction of design space (FDS) plot, where linear, low plots indicate low error in 
predictions made within the design space. Figure 3.36 shows an FDS for the design 
indicating a high degree of linearity for a majority of the design space, with slight 
increase in error at higher fractions of the design, which is to be expected. The 
evaluated design was therefore found to be appropriate for the evaluation of cyclic 
dipeptide encapsulated liposomes and was duplicated for both cyclo(His-Gly) and 
cyclo(His-Ala). 
 
Figure 3.35:  3D plot for predicted standard error within the design space for a CCRD RSM 
design for optimization of liposomes. 
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Figure 3.36:  FDS plot for CCRD RSM design, showing low error for a majority of the design 
space. 
 
 
3.2.3 Preparation of folate receptor-targeted liposomes 
3.2.3.1 Synthesis of Folate-PEG-cholesteryl hemisuccinate 
Folate-PEG-cholesteryl hemisuccinate (F-PEG-CHEMS) was used as the targeting 
molecule in liposome formulations as CHEMS incorporates into lipid bilayers much 
like cholesterol. F-PEG-CHEMS was synthesized by initial synthesis of its component 
parts, namely folate-PEG-amine (F-PEG-NH2) and N-hydroxysuccinimide-cholesteryl 
hemisuccinate (NHS-CHEMS). F-PEG-NH2 was synthesized according to the method as 
adapted from Lee and Low (1995) as shown in Figure 3.37. 40 mg folic acid (Sigma-
Aldrich, St Louis, USA) was dissolved in 1 ml DMSO, while 250 mg PEG-bis-amine 
(Sigma-Aldrich, St Louis, USA) was also dissolved in 1 ml DMSO and added to the folic 
acid mixture in a round bottomed flask. 23.1 mg dicylcohexylcarbodiimide (DCC) 
(Sigma-Aldrich, St Louis, USA) was dissolved in 500 l DMSO with 5 l pyridine and 
added to the round bottomed flask. The flask was closed with a nitrogen-filled 
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balloon to provide a positive inert pressure and covered with aluminium foil to 
protect from light. The reaction was allowed to continue overnight at room 
temperature.  
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Figure 3.37:  Synthesis of folic acid PEG-amine from folic acid and PEG-bis-amine according 
to a modified method of Lee and Low (1995) in the presence of 
dimethylsulphoxide (DMSO), dicyclohexylcarbodiimide (DCC) and pyridine.  
 
 
NHS-CHEMS was synthesized according to a method adapted from Xiang and 
colleagues (2008) (Figure 3.38). 1 g of CHEMS (Sigma-Aldrich, St Louis, USA) was 
dissolved in 10 ml tetrahydrofuran (Saarchem, Midrand, South Africa) and added to a 
250 ml round bottomed flask. 475 mg N-hydroxysuccinimide (NHS) (Sigma-Aldrich, St 
Louis, USA) was dissolved in 10 ml tetrahydrofuran along with 1.25 g of DCC. The 
reaction flask was closed with a nitrogen-filled balloon to provide a positive inert 
environment and the reaction was allowed to continue at room temperature 
overnight after which, a white precipitate, NHS-CHEMS, was noted in the flask. 
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Tetrahydrofuan was removed under vacuum at 30 C in a rotary evaporator until dry. 
In order to purify the product, NHS-CHEMS was re-dissolved in 200 ml chloroform 
and 2 g activated charcoal added and stirred for 15 minutes. The mixture was then 
filtered and the chloroform removed from the clear filtrate under vacuum at 30 C in 
a rotary evaporator until dry.  
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Figure 3.37:  Synthesis of CHEMS-NHS from cholesteryl hemisuccinate (CHEMS) and N-
hydroxysuccinimde (NHS) in the presence of DCC and tetrahydrofuran (THF) 
according to an adapted method of Xiang et al. (2008). 
 
For the synthesis of F-PEG-CHEMS, F-PEG-NH2 (274 mg, 80 mol) and NHS-CHEMS 
(58.4 mg, 100 mol) were dissolved in 100 ml chloroform (CHCl3) and reacted 
overnight (Figure 3.38). The product was dried under vacuum at 30 C in a rotary 
evaporator and re-hydrated with 20 ml 50 mM sodium carbonate buffer (pH 7.0) for 
1 hour at 40 C to form F-PEG-CHEMS micelles. Low molecular weight contaminants 
were removed by dialysis of the micelle suspension with reverse osmosis water 
through a 14 000 MWCO dialysis tube (Snakeskin®, Thermo Fisher Scientific Inc., 
Rockford, USA). Micelles of F-PEG-CHEMS were frozen at -85 C overnight and 
lyophilized to a dry powder. Purity and structure were confirmed using TLC and 1H-
NMR in deuterated-DMSO (Xiang et al., 2008). TLC was conducted using silica gel 
plates (TLC Silica gel 60 F254, Merck, Darmstadt, Germany). 5 mg of F-PEG-CHEMS was 
dissolved in 100 l chloroform and spotted, in triplicate, on a silica gel plate. The 
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mobile phase consisted of dichloromethane (CH2Cl2):methanol:glacial acetic acid in 
the ratio 70:30:0.5. Once the spots of F-PEG-CHEMS were dry, the plates were placed 
in a chromatography tank saturated with the mobile phase and the solvent front 
allowed to move up the plate until 1 cm from the top. The plate was removed from 
the tank and the solvent front clearly marked. The plate was allowed to dry and 
analysed under UV light and through staining in an iodine saturated tank. An Rf of 
0.47 was calculated which corresponded with that reported in the literature (Xiang et 
al., 2008). 
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Figure 3.38:  Synthesis of folic acid-PEG-CHEMS from CHEMS-NHS and Folic acid-PEG-amine 
in the presence of chloroform. 
   
The theoretical yield for the final step of the synthesis was 0.0527 mmol or 155.0 mg. 
After the lyphilisation of the micelle product, F-PEG-CHEMS, 103.6 mg of powder 
remained. The synthesis therefore had a yield of 66.8%. 
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3.2.3.2 Preparation of folic acid-tethered liposomes 
Targeted  liposomes containing the synthesized folic acid-PEG-CHEMS synthesis were 
prepared as described in Section 3.1.4.1 above with the exception that the same 
molar proportion of PEG2000-DSPE in the optimized liposomes, was replaced with folic 
acid-PEG-CHEMS and dissolved in the organic solvent to form the thin lipid film prior 
to hydration with drug solution. 
 
3.3 ANTICANCER ACTIVITY 
3.3.1 Cell lines and cell culture 
The immortalized cell lines, MCF-7 and HeLa were used in this study and were a 
donation from the Department of Biochemistry and Microbiology, Nelson Mandela 
Metropolitan University. The two cell lines were maintained under different 
conditions that are discussed in Sections 3.3.1.1 and 3.3.1.2 below. 
 
3.3.1.1 MCF-7 Cell Culture 
MCF-7 cells were maintained in RPMI-1640 supplemented with 10% foetal calf serum 
(FCS) at 37 C in 60 mm cell culture dishes in a 5% CO2 humidified environment. 
Media was changed every 3 – 4 days under standard aseptic conditions. Cells were 
subcultured when 80 – 90% confluent. Media was removed by aspiration through a 
sterile Pasteur pipette and the plate washed well with two 10 ml aliquots of sterile 
phosphate buffered saline (PBS) at pH 7.4. 200 l of trypsin solution containing 
0.25% m/v trypsin (Highveld Biological, Johannesburg, South Africa) and 1 mM EDTA  
in PBS (pH 7.4), was pipetted into the culture dish, carefully swirled around the plate 
for 30 – 60 seconds and the excess removed by aspiration. Cells were then incubated 
at 37 C for approximately 5 minutes or until cells appeared visibly lifted under a light 
microscope. Trypsin was deactivated by the addition of 1 ml fresh media which was 
further agitated through repeated aspirations using a 1000 l autopipette and 
removed from the culture dish and transferred into a sterile 15 ml centrifuge tube. 
100 l of cell suspension was transferred to a fresh cell culture dish and a further 10 
107 
 
ml fresh culture media added to the cells. The cells were then incubated at 37 C in a 
5% CO2 humidified incubator until further manipulation.  
 
3.3.1.2 HeLa Cell Culture 
HeLa cells were maintained under various levels (0.75, 0.5, 0.25 and 0.01 mg/l) of 
folic acid concentration in RPMI-1640 media. The low folate medium was used to 
induce up-regulation of folate receptors on the cell surface as reduced folic acid 
levels are known to cause up-regulation of surface folate receptors in a variety of cell 
lines, including HeLa cells (Zhang et al., 2004). Cells were conditioned to low folate 
conditions over a period of three months, by slowly reducing the quantity of folic 
acid in the media by 5% each time the cells were passaged. Once at the target 
concentration of folic acid, cells were conditioned to grow in the reduced folic acid 
content until the doubling time was the same or similar to that of the standard folic 
acid culture.  Reduction of folic acid in growth medium was achieved by a stepwise 
reduction in the amount of folic acid solution (0.1 mg/ml) in PBS (Ph 7.4) that was 
added to folic acid free RPMI-1640 medium (Gibco® brand, Celtic Molecular 
Diagnostics, Mowbray, South Africa). In order to achieve concentrations present in 
normal RPMI media, 100 l of the 0.1 mg/ml folic acid solution was added to 10 ml of 
medium used to culture cells in the 60 mm cell culture dishes. Cells were passaged 
when at 70 – 80 % confluence in the same manner as described for MCF-7 cells. 
 
3.3.2 IC50 determination of free and liposomal cyclo(His-Gly) and cyclo(His-Ala) 
Cytotoxicity assays were conducted as described previously (Zhang et al., 2004). 
Cells, as cultured in Section 3.3.1 above, were lifted from the surface of the culture 
dish by the addition of 1 ml 0.25% trypsin in 0.1% EDTA  solution and incubated for 5 
min at 37 °C. Cell concentration was determined under a light microscope with a 
haemocytometer. 20 l of cell suspension was transferred to a 1.5 ml sterile 
microcentrifuge tube along with 20 l tryphan blue stain. Cells that did not take up 
the stain were counted as viable. The concentration of the cell suspension was 
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adjusted to 6 × 104 cells/ml by dilution with culture medium. Wells of a 96-well 
microtitre tissue culture plate were seeded with 200 l of cell suspension, equating 
to 6 × 103 cells per well and incubated at 37 C with CO2 humidification for 24 hours 
prior to being exposed to liposome preparations or drug solutions.  
 
Liposomes suspensions were separated from free drug by gel filtration through 
Sepahdex G-50 loaded spin columns, equilibrated with PBS and subsequently filter 
sterilized by passing the suspension through sterile 0.2 m cellulose acetate filters to 
render them free from bacteria. Drug solutions were prepared by dissolving the 
appropriate quantity of drug in PBS and filter sterilizing through a sterile 0.22 m 
cellulose acetate filter.  
 
Medium from cells cultured for 24 hours as described above, was removed by careful 
aspiration of the medium and replacing it with 180 l fresh culture medium. 20 l of 
drug solution in PBS was then added to each well and the cells incubated for 48 
hours at 37 C with CO2 humidification.  
 
Free cyclic dipeptide, liposomal cyclic dipeptide and the positive controls, 
methotrexate and 5-fluorouracil, were prepared in PBS (pH 7.4). Free cyclic 
dipeptides, cyclo(His-Ala) and cyclo(His-Gly) are readily soluble in water and were 
easily dissolved in PBS in a concentration range of 0.078 mM to 5 mM. Liposomal 
cyclic dipeptides were separated from free cyclic dipeptide by gel filtration as 
described above and serially diluted to the same concentration range as the free 
drug. According to the British Pharmacopeia (B.P., 2008), methotrexate is sparingly 
soluble in water, but readily soluble in  dilute solutions of metal hydroxides. 9.08 mg 
(20 mmol) methotrexate (Sigma-Aldrich, St Louis, USA) was therefore initially 
solubilised in 5 ml of a solution of 0.01 M NaOH and the solution’s pH carefully 
reduced to 7.4 with 0.1 M HCl and the solution made up to 20 ml with PBS (pH 7.4). 
The solution was serially diluted with PBS to a concentration range of 0.0312 mM to 
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1 mM. 5-fluorouracil was prepared by dissolving the drug in PBS to a final 
concentration of 400 M. 
 
Cell viability was determined after incubation for 48 hours using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Denizot and Lang, 
1986; Fotakis and Timbrell, 2006). MTT, a water soluble tetrazolium salt, is readily 
converted by succinate dehydrogenase in the mitochondria of healthy cell to an 
insoluble formazan salt, which forms a purple colour when solubilised with DMSO. 
The purple dye formed can then be measured colourimetrically at 570 nm using a 
spectrophotometer (Fotakis and Timbrell, 2006). After drug exposure, cell medium 
was aspirated, washed with 200 l PBS and replaced with 180 l fresh culture 
medium. 20 l of MTT (5 mg/ml in PBS), was added to each well and incubated for a 
further 5 hours at 37 C. Plates were centrifuged in an Eppendorf Centrifuge 5810 
(Eppendorf, Hamburg, Germany) at 3000 rpm for 10 minutes. Culture medium was 
aspirated from the cells, washed with 200 l PBS and replaced with 100 l DMSO in 
order to solubilise the formazan crystals. Absorbance was read at a wavelength of 
570 nm on a PowerWave XS microplate spectrophotometer (BioTek, Winooski, USA).  
 
Cell viability was calculated as a percentage of the negative control according to the 
following formula: 
 
Cell  iability = 
Drug Treatment Absorbance (570 nm)
Nega ve Control Absorbance (570 nm)
   100 
 
The procedure above was used for all cytotoxicity studies and in all cases, each 
concentration was tested in quadruplicate and the assay repeated on separate 
occasions at least three times. 
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Ability of the assay to accurately determine viable cell numbers was tested by 
establishing whether a linear relationship existed between cell number and 
absorbance at 570 nm. In order to determine this relationship, wells of a 96-well cell 
culture plate were seeded with 60 000, 30 000, 15 000, 7 500, 3 750 and 1875 cell 
per well in 180 l RPMI-1640 medium. Cells were allowed to attach for 6 hours 
before adding 20 l of MTT solution (5 mg/ml in PBS) to each well. Plates were 
incubated at 37 C for 5 hours before centrifuging at 3000 rpm for 10 minutes. 
Culture medium was aspirated and 100 l DMSO added to each well, after which, the 
absorbance was measured at 570 nm. Linearity was tested with linear regression 
analysis using Prism version 5.03 (GraphPad Software Inc., San Diego, USA). The 
linear relationship between MTT response and cell number is shown in Figure 3.39. 
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Figure 3.40:  Relationship between absorbance at 570 nm and seeding density for HeLa () 
and MCF-7 () cells. r2 = 0.9926, y = 6.81×10-5x + 0.085 (MCF-7); r2 = 0.9939, y 
= 5.64 × 10-5x + 0.0057 (HeLa). 
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3.3.3 Uptake of liposomal carboxyfluorescein by HeLa and MCF-7 cells 
The uptake of 5(6)-carboxyfluorescein was measured according to the method of 
Kirby and colleagues (1980). Cells were cultured and lifted as described above. Cell 
suspensions were diluted to a final concentration of 250 000 cells/well and 200 l of 
suspension transferred to the wells of a 96-well cell culture plate. Cells were 
incubated for 24 hours at 37 C before exposure. 
 
After incubation, growth medium was aspirated and replaced with 180 l fresh 
medium. Carboxyfluorescein liposomes were filter sterilized and 20 l of 
concentration standardized suspension was transferred to each well and the cells 
returned to the incubator. At one hour intervals for four hours, the medium of 
selected wells was aspirated and washed three times with PBS pH 7.4 to ensure 
complete removal of the residual free and liposomal carboxyfluorescein. 100 l mild 
cell lysis buffer was transferred to the well and the plate returned to the incubator. 
After four hours had elapsed, the cells were allowed to digest for 3 hours at 37 C 
before the contents of each well was transferred to black non-sterile 96-well 
microtitre plates. The fluorescence of the samples was measured at an excitation 
wavelength of 485 nm and an emission wavelength of 512 nm using a Fluoroskan 
Ascent FL microtitre plate spectrofluorometer (Thermo Labsystems, Vantaa, Finland). 
Free carboxyfluorescein taken up by cells was used as a blank reading. 
 
3.3.4 Targetted drug delivery of liposomal cyclo(His-Gly) and cyclo(His-Ala) 
3.3.4.1 Conditioning of HeLa and MCF-7 cells for low folate media 
In order to up-regulate folate receptor expression in HeLa and MCF-7 cells, a 
stepwise reduction of folic acid content of the media was conducted. RPMI-1640 
medium, free of folic acid was supplemented with varying quantities of a solution of 
0.1 mg/ml folic acid in phosphate buffered saline (pH 7.4) so that the addition of 100 
l of folic acid solution to 10 ml folate-free medium would give the same quantity of 
folic acid in standard RPMI-1640 medium. The quantity of folic acid was reduced by 
112 
 
5% per passage until a physiological content of folic acid was achieved. Cells were 
allowed to grow in the folate-poor medium for at least two months before folate 
receptor levels were determined. Cells were also maintained at varying levels of folic 
acid, namely 1 mg/l (as for normal RPMI-1640 growth media), 0.75 mg/l, 0.5 mg/l, 
0.25 mg/l, and physiological folic acid concentration (25 M).  
 
3.3.4.2 Determination of folate receptor expression 
Folate receptor (FR) expression on HeLa and MCF-7 cells was determined for cells 
conditioned to grow in full folate media as well as 75%, 50% and 25% of normal 
RPMI-1640 content and physiological folic acid concentration. The number of folate 
receptors was quantified in order to determine the influence of folic acid on up-
regulation of folate receptors as one of the goals of liposome formulation was to 
target these receptors.  
 
Quantification of folate receptors was determined by a radiolabeled ligand binding 
assay (Zhang et al., 2004) utilizing tritiated folic acid ([3H]-folic acid) (ARC, St Louis, 
USA) at a specific activity of 40 Ci/mmol. Cells were cultured, as described above, in 
60 mm polystyrene cell culture plates to 80% confluence. Culture medium was 
aspirated and cells were then washed four times for 30 seconds each with 10 ml ice 
cold (4 C) PBS (pH 7.4), after which they were washed twice with 10 ml ice cold acid 
buffer containing 0.05 M sodium acetate and 0.15 M NaCl (pH 4.5). Cells were then 
washed a further two times with 10 ml ice cold (4 C) PBS (pH 7.4) to ensure removal 
of receptor bound folic acid. Cells were lifted from the surface of the culture dish by 
the addition of 200 l 0.25% trypsin and 0.1% EDTA solution in PBS and incubated for 
5 min at 37 °C after which cells were re-suspended in 1.0 ml PBS. Cells were counted 
using a haemocytometer and the concentration adjusted to a concentration of 1 × 
106 cells/ml with PBS. 1.0 ml of each cell suspension was then transferred to a 15 ml 
sterile centrifuge tube. Cells were separated from the trypsin/PBS solution by 
centrifuging at 3000 rpm for 10 minutes and then washed twice in 10 ml PBS, 
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separating the buffer from the cells each time with the centrifugation step described 
above. Cell pellets were stored at 4 C until used in the ligand binding assay (within 2 
hours). 
 
In order to quantify the number of folate receptors per cell, a standard curve for 
[3H]-folic acid was established. Standard solutions for [3H]-folic acid were prepared 
by serial dilution of a stock solution containing 5 pmol/ml such that the final 
concentration range was 5, 2.5, 1.25, 0.625, 0.313 and 0.156 pmol/ml. 1 ml of each 
standard was transferred to a 10 ml scintillation vial containing 1 ml scintillation 
cocktail and the radioactivity read using a scintillation counter. All concentrations 
were recorded in triplicate and a standard curve constructed from the data (Figure 
3.41). Linear regression analysis revealed a linear relationship between 
concentration and response with the straight line equation being y = 36467x + 197.6 
(r2 = 0.9999). Y-intercept analysis also revealed a non-significant deviation from the 
origin, with the y-intercept value being 0.22% of the 50% response (significant 
deviation is greater than 2%). 
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Figure 3.41:  Standard curve for the quantification of [3H]-folic acid. r2 = 0.9999, y = 36467x 
+ 197.6. 
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A saturation plot was constructed in order to determine the most appropriate dose 
of [3H]-Folic acid to expose cells to. HeLa cells cultured at physiological pH were used 
as they were most likely to express the highest quantity of folate receptors. Cells, 
suspended in 1 ml PBS were incubated at 4 C with 1, 5, 10, 20, 50 and 100 pmol 
[3H]-folic acid. Non-specific binding was determined through the addition of excess 
(20 mmol) unlabeled folic acid. After incubation, cells were separated by 
centrifugation at 3000 rpm for 10 minutes and washed twice with 10 ml ice cold (4 
C) PBS (pH 7.4). The resultant cell pellet was digested through the addition of 50 l 
1 N NaOH solution overnight. Radioactivity of the samples was determined by liquid 
scintillation counting by transferring the digested cell solution to 1 ml of Ultima Gold 
liquid scintillation cocktail (PerkinElmer, Waltham, USA) in a 2 ml microcentrifuge 
tube and counting on a Tri-Carb liquid scintillation counter (PerkinElmer, Waltham, 
USA). All assays were conducted in triplicate and a plot of radioactivity (in counts per 
minute) as a function of [3H]-folic acid constructed for total, non-specific and specific 
binding (Figure 3.42). The dose of 20 pmol (saturation point observed at the plateau 
of the curve) was used to determine receptor number in other cell lines. 
 
Cells were re-suspended in 1 ml of a solution containing 20 pmol [3H]-folic acid in PBS 
(pH 7.4) and incubated at 4 C for one hour. Non-specific binding was determined 
through the addition of excess (20 mmol) unlabeled folic acid to replicate tubes. 
After incubation, cells were separated by centrifugation at 3000 rpm for 10 minutes 
and washed twice with 10 ml ice cold (4 C) PBS (pH 7.4). The resultant cell pellet was 
digested through the addition of 50 l 1 N NaOH solution overnight. Radioactivity of 
the samples was determined by liquid scintillation counting by transferring the 
digested cell solution to 1 ml of Ultima Gold liquid scintillation cocktail (PerkinElmer, 
Waltham, USA) in a 2 ml microcentrifuge tube and counting on a Tri-Carb liquid 
scintillation counter (PerkinElmer, Waltham, USA). All determinations were 
conducted in triplicate (for each cell line and for non-specific binding). 
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Figure 3.42:  Saturation plot for [3H]-folic acid on HeLa cells at physiological folate 
concentrations, indicating total, non-specific (in the presence of excess 
unlabeled folic acid) and specific binding.  
 
3.3.4.3 Influence of folate receptor expression on 5-fluorouracil activity 
The influence of folate receptor expression in the cytotoxic activity of 5-fluorouracil, 
having an established anticancer effect due to its action as a thymidylate synthase 
inhibitor (Chu and Sartorelli, 2009) was investigated at various folate receptor 
expression levels. The cytotoxicity of 5-fluorouracil was determined using the 
cytotoxicity assay described above (Section 3.3.2) except medium used during 5-
fluorouracil exposure was folic acid-free in order to eliminate potential competition 
between folic acid and 5-fluorouracil for folate receptors. Surface folate receptor 
numbers were then related to IC50 for 5-fluorouracil. This was done in order to 
determine whether the use of elevated levels of folic acid in routine cytotoxic 
screening has any profound effect on the identification of potential anticancer drugs, 
which could display a false negative during screening, but be potentially active at 
physiological folic acid concentrations. Concentrations tested were the same as 
those stated in Section 3.3.2 above.   
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3.4 STATISTICAL ANALYSIS 
3.4.1 General descriptive and inferential statistics 
Replicate measurements were represented as means +/- standard deviation and 
displayed graphically using the software package Prism version 5.03 (GraphPad 
Software Inc., San Diego, USA). Where a comparison of two means was necessary, 
statistically significant differences were tested using Student’s unpaired t-test (two 
tailed, non-parametric) with significant difference defined as p<0.05. For paired 
observations, such as multiple measurements at varying time points, a paired t-test 
was used. Data was normalized when necessary, and raw measurements converted 
to % of control or % inhibition by using the transform function in Prism. This enables 
all raw and normalized data to be analysed within the same statistical software 
package, minimizing potential error in the re-transcription of data. 
 
For dose-response data, concentration was transformed using x = log(x) and data 
analysed using the sigmoidal dose-response analysis according to the following 
equation: 
          
            
                         
 
 
 
3.4.2 Multifactorial analysis 
3.4.2.1 Primary screening using fractional factorial design 
Analysis of variance (ANOVA) analysis for data captured in the 25-1 fractional factorial 
design was carried out using the software package Design-Expert version 8.0.1 (Stat-
Ease Inc., Minneapolis, USA). The software was used to determine model fit and 
appropriate fit was defined as a p-value, as derived from the ANOVA analysis, of less 
than 0.05. Main and interaction effects for the five variables chosen were analysed 
using interaction plots where two variables were compared at the mid-points for all 
other variables. Interaction between two variables was noted when a clear 
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convergence between the plots occurred and the p-value calculated using an F-test 
was less than 0.05 for the interaction term. 
 
3.4.2.2 Response surface methodology 
ANOVA analysis was used to determine the most appropriate model to fit each 
response and lack of fit and r2 statistics calculated for each model were used to aid in 
choice of model. Once data was fitted to an appropriate model, optimization of the 
formula was calculated based on all responses.  Criteria for each individual response 
was set such that an optimum formula would be obtained. Criteria for the design are 
shown in Table 3.11. 
 
Table 3.11:  Criteria used for optimization of factors in RSM design 
Response Criteria Importance Minimum Maximum 
Encapsulation Maximize High 0.045 0.15 
Cellular uptake Maximize High 0 250 
Zeta potential In range Low 20 50 
PDI Minimize Moderate 0.01 0.3 
Membrane 
leakage 
Minimize Moderate 0.2 1000 
 
When a criterion was set for a maximum or minimum response, linear optimum was 
used and no weighting was set. The optimized formulation was determined using the 
desirability function (or D(X)) as calculated in the following equation below (Myers et 
al., 2009): 
                 
 
  
Where d1, d2 etc. are the desirability for each response. Therefore, should a response 
for a particular formula fall below the minimum for a maximized response, the result 
for di would be zero and D would therefore also be 0 or completely undesirable. The 
formula with the highest D was chosen as the final formulation to be tested. 
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1 PHYSICOCHEMICAL CHARACTERISTICS OF CYCLO(HIS-GLY) AND CYCLO(HIS-
ALA) 
4.1.1 Log P 
The log P values calculated for cyclo(His-Gly) and cyclo(His-Ala) using the flask stirring 
method were -1.490 and -1.517 respectively. Theoretical log P calculations using 
chemical drawing software resulted in a log P prediction of -1.093 for cyclo(His-Gly) 
and -1.264 for cyclo(His-Ala) indicating that, experimentally, log P values were lower 
than those predicted by the software and could be for a number of reasons, 
including slight variation in temperature or incorrect conformation prediction by the 
software. Irrespective of the reason for the deviation between measured and 
predicted log P, both determinations indicate that cyclo(His-Gly) and cyclo(His-Ala) 
are extensively water soluble with low potential for permeation through biological 
membranes. According to Kerns and Di (2008), log P values of less than 1 are 
indicative of highly water soluble but poorly permeable molecules, making them 
improbable candidates for biological activity. Despite this, Lucietto and colleagues 
(2006) still showed significant activity of these compounds against three cancer cell 
lines in vitro. As was indicated by Smith and colleagues (2006), transport of drug 
substances across biological barriers such as the blood brain barrier in the central 
nervous system and brush border in the gastrointestinal system, occurs via three 
main transport mechanisms, including passive diffusion, passage through 
fenestrations and active transport molecules. Since Lucietto and colleagues (2006) 
tested these compounds on cell monolayers, passage through intercellular 
fenestrations could not have occured and passive diffusion is unlikely to have 
occurred due to low Log P values for both compounds. It was, however, noted that in 
their cytotoxicity assay, DMSO was used at a concentration of 0.25% v/v to aid in 
dissolution of the positive controls and therefore included for the cyclic dipeptides 
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assays as well. It is widely accepted that DMSO acts as a penetration enhancer for 
drugs in transdermal delivery by interacting with the lipid bilayer and enhancing 
transcellular diffusion (Barry, 1987). This concept could explain why cyclo(His-Gly) 
and cyclo(His-Ala) had such pronounced effects in cell culture, provided, of course, 
that their mechanism of cytoxicity occurs within the cell. Another possible 
explanation for activity despite poor permeability could be the presence of active 
transport peptides in the cells that transport the cyclic dipeptides across the lipid 
membrane. It has been reported that oligopeptide transporters in the 
gastrointestinal tract of the rat are responsible for transport of cyclic dipeptides 
across lipid membranes (Mizuma et al., 1998) providing a possible mechanism for 
cellular entry of cyclo(His-Gly) and cyclo(His-Ala). However, if DMSO used in the 
cytotoxicity assay is implicated for enhanced cellular entry of the cyclic dipeptides, 
this does not bode well for their activity in vivo, as physiological fluids do not contain 
DMSO, thus justifying the design of a delivery system such as liposomes. 
 
The topological polar surface areas calculated for cyclo(His-Gly) and cyclo(His-Ala) 
were both 86.88 Ă2 (Table 4.1), and large surface areas are indicative of poor 
permeability (Ertl et al., 2000), further highlighting the potentially poor drug 
properties of these cyclic dipeptides and the need for an effective drug delivery 
system. 
 
Table 4.1: Topological polar surface area calculation for cyclo(His-Gly) and cyclo(His-Ala) . 
Contributing 
group 
(According 
to Table 3.1) 
Cyclo(His-Gly) 
3
O
13
2
7
NH
1
8
N
9
10
N
H
11
12
6
O
14
NH
4
5
 
Cyclo(His-Ala) 
3
O
13
2
7
NH
1
8
N
9
10
N
H
11
12
6
O
15
5
NH
4
14
 
Atoms PSA contribution Atoms PSA contribution 
*NH+(−*)−* N1, N4 12.03 × 2 N1, N4 12.03 × 2 
[O] * O14, O13 17.07 × 2 O14, O13 17.07 × 2 
[n](:*):* N9 12.89 N9 12.89 
[nH](:*):* N11 15.79 N11 15.79 
TPSA  86.88 Ă2  86.88 Ă2 
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4.1.2 Stability 
Although the manner by which degradation occurs can often be seen as complex, 
with multiple reactions occurring, it is of benefit to attempt to fit stability data to a 
simple mathematical model in order to make reasonable predictions regarding the 
stability of the drug substance during storage (Qiu et al., 2008). These simplified 
mathematical models include zero, first and second order reactions and the manner 
in which data is analysed and interpreted is dependent upon the reaction order 
(Aulton, 2007). Table 4.2 illustrates the mathematical models of zero, first and 
second order reactions. It was therefore necessary to establish reaction order before 
any analysis with regards to stability on storage could be done.   
 
Table 4.2:  Mathematical models for reaction kinetics for zero-, first- and second order 
reactions (Qiu et al., 2008). 
Reaction 
order 
Rate equation 
Concentration-time 
profile 
Half-life 
Zero  
d*A+
dt
 = k [A]t = [A]0 - kt t1 2  = 
*A+0
2k
 
First  
d*A+
dt
 = k*A+ [A]t = [A]0exp(-kt) t1 2  = 
ln2
k
 
Second  
d*A+
dt
 = k*A+2 
1
    
 
1
    
 = k  t1 2   = 
1
k*A+0
 
 
In order to establish reaction rate, graphs of concentration (C), lnC and reciprocal 
concentration (1/C) were constructed as a function of time and the graph with the 
greatest degree of linearity was an indication of the reaction order. Figures 4.1, 4.2 
and 4.3 show the C, ln(C) and 1/C graphs respectively. 
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Figure 4.1:  Concentration as a function of time (in weeks) for cyclo(His-Gly) and cyclo(His-
Ala) stored at 70 C with linear regression. r2 = 0.9763 (cyclo(His-Gly)) and 
0.9675 (cyclo(His-Ala)) (n = 6 for each point). 
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Figure 4.2:  Natural logarithm (ln) of concentration as a function of time (in weeks) for 
cyclo(His-Gly) and cyclo(His-Ala) stored at 70 C with linear regression. r2 = 
0.9898 (cyclo(His-Gly)) and 0.9891 (cyclo(His-Ala)) (n = 6 for each point). 
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Figure 4.3:  Reciprocal concentration as a function of time (in weeks) for cyclo(His-Gly) and 
cyclo(His-Ala) stored at 70 C with linear regression. r2 = 0.9763 (cyclo(His-Gly)) 
and 0.9765 (cyclo(His-Ala)) (n = 6 for each point). 
 
 
A linear relationship between each of the y-terms (C, lnC or 1/C) and time would 
indicate that a mathematical model would best describe the reaction kinetics. In the 
case of both cyclo(His-Gly and cyclo(His-Ala), the graphs of lnC as a function of time 
showed the greatest degree of linearity, with linearity coefficients (r2) of 0.9898 and 
0.9891 for cyclo(His-Gly) and cyclo(His-Ala) respectively. This is an indication that the 
degradation reaction for both cyclic dipeptides follows first order or pseudo-first 
order reaction kinetics (Aulton, 2007). As the cyclic dipeptides were in solution 
during storage, the most likely degradation route would be hydrolysis, which involves 
bond cleavage as a result of interaction with water, implying that two molecular 
species are involved in the reaction (Qiu et al., 2008), however, since water is in a 
large excess in the reaction, the rate cannot be dependent on its concentration and 
the order is therefore assumed to be pseudo-first order and can be described using 
simple first order kinetic models. 
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As the degradation kinetics of cyclo(His-Gly) and cyclo(His-Ala) were shown to be first 
order, or pseudo-first order, it was then necessary to determine the influence of 
temperature on the reaction rate constant (k). Plots of lnC as a function of time were 
constructed for each cyclic dipeptide at the three storage temperatures (45, 60 and 
70 C) and are shown in Figures 4.4 and 4.5. The linear equation for this graph is as 
follows                  (Aulton, 2007) indicating that the slope of the linear 
graph is equal to –k and can therefore be derived from the graph. What is interesting 
to note from these graphs, is that for all temperatures, cyclo(His-Ala) has slower 
degradation rates than cyclo(His-Gly), indicating it to be more stable in solution. The 
only difference between these two diketopiperazines is a methyl-substituted α-
carbon in the alanine moiety of cyclo(His-Ala) and it therefore proposed that this 
group is responsible for higher stability. 
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Figure 4.4:  Influence of storage temperature on degradation for cyclo(His-Gly). k45 = 
0.0618 weeks-1 , k60 = 0.1507 weeks
-1  and k70 = 0.2385 weeks
-1 (n = 6 for each 
point). 
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Figure 4.5:  Influence of storage temperature on degradation for cyclo(His-Ala). k45 = 
0.0165 weeks-1 , k60 = 0.1212 weeks
-1  and k70 = 0.1934 weeks
-1 (n = 6 for each 
point). 
 
The Arrhenius equation is a relatively simple thermodynamic equation that enables 
the scientist to calculate reaction rate constants at a given temperature in order to 
predict stability, provided that the activation energy (Ea) and the frequency factor (A) 
for the reaction are known. The Arrhenius equation is shown below: 
 
           
 
where Ea is the activation energy, A is the frequency factor, R is the gas constant and 
T is the temperature in Kelvin (Kotz et al., 2009). Manipulation of the Arrhenius 
equation by determining the natural logarithm of each side and rearranging the 
factors, one can derive the following equation: 
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The straight line equation (y = mx + c) can be used to construct a linear graph, the 
Arrhenius plot, from the relationship between lnk (y-axis) and 1/T (x-axis) with the 
term  
  
 
 being the slope and lnA being the y-intercept (Kotz et al., 2009). This then 
enables a researcher, without having knowledge of the activation energy or 
frequency factor, to determine the reaction rate at different temperatures using 
accelerated stability data. 
 
The reaction rate constants (k) (shown in Table 4.3) were derived from the straight 
line equation determined using linear regression analysis and were used to 
extrapolate the reaction rate constant for potential storage temperatures (4 and 25 
C) using the Arrhenius plot (Figure 4.6).  
 
Table 4.3:  Graphically derive reaction rate constants (k) for degradation of cyclo(His-Gly) 
and cyclo(His-Ala) at 45, 60 and 70 C. 
Storage 
temperature (C) 
Reaction rate constant (k) (weeks-1) 
Cyclo(His-Gly) Cyclo(His-Ala) 
45 0.0618 0.0165 
60 0.1507 0.1212 
70 0.2385 0.1934 
 
Based on the linear regression data of the Arrhenius plots shown in Figure 4.6, a 
graphical determination of the reaction rate constants at 4 C and 25 C was 
determined as well as the predicted half-life and storage-life for cyclo(His-Gly) and 
cyclo(His-Ala). Half-life was calculated using the first order half-life equation as 
shown above in Table 4.2, while storage life was calculated through deriving the 
equation from the straight line equation for first order reactions such that C = 0.95Co, 
yielding the following equation: 
  
       
 
 
 
The results of these predictions are shown in Table 4.4. 
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Figure 4.6:  Arrhenius plot for the prediction of storage life of cyclo(His-Gly) and cyclo(His-
Ala) in solution at physiological pH and osmotic pressure. 
 
Table 4.4:  Reaction rate constants (k) and predicted half-life and shelf-life for cyclo(His-
Gly) and cyclo(His-Ala) at 4 C and 25 C. Shelf-life was defined as the storage 
duration required to reduce the concentration by 5%. 
Cyclic dipeptide 
Storage 
temp. 
K (weeks-1) 
Half-life 
(weeks) 
Shelf-life 
(weeks) 
cyclo(His-Gly) 
4 C 6.387×10-3 108.5 8.1 
25 C 2.281×10-2 30.4 2.3 
cyclo(His-Ala) 
4 C 2.920×10-4 2373.6 176.6 
25 C 2.997×10-3 231.3 17.2 
 
From the results above, it is clear that cyclo(His-Ala) is far more stable in aqueous 
solution at pH 7.4 than cyclo(His-Gly), having a shelf-life 23 times longer under 
refrigerated conditions. Very little literature is available on the topic of cyclic 
dipeptide stability. Grant (2002), investigated the aqueous stability of cyclo(Gly-Gly), 
cyclo(Gly-Trp) and cyclo(Trp-Trp) at various pH and buffer concentrations. His study 
found that the cyclic dipeptides investigated showed second order kinetics. It is 
generally for degradation reactions in solution to take place via second order 
reaction kinetics as the reaction rate is dependent on the concentration of two 
components of the solution, which in the case of a hydrolytic reaction, would require 
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the concentration of both the solute and the water to be used in the calculation. This 
is often pointless as the relative decrease in the concentration of the solvent, water, 
is not comparable to the decrease shown by the solute, a concept known as sink 
conditions (Aulton, 2007; Qiu et al., 2008). Although Grant (2002) conducted a 
formal stability protocol at various buffer levels and pH, this was not the goal of this 
study, as the primary aim was merely to establish aqueous stability at physiological 
pH and concentration in order to assess whether the stability of the liposome 
formulation would be greatly influenced by the degradation of the active 
component. The predicted shelf-life for cyclo(His-Gly) of 2.3 weeks at 25 C was 
concerning, as the process used to prepare the liposome suspensions required 
prolonged hydration as well as extrusion at a temperature above the transition 
temperatures (Tm) of the lipids used to form the liposomes. The temperature chosen 
for this study, to ensure that it was above the Tm of both lipids investigated, was 60 
C and hydration took place over an hour period. However, during encapsulation 
analysis, significant degradation was not noted after the hydration period. It was also 
decided that all solutions of cyclo(His-Gly) be made freshly as needed and stored at 4 
C.  
 
On the other hand, the stability and predicted shelf-life calculated for cyclo(His-Ala) 
was longer than anticipated and was shown to be sufficiently stable at room 
temperature (25 C) for a period of more than four months. Despite this, however, it 
was still decided that the same stringent conditions used for cyclo(His-Gly) would 
also be applied to cyclo(His-Ala). 
 
4.2 FORMULATION DEVELOPMENT OF LIPOSOMAL CYCLO(HIS-GLY) AND 
CYCLO(HIS-ALA)  
4.2.1 Factor screening 
Once factors pertinent to the stability of the formulation were identified in 
preliminary experimentation, these factors were screened for their relationship with 
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each other in terms of interaction. The first step in any optimization study utilizing 
RSM as a statistical tool, is to initially conduct a screening study, using a two level 
factorial design in order to establish which factors should be carried forward to more 
intense five-level studies (as is the case with CCRD) (Anderson and Whitcomb, 2005). 
The factors that were investigated in the screening phase included: proportion of 
hydrogenated soy phosphatidylcholine (HSPC) to non-hydrogenated SPC, 
stearylamine content, vitamin E content, cholesterol content and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (PEG-DSPE) 
content. The study was designed according to a fractional factorial design (25-1) in 
order to minimize experimental runs. The influence of each factor on the responses 
for cyclo(His-Gly) liposomes will be discussed below according to each of the three 
responses analysed (encapsulation, lipid peroxidation and polydispersity index). 
Cyclo(His-Gly) only, and not cyclo(His-Ala), was used as the model for the design in 
order to reduce the number of total experiments and ultimately the cost, as 
cyclo(His-Ala) is more costly. 
 
4.2.1.1 Effects on drug encapsulation 
ANOVA analysis of the model for the response showed that the model (quadratic) 
chosen for the analysis had a significant fit with an F-value of 9.77 (p = 0.0099) and a 
lack of fit test showed that there was non-significant lack of fit (p = 0.9570), 
indicating that this model could be used to evaluate the design space. 
 
A graph of predicted response as a function of actual response was constructed to 
determine how well the model was suited to make predictions within the design 
space. As can be noted from the graph (Figure 4.7), most design points fall close to 
the 45  line, showing that the predicted value is close to that tested within the 
model. 
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Figure 4.7:  Predicted versus actual value plot for encapsulation efficiency. 
 
The influence of the factors on encapsulation efficiency is shown in Figure 4.8, and 
indicates general trends for each factor independent on the potential interactive 
effects of the other factors. In order for this to be done, levels of other factors were 
set at those used at the centre points. Although these graphs are not effective at 
making predictive decisions regarding the influence of the factors on the response, it 
is useful to identify general trends at the centre points. 
 
From the graphs in Figure 4.8, the general trends identified graphically were that 
increasing levels of HSPC, cholesterol and, to a small extent, stearylamine, resulted in 
an increase in the quantity of drug encapsulated. Increased PEG-DSPE levels showed 
lower encapsulation, while vitamin E showed no significant effects on the 
encapsulation efficiency when other factors were constrained to the mid-point. 
ANOVA analysis of these trends indicated that only changing levels of cholesterol had 
significant effects on encapsulation efficiency (p = 0.0205). This has been highlighted 
as being one of the downfalls of using fractional factorial design, as the elimination 
of design points, done purely for economical reasons, limits the statistical power of 
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the model (Anderson and Whitcomb, 2005). This design, therefore, showed that 
increasing cholesterol levels within the range of 20 – 50 molar % will improve 
encapsulation of the drug. Conflicting evidence is available on the effect of 
cholesterol on encapsulation efficiency. Some studies (Gürsel and Hasirci, 1995; 
Coderch et al., 2000) have also shown that increasing the levels of cholesterol within 
a liposome membrane, increase the quantity of encapsulated drug. However, 
another, and more recent study, showed that increased levels of cholesterol 
decreased drug encapsulation (Kaiser et al., 2003).  In the first two studies, 
encapsulation of fluorescent markers that had high water solubility and low Log P 
values were used, while in the study by Kaiser and colleagues (2003), the anticancer 
drug, 5-fluorouracil, was investigated. While 5-fluorouracil is by no means lipophilic, 
it has been shown to have limited water solubility (Buur and Bundgaard, 1987), this 
may have influenced the differences in observations. Both cyclo(His-Gly) and 
cyclo(His-Ala) are readily soluble in water. 
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Figure 4.8:  One factor plots for the response, encapsulation efficiency, with other factors 
set at mid-point levels. 
 
Interaction plots are useful tools in predicting interaction between two factors. In 
order for an effective prediction of interaction to be made for designs that 
encompass more than two factors, however, the other factors have to be set at 
constant levels (usually the mid-point) (Anderson and Whitcomb, 2005). The 
interactions between all factors tested against the response, encapsulation efficiency 
are shown in Figure 4.9. In order to interpret these plots, one must be familiar with 
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the format used. The high and low levels of one factor is plotted on the linear x1 axis, 
while the high and low levels of the other factor are plotted as separate curves as an 
x2 axis. In the graphs shown below, the red curve denotes the high level (coded as 
+1) while the black curve denotes the low level (coded as -1). For interaction to 
occur, crossing of the two curves must take place, as this is an indication that 
different levels of the factor represented on the x2 axis, affects the factor 
represented on the x1 axis has on the response. An example from Figure 4.9 of two 
factors that don’t show interaction is stearylamine and HSPC content which is 
represented by two almost parallel lines. The greatest interaction was shown 
between vitamin E content and HSPC content as well as between vitamin E content 
and PEG-DSPE content, represented by two lines that completely converge. In most 
cases, interaction did occur between the factors (except for stearylamine and HSPC 
and stearylamine and PEG-DSPE) which indicates the extreme complexity of the 
formulation process for liposomes, as altering one factor at a time would not yield 
optimal formulations. 
 
 
 
Figure 4.9:  Interaction between five factors with reference to encapsulation efficiency. 
Red plot is at the high level and black plot is at the low level for the X2 axis. 
(Continued on next page). 
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Figure 4.9 (cont.):  Interaction between five factors with reference to encapsulation 
efficiency. Red plot is at the high level and black plot is at the low level for X2 
axis. 
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While several of the graphs in Figure 4.9 show blatant convergence with some, such 
as the interaction between PEG-DSPE content and vitamin E, clearly crossing in the 
middle of the design space, the only reliable test for assessing interaction between 
variables is by evaluating the results using ANOVA analysis (Anderson and Whitcomb, 
2005). Of the interactions assessed within the design, the only interactions showing 
significance (p < 0.05) were those between cholesterol content and HSPC content as 
well as between stearylamine and PEG-DSPE content and are summarized in Table 
4.5 with bolded values superscripted with an asterisk being an indication of statistical 
significance (p < 0.05). This shows, that in all cases, cholesterol was involved in the 
interaction. For this reason, it was decided that cholesterol content would be one of 
the two factors taken forwards in the optimization phase of the study. Cholesterol 
content is routinely investigated for interaction with formulation variables and in a 
recent study investigating the encapsulation efficiency nobiliside liposomes, 
cholesterol was also involved in interactions with other factors in their design (Xiong 
et al., 2009). 
 
Table 4.5:  Results of ANOVA analysis for the interaction effects on encapsulation 
efficiency. Values shown indicate p-values. Significance of interaction was 
defined as p < 0.05. 
 A B C D E 
A: HSPC  0.9643 0.0612 0.0134* 0.4236 
B: Stearylamine 0.9643  0.7307 0.0470* 0.8342 
C: Vitamin E 0.0612 0.7307  0.3190 0.2611 
D: Cholesterol 0.0134* 0.0470* 0.3190  0.0497* 
E: PEG-DSPE 0.4236 0.8342 0.2611 0.0497*  
 
4.2.1.2 Effects on lipid peroxidation 
ANOVA analysis of the model for the response of lipid peroxidation showed that the 
model (quadratic) chosen for the analysis had a significant fit with an F-value of 5.75 
(p = 0.0317, r2 = 0.9452). However, the lack of fit test showed that there was a 
significant lack of fit (p < 0.001). A reason for this lack of fit could be due to only two 
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of the three factors having any significant effect on lipid peroxidation, namely, HSPC 
content (p=0.0307) and vitamin E content (p = 0.0021). Their effect on lipid 
peroxidation are to be expected as it is well known that vitamin E acts as an 
antioxidant and prevents peroxidation of lipids (Torchilin and Weissig, 2003) while 
HSPC has also been shown to resist peroxidation more than its non-hydrogenated 
form (Haran et al., 1993; Ishida et al., 2002). 
  
As for the previous response, a graph of predicted response as a function of actual 
response was constructed (Figure 4.10) which showed that most design points fall 
close to the 45  line, indicating that, despite the lack of fit result, the predicted value 
is close to that tested within the model. 
 
 
Figure 4.10:  Predicted versus actual value plot for lipid peroxidation. 
 
The effect of single factors on lipid peroxidation, independent on the interaction 
from other factors, was determined at the centre point levels for other factors and is 
shown in Figure 4.11. Of the factors analysed, only an increase in HSPC proportion of 
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the phospholipid and vitamin E content resulted in significant effects on lipid 
peroxidation (p = 0.0307 and 0.0021 respectively, ANOVA). As the degree by which 
vitamin E reduced lipid peroxidation in the formulations was large, it was therefore 
decided that this would be included in the final formulation to promote stability. 
 
 
Figure 4.11:  Effects of single factors on the degree of lipid peroxidation in liposomal 
formulations. 
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As has been indicated above, analysis of a single factor’s influence on a particular 
response is not sufficient at describing the design space fully. Interaction plots for all 
factors were therefore derived from the data and are shown in Figure 4.12. 
 
 
   
 
Figure 4.12:  Interaction between five factors with reference to lipid peroxidation. Red plot 
is at the high level and black plot is at the low level for X2 axis. (Continued on 
next page). 
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Figure 4.12 (contd):  Interaction between five factors with reference to lipid peroxidation. 
Red plot is at the high level and black plot is at the low level for X2 axis. 
 
Table 4.6:  Results of ANOVA analysis for the interaction effects on lipid peroxidation. 
Values shown indicate p-values and significance of interaction was defined as p 
< 0.05. 
 A B C D E 
A: HSPC  0.9681 0.8335 0.4743 0.8568 
B: Stearylamine 0.9681  0.5804 0.7563 0.9415 
C: Vitamin E 0.8335 0.5804  0.6149 0.9147 
D: Cholesterol 0.4743 0.7563 0.6149  0.8296 
E: PEG-DSPE 0.8568 0.9415 0.9147 0.8296  
 
No interactions between the factors were evident from the data, indicating that, 
while HSPC content and vitamin E content had an effect on the susceptibility of the 
liposome formulations to peroxidation, none had any influence on each other. 
 
4.2.1.3 Effects on polydispersity index 
ANOVA analysis of the model for polydispersity index as a response showed that the 
model chosen for the analysis had a significant fit with an F-value of 5.26 (p = 0.0383) 
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and a lack of fit test showed that there was non-significant lack of fit (p = 0.9373), 
indicating that this model could be used to evaluate the design space. 
 
Evaluation of the model fit was conducted by deriving a graph of predicted versus 
actual response. It can be noted from the graph in Figure 4.13 that most design 
points fall close to the 45  line indicating that the predicted value is close to that 
tested within the model. 
 
 
Figure 4.13:  Predicted versus actual value plot for lipid peroxidation. 
 
 
The polydispersity index is an important parameter when assessing the homogeneity 
of colloidal dispersions such as liposomes, particularly for ensuring predictable drug 
release prompted by a uniform surface area available for diffusion (Pereira-
Lachataignerais et al., 2006) and it is therefore necessary to assess how each factor 
can be manipulated to minimize the polydispersity of a liposome suspension, 
ensuring homogenous particle size distribution. Each factor’s effect on polydispersity 
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index is shown in Figure 4.14 and is an indication of their effects independent of the 
other factors, whose levels were set at the centre point. Of the five factors tested, 
the only statistically significant effect was for HSPC which showed a concentration 
dependent decrease in polydispersity index with increase in concentration (p = 
0.0115), indicating that hydrogenated versions of the phospholipid resulted in 
narrower, more stable dispersions of liposomes. Chou and colleagues (2003) 
proposed that increasing levels of phospholipids such as HSPC and DSPC, with high 
transition temperatures, result in more stable liposomes with respect to potential 
drug leakage, as the permeability of the membrane decreases as its fluidity 
decreases. This, however, is not always desirable, as a decrease in membrane fluidity 
due to increases in lipid transition temperatures, may adversely impact cellular 
interactions and drug release in vivo (Jia et al., 2008)  
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Figure 4.14:  Effects of single factors on the polydispersity in liposomal formulations. 
 
Interaction plots for the five factors on polydispersity measurements for cyclo(His-
Gly) liposomes (Figure 4.15) indicated that, of the ten possible interactions analysed, 
only HSPC content was shown to  interact with PEG-DSPE content in terms of particle 
size distribution (p = 0.0176, ANOVA). A summary of the ANOVA data is shown in 
Table 4.7.  
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Figure 4.15:  Interaction between five factors with reference to polydispersity index. Red 
plot is at the high level and black plot is at the low level for X2 axis. (Continued 
on next page). 
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Figure 4.15 (contd.):  Interaction between five factors with reference to polydispersity 
index. Red plot is at the high level and black plot is at the low level for X2 axis. 
 
Table 4.7:  Results of ANOVA analysis for interaction effects on polydispersity index. 
Values shown are p-values and significant interaction was defined as p < 0.05. 
 A B C D E 
A: HSPC  0.7537 0.2352 0.1233 0.0176* 
B: Stearylamine 0.7537  0.4857 0.2965 0.6995 
C: Vitamin E 0.2352 0.4857  0.7570 0.3072 
D: Cholesterol 0.1233 0.2965 0.7570  0.4504 
E: PEG-DSPE 0.0176* 0.6995 0.3072 0.4504  
 
As a result of the multiple interactions that cholesterol content had on various 
responses analysed in the screening study, this factor was chosen to be included in 
the optimization phase of the study, utilizing response surface methodology. The 
other factor chosen for inclusion in the optimization phase was stearylamine. This 
factor was chosen for several reasons. The first reason was due to its interaction 
effects with cholesterol, and the second was due to its known effects on improving 
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cell membrane interactions, and ultimately, uptake into cells (Düzgüneş and Nir, 
1999). As the response of cellular uptake was not analysed during the screening 
phase, it was therefore necessary to investigate this factor further. Other factors 
investigated in the screening phase that were not to be included in the optimization 
phase included vitamin E content, PEG-DSPE content and HSPC proportion of the 
phospholipid. Vitamin E, although showing interactions with other factors, was not 
included in the optimization phase as its benefits of minimizing lipid peroxidation, 
and thus liposome stability, outweighed potential interactions, and it was included in 
all formulations at the high level. HSPC and PEG-DSPE were also included in all 
formulations at their centre point levels. 
  
4.2.2 Response surface methodology 
Response surface methodology was used as a tool to gain greater insight into the 
design space and the two factors chosen, cholesterol content and stearylamine 
content, were analysed against encapsulation efficiency, cellular uptake, 
polydispersity index, zeta potential and membrane leakage as responses. Each 
response will be discussed in the proceeding sections for both cyclo(His-Gly) and 
cyclo(His-Ala). The effects of the two factors on lipid peroxidation were tested, 
however, all values measured were too low due to the presence of high levels of 
HSPC and vitamin E selected based on the screening study and were therefore not 
included in the optimization of the final formulation. 
 
4.2.2.1  Encapsulation efficiency 
The quadratic model (2nd order polynomial model) was used in the analysis of 
encapsulation efficiency data for both cyclo(His-Gly) and cyclo(His-Ala) liposomes. 
ANOVA analysis for cyclo(His-Gly) liposomes showed the model to be significant (p = 
0.0005, r2 = 0.8120) with insignificant lack of fit (p = 0.0956). ANOVA analysis for 
cyclo(His-Ala) liposomes indicated that the model was significant (p = 0.0003, r2 = 
0.7421), also with insignificant lack of fit (p = 0.0594). A graph of predicted versus 
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actual values for both cyclo(His-Gly) and cyclo(His-Ala) liposomes was assessed to 
determine if the model was appropriate for prediction within the design space 
(Figure 4.16) and showed that there was a good correlation between the predicted 
and actual values that were close to the 45 line. 
 
 
Figure 4.16:  Predicted versus actual value for encapsulation efficiency for both cyclo(His-
Gly) and cyclo(His-Ala). 
 
Interaction between the two factors was assessed using the model, and although the 
interaction plot showed convergence of the two lines for both cyclo(His-Gly) and 
cyclo(His-Ala) liposomes (Figure 4.17), which are an indication of interaction, ANOVA 
analysis showed this interaction not to be statistically significant for both liposome 
preparations (p = 0.6345 and 0.6680 for cyclo(His-Gly) and cyclo(His-Ala) 
respectively). 
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Figure 4.17:  Interaction plot for encapsulation efficiency for liposomal cyclo(His-Gly) and 
cyclo(His-Ala). Although plots show a trend of convergence, a sign of 
interaction, ANOVA analysis showed insignificant interactions (p =0.6345 and 
0.6680 for cyclo(His-Gly) and cyclo(His-Ala) respectively). 
 
The three-dimensional surface plot for encapsulation efficiency for cyclo(His-Gly) 
liposomes (Figure 4.18) clearly demonstrates that simple two level factorial designs 
are inadequate at fully characterizing the design space when formulating liposomes 
as a non-linear relationship exists between factors and responses. The response 
surface shows that increasing levels of stearylamine significantly decreases the 
encapsulation of cyclo(His-Gly) (p = 0.0004).  
 
 
Figure 4.18:  Three–dimensional response surface for cyclo(His-Gly) liposomes with respect 
to encapsulation efficiency. 
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The polynomial equation for encapsulation efficiency, based on the response surface 
is shown in the equation below where A is stearylamine content, B is cholesterol 
content and EE is encapsulation efficiency: 
 
                                                             
 
The response surface for cyclo(His-Ala) liposomes on encapsulation efficiency (Figure 
4.19) shows a similar trend to that of cyclo(His-Gly) liposomes and also demonstrates 
a significant effect of stearylamine content, decreasing encapsulation efficiency with 
increasing content (p = 0.002). 
 
 
Figure 4.19:  Three-dimensional response surface for cyclo(His-Ala) liposomes with respect 
to encapsulation efficiency. 
 
The second order polynomial equation derived from the model, used to 
mathematically navigate the design space, is shown below: 
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4.2.2.2 Cellular uptake of carboxyfluorescein liposomes 
Carboxyfluorescein was used as a fluorescent marker to detect the quantity of 
liposomal content taken up by cultured cells. The average uptake was determined on 
both HeLa and MCF-7 cells. Data was fitted to a quadratic model and assessed for its 
ability to make predictions within the design space. A plot of predicted response 
versus actual response is shown in Figure 4.20 below. Good correlation exists 
between the predicted and actual responses with most values falling close to the 45 
line. As for the previous response, the model was evaluated using ANOVA with the 
model calculated to be significant (p = 0.0342, r2 = 0.5950) with a non-significant lack 
of fit (p = 0.8467) indicating that the second order polynomial model was appropriate 
in effectively navigating the design space. 
 
 
  
Figure 4.20:  Predicted versus actual value for cellular uptake of liposomal 
carboxyfluorescein. 
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Stearylamine content was shown to significantly increase cellular uptake of 
encapsulated carboxyfluorescein in cultured cells (p = 0.0122). Interaction effects 
between stearylamine content and cholesterol content was shown to be significant 
(p = 0.0216) indicating the one factor cannot be changed independent of the other 
(Figure 4.21). Literature has shown that liposomes containing cationic lipids, such as 
stearylamine, increases liposome interaction with cellular membranes, increasing the 
likelihood of endocytosis and intracellular drug delivery (Gao and Huang, 1995; 
Düzgüneş and Nir, 1999). 
 
 
Figure 4.21:  Interaction plot for cellular uptake of carboxyfluorescein liposomes. A trend of 
convergence was noted indicating interaction between the two factors (p = 
0.0496). 
 
The three-dimensional response surface plot (Figure 4.22) further illustrates the 
interaction effects between the two factors within the design space. 
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Figure 4.22:  Three-dimensional response surface for carboxyfluorescein liposomes with 
respect to cellular uptake. 
 
The second order polynomial equation used to mathematically navigate the design 
space for the response of cellular uptake (CU) is shown below: 
 
                                                
 
4.2.2.3 Polydispersity index 
The quadratic model (2nd order polynomial model) was used in the analysis of 
polydispersity index data for cyclo(His-Gly) and cyclo(His-Ala) liposomes. ANOVA 
analysis for cyclo(His-Gly) and cyclo(His-Ala) liposomes showed that fitting of both 
models was significant (p = 0.0035, r2 = 0.7341 for cyclo(His-Gly) and p = 0.0020, r2 = 
0.7595 for cyclo(His-Ala)) with insignificant lack of fit (p = 0.1425 and 0.1278 for 
cyclo(His-Gly) and cyclo(His-Ala) respectively). A graph of predicted versus actual 
values for both cyclo(His-Gly) and cyclo(His-Ala) liposomes was assessed to 
determine if the model was appropriate for the prediction of polydispersity within 
the design space (Figure 4.23) and it showed that there was a good correlation 
between the predicted and actual values that were close to the 45 line. 
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Figure 4.23:  Predicted versus actual value for polydispersity index for both cyclo(His-Gly) 
and cyclo(His-Ala). 
 
Interaction effects between cholesterol content and stearylamine content were 
analysed and it was determined that no interaction existed between the two factors 
with respect to polydispersity (Figure 4.24). The three dimensional response surface 
for polydispersity index shown in Figure 4.25 (cyclo(His-Gly)) and Figure 4.26 
(cyclo(His-Ala)) illustrates that for increasing levels of cholesterol, increased 
polydispersity of liposome samples occurred for both cyclo(His-Gly) and cyclo(His-
Ala) liposomes. This occurred at all levels of stearylamine. In their study, Corti and 
colleagues (2006), reported that increasing levels of cholesterol results in more rigid 
membranes and act to stabilize them. This is further confirmed where differential 
scanning calorimetric measurements have shown that increasing levels of cholesterol 
in the liposome membrane results in an increase in the transition temperature of the 
lipid membrane (Chong and Choate, 1989). This could potentially influence the 
efficiency of the extrusion process, resulting in broader particle size distributions, 
characteristic of a large polydispersity index. Controlling particle size of any 
nanoparticulate drug delivery system is essential in ensuring predictable responses 
with respect to biodistribution, toxicity, RES elimination and targeting ability (Chang 
et al., 2009) making it essential to produce particles with a homogenous size 
distribution and low polydispersity index. 
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Figure 4.24:  Interaction plot for polydispersity index for liposomal cyclo(His-Gly) and 
cyclo(His-Ala) liposomes. ANOVA analysis showed insignificant interactions for 
both cyclo(His-Gly) and cyclo(His-Ala). 
 
 
 
Figure 4.25:  Three-dimensional response surface for cyclo(His-Gly) liposomes with respect 
to polydispersity index. 
 
The 2nd order polynomial equation, derived from the model, can be used to define 
the design space with reference to polydispersity index (PI) for cyclo(His-Gly) 
liposomes and is shown in the equation below: 
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Figure 4.26:  Three-dimensional response surface for cyclo(His-Ala) liposomes with respect 
to polydispersity index. 
 
The 2nd order polynomial equation, derived from the model, can be used to define 
the design space with reference to polydispersity index for cyclo(His-Ala) liposomes 
and is shown in the equation below: 
 
                                                             
 
 
4.2.2.4 Zeta potential 
Zeta potential data for cyclo(His-Gly) and cyclo(His-Ala) liposomes was fitted to a 
quadratic model an assessed for its ability to make predictions within the design 
space. A plot of predicted response versus actual response is shown in Figure 4.27 
and indicates that correlation exists between the predicted and actual responses 
with most values falling close to the 45 line. The data was also evaluated using 
ANOVA, fitting zeta potential as the response for cyclo(His-Gly) and cyclo(His-Ala) 
liposomes to a 2nd order polynomial model, with an F-test indicating reasonable 
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goodness of fit for both data sets (p = 0.0001, r2 = 0.7875 for cyclo(His-Gly) and p = 
0.0251, r2 = 0.6182 for cyclo(His-Ala)) with a non-significant lack of fit for both cyclic 
dipeptide liposome data sets (p = 0.8929 and 0.6229 for cyclo(His-Gly) and cyclo(His-
Ala) respectively) indicating that the second order polynomial model was appropriate 
in effectively navigating the design space. 
 
   
Figure 4.27:  Predicted versus actual value for zeta potential for both cyclo(His-Gly) and 
cyclo(His-Ala). 
 
Analysis of the main effects revealed that for both cyclo(His-Gly) and cyclo(His-Ala) 
liposomes, only stearylamine content had significant influence on the zeta potential 
of the liposomes (p = 0.0001 for cyclo(His-Gly) and p = 0.0053 for cyclo(His-Ala) 
liposomes). Increasing stearylamine content was found to significantly increase the 
zeta potential in both data sets as shown in Figure 4.28. This is to be expected as 
stearylamine is a cationic lipid and it is well established that its inclusion in liposome 
formulations aids in the formation of cationic liposomes (Kotynska and Figaszewski, 
2007). However excessive or insufficient surface charge can lead to the instability of 
colloidal dispersions due to the influence surface charge has on colloidal stability 
according to the DLVO (Derjaguin and Landau, Verwey and Overbeek) theory, which 
describes how colloidal particles interact with one another in a dispersion (Aulton, 
2007). The optimal value for zeta potential of a liposome formulation is not well 
reported and depends on many factors, including the drug being encapsulated. 
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However, Du Plessis and colleagues (1996) have reported that liposomes with zeta 
potentials of above 30 mV show moderate to good stability, while those with zeta 
potentials of 30 mV and below could result in particle aggregation. Of all the 
measurements of zeta potential made, only one fell outside of the stable range with 
a reading of 28.13 mV. The difference between zeta potential measured for the 
centre point batches of cyclo(His-Gly) and cyclo(His-Ala) liposomes was tested and 
cyclo(His-Gly) liposomes had, on average, significantly higher zeta potential than 
those containing cyclo(His-Ala) (p = 0.00012, t-test). It is unsure why this was 
observed, as both cyclic dipeptides have very similar physicochemical properties and 
showed non-significant differences between responses for the centre points for all 
other responses except encapsulation efficiency (p = 0.0327, t-test). 
 
  
Figure 4.28:  Influence of stearylamine content on zeta potential measured for cyclo(His-
Gly) and cyclo(His-Ala) liposomes. Cholesterol content level set to 0 (coded). 
 
No significant interaction effects were noted for both cyclo(His-Gly) (p = 0.1859) and 
cyclo(His-Ala) (p = 0.3962) liposomes (Figure 4.29). A three-dimension surface plot, 
used to visualize the design space, is shown for cyclo(His-Gly) (Figure 4.30) and 
cyclo(His-Ala) (Figure 4.31) liposomes. 
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Figure 4.29:  Interaction plot for polydispersity index for liposomal cyclo(His-Gly) and 
cyclo(His-Ala) liposomes. ANOVA analysis showed insignificant interactions for 
both cyclo(His-Gly) and cyclo(His-Ala). 
 
 
 
 
Figure 4.30:  Three–dimensional response surface for cyclo(His-Gly) liposomes with respect 
to zeta potential. 
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Figure 4.31:  Three-dimensional response surface for cyclo(His-Ala) liposomes with respect 
to zeta potential. 
 
The visual response surfaces shown above can be mathematically represented in the 
second order polynomial equations for zeta potential (ZP) as a response as shown in 
the following equations for cyclo(His-Gly) (cHG) and cyclo(His-Ala) (cHA): 
 
                                     
               
 
                                     
              
 
 
4.2.2.5 Membrane leakage 
The degree to which a drug leaks out of a liposome is an important parameter in 
assessing the stability of the suspension. 5(6)-carboxyfluorescein was used as a 
fluorescent marker in determining the rate at which a hydrophilic substance is 
released from a liposome preparation. The data below represents the percentage 
release over a four hour incubation period with a 1:1 mixture of PBS and FCS at 37 
C. Data was analysed using ANOVA analysis and fitted to a quadratic model. ANOVA 
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analysis indicated the model to be extremely significant (p < 0.0001, r2 = 0.8601) and 
it was also shown to have insignificant lack of fit (p = 0.1407), indicating that the 
quadratic model was appropriate in navigating the design space. A graph of 
predicted versus actual response was derived from the data (Figure 4.32) and 
demonstrates correlation between the values predicted by the model equation and 
the actual measurements taken. The second order polynomial equation used to 
mathematically describe the model for the response of membrane leakage (ML) is 
shown below: 
 
                                                 
 
 
Figure 4.32:  Predicted versus actual values for membrane leakage for carboxyfluorescein 
liposomes. 
 
Cholesterol content in the liposome preparations was found to have a marked effect 
on the rate at which carboxyfluorescein escaped from the liposomes, decreasing the 
quantity escaping in 4 hours drastically with increasing cholesterol content in the 
liposome membrane as shown in Figure 4.33. The main effect of cholesterol content 
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on membrane leakage was therefore found to be extremely significant (p<0.0001). 
Several authors have indicated that cholesterol’s stabilizing effect on the lipid bilayer, 
possibly due to enhanced packing of the membrane, decreases its permeability and 
thereby improving its ability to retain encapsulated material (Kirby et al., 1980; Du 
Plessis et al., 1996). This result was therefore expected. 
 
 
Figure 4.33:  Influence of cholesterol content on the extent of leakage from 
carboxyfluorescein liposomes showing a significant reduction in leakage with 
increasing concentration (p < 0.0001). 
 
Interaction effected between cholesterol content and stearylamine content of 
carboxyfluorescein release was also tested using ANOVA. No significant interaction 
effects were statistically detectable and the interaction plot for the two factors 
showed no convergence (Figure 4.34), indicating that the two factors have no 
influence on each other with respect to membrane leakage. The response surface 
plot for the response of membrane leakage, as shown in Figure 4.35, displays the 
data visually in order to better understand the design space. 
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Figure 4.34:  Interaction plot for membrane leakage for carboxyfluorescein liposomes. 
ANOVA analysis showed insignificant interaction between stearylamine and 
cholesterol content (p = 0.7095). 
 
 
 
Figure 4.35:  Three-dimensional response surface for carboxyfluorescein liposomes with 
respect to membrane leakage. 
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4.2.3 Formulation optimization 
4.2.3.1 Statistical optimization  
One of the benefits of using a 5-level factorial design such as the central composite 
rotatable design used in this study, is that the responses are assessed at more than 
two levels, as with a 2n factorial design, enabling the researcher to make better 
predictions regarding the design space. This is due to the fact that the true 
relationship between independent and dependent variables is determined as 
opposed to the assumed linear relationship for 2n factorial designs (Myers et al., 
2009). As a result, better optimization of the formula is possible due to greater 
knowledge of the design space. Ordinarily, with a design investigating a single 
response, the response surface generated for that response can be used to choose a 
point on the surface where the optimal response is achieved (Anderson and 
Whitcomb, 2005). However, if more than one response is being investigated, the 
process of optimization becomes more complex. In this study, five responses were 
analysed for two factors, requiring an additional optimization step. In this step, a 
desirability factor was calculated based in the criteria outlined in Section 3.4.2.2 
above. In order to optimize a formulation for more than one response, it is necessary 
to compromise some factors in order to optimize others and the desirability may 
therefore not be at its optimum, which is 1.0 (Anderson and Whitcomb, 2005). The 
three-dimensional surface plot for the desirability factor as a function of cholesterol 
and stearylamine content for cyclo(His-Gly) and cyclo(His-Ala) liposomes are 
illustrated in Figures 4.36 and 4.37 below. A point on the surface that showed the 
greatest desirability is shown on both graphs, and it was at this point that the 
optimum formulation for both cyclic dipeptides was chosen. The optimized 
compositions along with their predicted responses are shown in Table 4.8. These 
formulations were then prepared in duplicate and analysed for all five responses as 
discussed in Section 4.2.4.2 below . 
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Figure 4.36:  Three–dimensional response surface for cyclo(His-Gly) liposomes evaluating 
desirability for optimization. 
 
 
 
 
Figure 4.37:  Three–dimensional response surface for cyclo(His-Ala) liposomes evaluating 
desirability for optimization. 
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Table 4.8: Optimized formulations for cyclo(His-Gly) and cyclo(His-Ala) liposomes. 
Optimized parameter 
Cyclo(His-Gly) 
Liposomes 
Cyclo(His-Ala) 
Liposomes 
Stearylamine content 0.5 % of lipid 0.5 % of lipid 
Cholesterol content 29.2 % of lipid 26.3 % of lipid 
Predicted responses   
Encapsulation efficiency 0.128 mg/mg lipid 0.118 mg/mg lipid 
Cellular uptake 137.1% 150.0 % 
Polydispersity index 0.073 0.067 
Zeta potential 36.65 mV 29.23 mV 
Membrane leakage 27.43% 30.32 % 
Desirability 0.706 0.695 
 
The final formulae for the lipid component of both cyclo(His-Gly) and cyclo(His-Ala) 
liposome formulations are shown in Table 4.9. 
 
Table 4.9:  Composition of lipid films for optimized liposome formulations.  
Component 
Cyclo(His-Gly) 
Liposomes 
Cyclo(His-Ala) 
Liposomes 
Phosphatidylcholine 
(Soy) 
13.7 mg 14.3 mg 
Hydrogenated soy 
phosphatidylcholine 
13.5 mg 14.0 mg 
Cholesterol 5.6 mg 5.1 mg 
Stearylamine 0.07 mg 0.07 mg 
Vitamin E 1 mg 1 mg 
PEG-DSPE 0.7 mg 0.7 mg 
 
4.2.3.2 Characterization of optimized formulations 
4.2.3.2.1 Encapsulation efficiency 
The measured encapsulation of the optimized liposomes for cyclo(His-Gly) and 
cyclo(His-Ala) was marginally lower than the predicted values, with optimized 
cyclo(His-Gly) liposomes having an encapsulation of 0.115 +/- 0.012 mg/mg lipid, a 
difference of 10.2%. Optimized cyclo(His-Ala) liposome encapsulation was 0.105 +/- 
0.005 mg/mg lipid, having an 11.0% difference from the predicted value (Figure 
4.38). The difference in measured and predicted encapsulation is relatively low 
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considering that inter batch variability is often a problem with liposome formulations 
(Barenholz, 2001). 
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Figure 4.38: Comparison of predicted versus measured encapsulation efficiency for 
cyclo(His-Gly) and cyclo(His-Ala) liposomes.  
 
 
4.2.3.2.2 Cellular uptake of 5(6)-carboxyfluorescein 
Both formulations used for cyclo(His-Gly) and cyclo(His-Ala) were used to 
encapsulate 5(6)-carboxyfluorescein and assessed for uptake into HeLa cells. Both 
formulations showed a significant increase in uptake when compared to the control 
of free carboxyfluorescein. The percentage increase in cellular uptake of 
carboxyfluorescein over a four hour incubation was calculated and the formulation 
used for cyclo(His-Gly) showed an increase of 142.2% when compared to free 
carboxyfluorescein, while the formulation used for cyclo(His-Ala) liposomes had a 
148.7% increase in cellular uptake. The difference between the two formulations was 
not statistically significant (p = 0.8018), which is not surprising since the two 
formulations were very similar in composition. The predicted values for cellular 
uptake as calculated using the RSM design were 137.1% and 150.0% for cyclo(His-
Gly) and cyclo(His-Ala) liposome formulations respectively. The percentage 
difference between measured and predicted values were 3.72% and 0.87% for 
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cyclo(His-Gly) and cyclo(His-Ala) formulations respectively, which indicates a very 
close correlation between the predicted and actual values for this response. The 
uptake profile, measured every hour for the four hour incubation period, is shown in 
Figure 4.39, indicating that both formulations displayed very similar kinetics. 
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Figure 4.39:  Profiles for cellular uptake of encapsulated 5(6)-carboxyfluorescein into HeLa 
cells (n = 4 for each point). 
 
 
4.2.3.2.3 Particle size distribution, zeta potential and particle shape 
The mean particle diameter for cyclo(His-Gly) liposomes was 134.5 +/- 1.082 nm 
while the mean diameter for cyclo(His-Ala) liposomes was found to be slightly larger 
at 145.3 +/- 0.20 nm. Figure 4.40 represents the particle size distribution for samples 
of cyclo(His-Gly) and cyclo(His-Ala) liposomes. 
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Figure 4.40: Particle size distribution of cyclo(His-Gly) (red curve) and cyclo(His-Ala) (green 
curve) liposomes. 
 
Zeta potential measured for both samples was found to be outside of the range 
predicted. Cyclo(His-Ala) liposomes showed much lower zeta potential than 
predicted at a mean zeta potential of 8.35 +/- 0.579 mV, while cyclo(His-Gly) 
liposomes had higher measured potentials at 21.2 +/- 1.22 (Figure 4.41). Reasons for 
the difference between the predicted value and the measured value are uncertain, 
but may be due to the optimization criteria on specifying that the zeta potential be 
within a particular range and not maximized. Implications of lower zeta potentials, 
could result in instability of the colloidal liposome dispersion and possible 
aggregation for zeta potentials lower than 10 mV (Du Plessis et al., 1996), which is of 
particular concern for cyclo(His-Ala) liposomes. 
 
 
Figure 4.41:  Zeta potential distribution for cyclo(His-Gly) (red) and cyclo(His-Ala) (green) 
liposomes. Single measurements are shown, but mean zeta potential was 
calculated from three replicate measurements. 
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Particle shape and morphology was assessed using transmission electron microscopy 
(TEM). TEM images of cyclo(His-Gly) and cyclo(His-Ala) (Figure 4.42) show spherical 
particles with what can be described as ‘fuzzy’ edges that are attributed to the PEG 
chains. Particle size correlates well with data obtained using photon correlation 
spectroscopy. No particle aggregation was noted in samples. The particles show a 
relatively low electron density as samples were not stained. 
 
  
Figure 4.42:  Transmission electron microscope images of cyclo(His-Gly) (left) and cyclo(His-
Ala) (right) liposomes (magnification: 80 000×) 
 
4.2.3.2.4 5(6)-Carboxyfluorescein leakage 
The rate at which carboxyfluorescein was released from 5(6)-carboxyfluorescein that 
leaked from formulations prepared from the same composition as those used to 
prepare the optimized cyclo(His-Gly) and cyclo(His-Ala) liposomes was evaluated for 
the extent to which they release the hydrophilic fluorescent marker in the presence 
of plasma components. The release of both formulations was found to be similar to 
that predicted by the RSM design (Figure 4.43). 
cyclo(His-Gly)                              cyclo(His-Ala)  
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Figure 4.43:  Release of 5(6)-carboxyfluorescein from liposomes with the same composition 
as those optimized for the delivery of cyclo(His-Gly) and cyclo(His-Ala) (n = 4 
for each point). 
 
4.2.3.2.5 Stability 
The stability of the liposome dispersions were assessed by analysing the particle size 
and polydispersity index of liposomes stored at 4 C for one month and at 
accelerated temperature conditions (45 C) for one week. The particle size 
distribution of both cyclo(His-Gly) and cyclo(His-Ala) showed little change in particle 
size and polydispersity index when stored at 4 C with mean particle diameters of 
154.4 +/- 1.40 nm and 172.5 +/- 2.54 nm for cyclo(His-Gly) and cyclo(His-Ala) 
respectively, however notable increase in particle size occurred for both cyclic 
dipeptide liposome dispersions stored at accelerated conditions. Cyclo(His-Gly) 
liposomes had a mean particle diameter of 315.3 +/- 8.26 nm, more than double the 
original mean particle diameter of 134.5 +/- 1.082 nm. Cyclo(His-Ala) also showed a 
marked increase in particle diameter with a mean diameter of 379.6 +/- 3.82 nm as 
opposed to 145.3 +/- 0.20 nm that was measured prior to incubation at 45 C. A 
comparison of particle size distributions is shown in Figure 4.44. TEM images of 
liposomes, stored at 45 C, indicate that liposome vesicles appeared to have 
coalesced at elevated temperatures (Figure 4.45). Increased fluidity of the liposome 
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membrane due to elevated temperatures may have resulted in this phenomenon. 
Long term storage of the liposome formulations at room temperature may therefore 
not be likely, however, lyophilization of liposome preparations could prevent this and 
it has been shown that freeze drying of liposomes is possible with little loss of 
stability over long term storage (Cui et al., 2006; Chen et al., 2010).  
 
 
 
Figure 4.44: Particle size distribution of cyclo(His-Ala) and cyclo(His-Gly) liposomes stored at 
4 C and 45 C. 
 
 
  
Figure 4.45: TEM images of cyclo(His-Gly) and cyclo(His-Ala) liposomes stored at 45 C. 
Magnification varies and is indicated on each image. 
 
 
cyclo(His-Gly)      40 000X                          cyclo(His-Ala)   12 000X 
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4.3 ANTICANCER ACTIVITY OF LIPOSOMAL CYCLO(HIS-GLY) AND CYCLO(HIS-ALA) 
4.3.1 Cytotoxicity of free cyclic dipeptides 
The cytotoxicity of cyclo(His-Gly) and cyclo(His-Ala) was evaluated against both HeLa 
and MCF-7 cell lines. HeLa cells are human cervical adenocarcinoma cells while MCF-
7 cells are human breast epithelial carcinoma cells (Freshney, 2010). These cell lines 
were chosen as cyclo(His-Gly) and cyclo(His-Ala) have exhibited activity against these 
lines in a previous study (Lucietto et al., 2006) and HeLa, in particular, have been 
shown to readily upregulate folate receptors when exposed to reduced levels of folic 
acid (Lee and Low, 1995) which was a necessary characteristic for the folate receptor 
targeting studies. 
 
Lucietto and colleagues (2006) reported that 100 M of both cyclo(His-Gly) and 
cyclo(His-Ala) exhibited significant inhibition of, in some cases, greater than 80%. 
Despite this report, the inhibitory actions of both cyclic dipeptides was found to be 
relatively limited and IC50 values for cyclo(His-Gly) and cyclo(His-Ala) were 1.103 mM 
and 0.3244 mM respectively for HeLa cells (Figure 4.46) and 0.630 mM and 1.258 
mM respectively for MCF-7 cells (Figure 4.47). Despite using the same MTT assay for 
the determination of cell viability, the results obtained in the previous study could 
not be duplicated. Cyclo(His-Gly) and cyclo(His-Ala) did, however, still exhibit 
promising activity. Reasons for the discrepancy in activity may be due to slight 
variations in cell lines cultured in different laboratories and the development of 
resistance.  
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Figure 4.46:  Dose-response relationship for the cytotoxicity of cyclo(His-Gly) and cyclo(His-
Ala) tested on HeLa cells (n = 4 for each point, r2=0.9441 and 0.9549 for 
cyclo(His-Gly) and cyclo(His-Ala) respectively). Positive controls, methotrexate 
and 5-Fluorouracil yielded inhibitions of 79.3% and 82.9% respectively at 100 
M. 
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Figure 4.47:  Dose-response relationship for the cytotoxicity of cyclo(His-Gly) and cyclo(His-
Ala) tested on MCF-7 cells (n = 4 for each point, r2=0.9359 and 0.9618 for 
cyclo(His-Gly) and cyclo(His-Ala) respectively). Positive controls, methotrexate 
and 5-Fluorouracil yielded inhibitions of 83.2% and 88.4% respectively at 100 
M. 
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4.3.2 Influence of liposome encapsulation on cyclic dipeptide cytotoxicity 
Encapsulation of cyclo(His-Gly) into liposomes showed a slight apparent increase in 
activity against HeLa cells, although not significant within the concentration range 
tested. As can be seen from Figure 4.48, the IC50 value for cyclo(His-Gly) liposomes 
was slightly higher than free drug (1.699 mM as opposed to 1.103 mM). The 
concentration range tested for cyclo(His-Gly) liposomes indicated that at the highest 
concentration tested, inhibition was still in an exponential increase phase. Slower 
inhibitory response of liposome encapsulated drug may have been as a result of 
slower release of the drug, and thus lower levels of free drug available for inhibition. 
As the liposomes were not targeted to the cells, cellular uptake may have been 
slower than anticipated. Many studies have shown that drugs encapsulated into non-
targeted liposomes display a decrease in IC50 when compared to the free drug (Lee 
and Low, 1995; Serpe et al., 2004; Zhang et al., 2004) and the benefits should not 
been viewed in the light of a decrease in IC50, but rather the decreased non-specific 
cytotoxic effects on free cytotoxic agents that leads to high side effect profiles.  
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Figure 4.48:  Comparison of the dose-response relationship for the cytotoxicity of free 
cyclo(His-Gly) with liposome encapsulated cyclo(His-Gly) tested on HeLa cells 
(n = 4 for each point). IC50 for cyclo free cyclo(His-Gly) was 1.103 mM (r
2 = 
0.9441) and 1.699 mM (r2 = 0.9014) for cyclo(His-Gly) liposomes. 
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A similar trend was noted for cyclo(His-Ala) liposomes against HeLa cells as indicated 
in Figure 4.49. An IC50 value of 0.3532 mM was calculated for liposomal cyclo(His-Ala) 
as opposed to 0.3244 mM for free drug using non-linear dose-response regression 
analysis.  
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Figure 4.49:  Comparison of the dose-response relationship for the cytotoxicity of free 
cyclo(His-Ala) with liposome encapsulated cyclo(His-Ala) tested on HeLa cells 
(n = 4 for each point). IC50 for liposomal cyclo(His-Ala) was 0.3532 mM (r
2 = 
0.9758) as opposed to 0.3244 mM (r2 = 0.9549) for free cyclo(His-Ala). 
 
 
The effects of encapsulation was more notable in MCF-7 cells where both 
encapsulated drugs showed a marked decrease in calculated IC50 as shown in Figures 
4.50 and 4.51. IC50 for cyclo(His-Gly) liposomes decreased to 0.3584 mM from 0.6296 
mM for the free drug, while the IC50 for cyclo(His-Ala) liposomes reduced to 0.4978 
mM from 1.258 mM of free cyclo(His-Ala). Therefore, for MCF-7 cells, cellular entry 
of liposome encapsulated drug was improved when compared to non-encapsulated 
drug. The Log P for both drugs was low as reported in Section 4.1.1 and could result 
in poor cellular uptake of the drugs. Encapsulation would therefore enhance cellular 
entry and promote cytotoxicity. A summary of the results is given in Table 4.10. 
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Figure 4.50:  Comparison of the dose-response relationship for the cytotoxicity of free 
cyclo(His-Gly) with liposome encapsulated cyclo(His-Gly) tested on MCF-7 cells 
(n = 4 for each point). IC50 for free cyclo(His-Gly) was 0.6296 mM (r
2 = 0.9359) 
compared to 0.3584 mM (r2 = 0.9483). 
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Figure 4.51:  Comparison of the dose-response relationship for the cytotoxicity of free 
cyclo(His-Ala) with liposome encapsulated cyclo(His-Ala) tested on MCF-7 cells 
(n = 4 for each point). IC50 for free cyclo(His-Ala) was 1.258 mM (r
2 = 0.9618) 
compared to 0.4978 mM (r2 = 0.9811). 
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Table 4.10:  Summary of IC50 cytotoxicity results for free and liposome encapsulated cyclic 
dipeptides. Figures represent IC50 values calculated from dose-response 
analysis and are in mM. The positive controls, methotrexate and 5-fluorouracil 
were tested at concentrations of 100 M to validate the assays and all resulted 
in inhibitions above 80%. 
Cell Line 
Liposome encapsulated Free 
cyclo(His-Gly) cyclo(His-Ala) cyclo(His-Gly) cyclo(His-Ala) 
HeLa 1.699 mM 0.353 mM 1.103 mM 0.324 mM 
MCF-7 0.358 mM 0.498 mM 0.630 mM 1.258 mM 
 
Despite showing no improvement over the inhibitory effect of the cyclic dipeptides 
against HeLa cells, improvement was noted against MCF-7 cells. The difference in the 
IC50 parameter for liposome cyclic dipeptides was not large for HeLa cells. In their 
study, Lee and Low (1995) showed that the IC50 of free doxorubicin was 0.43 M as 
opposed to non-targeted liposomal doxorubicin with an IC50 of 25.3 M. As free 
doxorubicin shows good permeation into cells, it was concluded by the authors that 
a reduction in the cytotoxic activity was due to slower release of doxorubicin from 
liposome formulations. The results obtained in this study are therefore promising as 
the difference between encapsulated and non-encapsulated drug for HeLa cells was 
marginal, while an improvement in activity was noted for encapsulated cyclic 
dipeptides on MCF-7 cells. This further emphasizes the problems faced with drugs 
exhibiting low permeation due to poorly lipophilic properties. Lee and Low (1995) as 
well as others (Gabizon et al., 1999; Saul et al., 2003; Gabizon et al., 2004; Zhang et 
al., 2004; Yoshida et al., 2006; Xiang et al., 2008) have proposed that, while non-
targeted liposomes reduce the side effect profile of cytotoxic drugs, incorporation 
into liposomes targeted to a particular receptor that over express in tumour cells, 
such as the folate receptor, would enhance cellular uptake of the liposome contents 
through receptor mediated endocytosis. This strategy was therefore used to improve 
the cytotoxic actions of cyclo(His-Gly) and cyclo(His-Ala) and is discussed in Section 
4.4 below. 
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4.4 FOLATE RECEPTOR TARGETING 
4.4.1 Influence of folic acid on folate receptor expression 
The influence of folic acid concentration in culture medium on folate receptor 
expression is shown in Figure 4.52 below. Folate receptor density was approximately 
five-fold higher in cells cultured at physiological folic acid levels for 8 weeks, which is 
comparable to previous studies (Kane et al., 1988), indicating significant upregulation 
of the receptor with reduced folic acid. The relationship between extracellular folic 
acid and folate receptor expression appears to follow an exponential decay of 
receptor expression with increasing folic acid concentration.  
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Figure 4.52:  Influence of folic acid content of growth medium on folate receptor 
upregulation in HeLa cells (n = 3 for each point). Folic acid concentration is 
represented as a percent of total folic acid in normal RPMI-1640 medium 
(containing 1 mg/L folic acid). 
 
 
4.4.2 Influence of folate receptor expression on the cytotoxicity of 5-fluorouracil 
5-Fluorouracil, a thymine analogue, is a chemotherapeutic agent used in the 
treatment of various forms of neoplasia, most commonly gastrointestinal cancer, and 
is often used in combination with other agents (Jackman, 1999). Its mechanism of 
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action is mostly due to its conversion to one of its metabolites, 5'-fluorouridylate 
monophosphate (5FdUMP) which inhibits the enzyme thymidylate synthase, 
responsible for the methylation of deoxyuridylate monophosphate (dUMP) into 
deoxythymidylate monophosphate (dTMP). The methyl donor for this reaction is a 
folic acid derivative and the product, dTMP, is essential in DNA synthesis (Jackman, 
1999; Jackman et al., 2004). 5-Fluorouracil was used as a control drug in all 
cytotoxicity assays and was chosen specifically for its actions on folic acid 
metabolism. It was therefore of interest to determine the role folate receptor 
expression played in the effectiveness of 5-fluorouracil. 
 
While there are several reports illustrating the influence of folic acid content of 
culture medium on the upregulation of folate receptors in cell cultures (Gates et al., 
1996; Antony et al., 2004; Zhang et al., 2004), little is known about the influence of 
extracellular folic acid concentration on the degree of folate receptor upregulation or 
its influence on the cytotoxicity of anticancer drugs. Figure 4.53 illustrates the effects 
of folic acid content in culture medium on the inhibitory action of 5-fluorouracil. The 
cells used in these assays had been conditioned to grow in the reduced levels of folic 
acid over a period of 8 weeks before testing and cells were washed three times with 
PBS and the culture medium replaced with folic acid free medium during the 
incubation phase. The results were therefore not due to folate receptor competition, 
but were attributable to the influence of receptor upregulation. The summarized 
statistical parameters (IC50, Hill slope and r
2) are shown in Table 4.11 below the 
graph. A significant decrease in the IC50 parameter was noted for increasing folic acid 
content and ranged from as low as 5.88 M for cells exposed to physiological folic 
acid concentrations and as high as 51.05 M for cells exposed to folic acid 
concentrations routinely used in cell culture and, more specifically, for cytotoxicity 
assays. 
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Figure 4.53:  Influence of folic acid content of growth medium on the inhibitory action of 5-
fluorouracil on HeLa cells (n = 3 for each point). 
 
Table 4.11:  Influence of extracellular folic acid concentration on the inhibitory actions of 5-
fluorouracil (as determined by non-linear regression analysis). 
[Folic Acid] IC50 
Correlation 
coefficient (r2) 
Hillslope factor 
1.00 mg/L 51.05 M 0.9771 1.958 
0.75 mg/L 46.58 M 0.9819 1.287 
0.50 mg/L 39.08 M 0.9822 1.563 
0.25 mg/L 31.50 M 0.9734 2.386 
0.001 mg/L 5.88 M 0.9014 0.991 
 
In order to establish a mathematical relationship between folic acid concentration 
and cytotoxic activity of 5-fluorouracil, a graph of IC50 as a function of folic acid 
concentration was derived from the data (Figure 4.54). The best fit model for the 
relationship between the dependent and independent variable was a 2nd order 
polynomial equation (r2 = 0.9731). This therefore indicates plateau behaviour and 
indefinitely increasing folic acid concentration will not indefinitely increase the IC50 of 
the drug. This finding could potentially influence the manner in which we screen for 
anticancer agents, as physiologically inappropriate levels of folic acid could mask the 
179 
 
potential cytotoxic potential of agents being screened, masking their benefits as new 
anticancer drugs. 
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Figure 4.54:  Relationship between folic acid content of growth medium with the IC50 of 5-
fluorouracil in HeLa cells. Data was fitted to a 2nd order polynomial equation (r2 
= 0.9731, y = 7.68 + 90.60x – 48.43x2). 
 
The relationship between receptor density (reported in Section 4.4.1 above) and IC50 
for 5-fluoruracil, was also determined. The graph of 5-fluorouracil as a function of 
folate receptor concentration is shown in Figure 4.55 below. The mathematical 
relationship was investigated and two possible models are proposed. The first is a 
linear relationship with the linear equation y = -5.374x +58.14 (r2 = 0.9661) as well as 
a 3rd order polynomial equation that resulted in a greater degree of correlation (r2 = 
0.9939) than the linear model, with the equation y = 72.71 – 19.51x + 3.54x2 – 
0.238x3. Both of the proposed models are not ideal, as they would result in the graph 
intercepting with the x-axis, implying that the IC50 for 5-fluorouracil would be 
negative for higher folic acid concentrations, which is impossible. It is therefore 
recommended that the effects of 5-fluorouracil on cells stabilized at even higher folic 
acid levels be investigated. 
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Figure 4.55:  Relationship between folate receptor expression and IC50 of 5-fluorouracil in 
HeLa cells. Data was fitted to a linear equation shown as a solid blue line (r2 = 
0.9661, y = -5.374x + 58.14) as well as a 3rd order polynomial equation (r2 = 
0.9939, y = 72.71 – 19.51x + 3.54x2 – 0.238x3).  
 
4.4.3 Characterization of folic acid tethered liposomes 
4.4.3.1 Encapsulation efficiency 
Encapsulation efficiency for folate tethered liposomal cyclo(His-Gly) was calculated 
at 0.1354 +/- 0.00739 mg/mg lipid which was significantly higher (p = 0.0163) than 
for cyclo(His-Ala) which had an encapsulation of 0.090623 +/- 0.0141 mg/mg lipid. 
When compared to non-targeted liposomes, encapsulation was higher for targeted 
cyclo(His-Gly) liposomes than non-targeted liposomes (0.1354 as opposed to 0.115 
mg/mg lipid, p = 0.0341) while lower encapsulation was measured for targeted 
cyclo(His-Ala) liposomes as opposed to the non-targeted liposomes (0.09062 as 
opposed to 0.105 mg/mg lipid, p = 0.0475).  
 
4.4.3.2 Particle size, shape and charge  
Particle size distribution as measured by photon correlation spectroscopy (Figure 
4.56) showed that there was no notable difference in particle size distribution for 
cyclo(His-Gly) and cyclo(His-Ala) targeted liposomes (p = 0.590) with mean particle 
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diameters of 150.0 +/- 1.021 nm and 152.5 +/- 6.780 nm for cyclo(His-Gly) and 
cyclo(His-Ala) liposomes respectively.  
 
Figure 4.56:  Particle size distribution of folate-targeted cyclo(His-Gly) (red) and cyclo(His-
Ala) (green).  
 
Zeta potentials for folate-targeted liposomes were lower than non-targeted 
liposomes (21.2 +/- 1.22 mV for cyclo(His-Gly) and 8.35 +/- 0.579 mV for cyclo(His-
Ala) liposomes). Of particular concern were the low zeta potentials measured for 
cyclo(His-Ala) folate-targeted liposomes as particularly low zeta potential for cationic 
liposomes could lead to problems in colloid stability, resulting in particle aggregation 
or coalescence during storage (Du Plessis et al., 1996). Section 4.4.3.3 below outlines 
the problems experience on storage for these liposomes. Inclusion of the folic acid 
moiety on the PEG chain seems to have decreased the measured zeta potential, 
which found to be particularly profound for cyclo(His-Ala) liposomes. Interaction 
between cyclo(His-Ala) and the folate is suspected and requires further investigation. 
 
Shape and morphology of the liposomes as viewed using TEM imaging was consistent 
with previous results and particle size observed was consistent with data obtained 
using photon correlation spectroscopy (Figure 4.57). 
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Figure 4.57: TEM images of folate-targeted liposomes encapsulating cyclo(His-Gly) (left) 
and cyclo(His-Ala) (right). Magnification was 80 000× and 50 000× respectively. 
 
4.4.3.3 Cellular uptake of 5(6)-carboxyfluorescein loaded folate-targeted liposomes 
Cellular uptake of folate-targeted liposomes was markedly increased when compared 
to non-targeted liposomes (Figure 4.58). Uptake of liposomal carboxyfluorescein by 
HeLa cells conditioned to grow in low folate medium showed an approximate 
doubling of the uptake of the fluorescent marker after four hours incubation, which 
was to be expected. Several reports (Lee and Low, 1995; Zhang et al., 2004) have 
shown similar results for cellular uptake in low folate HeLa cells and can be 
attributed to the upregulation of the folate receptors in response to depleted folic 
acid. In a study by Saul and colleagues (2003), similar increases of 2 – 3 fold in 
cellular uptake of doxorubicin was reported for cells cultured, while Lee and Low 
(1995) reported a 30-fold increase in doxorubicin uptake in HeLa cells cultured in low 
folic acid medium. In the latter study, however, doxorubicin was entrapped into 
liposomes using the remote loading method and showed very high encapsulation 
rates which would deliver more drug per liposome. The results obtained here are 
therefore consistent with the literature. 
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Figure 4.58:  Uptake of 5(6)-carboxyfluorescein from targeted and non-targeted liposomes 
(n = 4 for each point). 
 
4.4.3.4 Stability 
The physical stability of the liposome dispersions was assessed against particle size at 
4 C for one month and 45 C for one week. Both folate-targeted cyclic dipeptide 
liposomes showed no significant change in particle size when stored at 4 C. Storage 
at 45 C, however, showed significant increases in particles size with subsequent 
instability associated with particle aggregation. Particle size distribution revealed 
bimodal distributions for both liposome preparations stored at 45 C with higher 
intensities displayed for modes at the higher particle diameter which is an indication 
of particle aggregation (Figure 4.59). TEM images of liposomes stored at 45 C 
confirmed these findings showing significant particle growth, most likely due to 
coalescence above the transition temperature of the lipids (Figure 4.60). Addition of 
the folic acid moiety appears to have decreased the stability of the liposome 
dispersion. Very few reports have highlighted potential instability of folate-targeted 
liposomes. One study (Shi et al., 2002) showed that decreasing pH may result in 
aggregation of liposomes, but did not investigate elevated temperatures. A 
recommendation would therefore be to further investigate the apparent 
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temperature-dependent particle aggregations demonstrated by the folic acid-
tethered liposomes. Also, this finding highlights the need to optimize formulations 
using statistical design, as simple substitution of PEG with folic acid conjugated PEG 
has resulted in instability of the formulation.  
 
 
 
Figure 4.59:  Particle size distribution of folate-targeted liposomes containing cyclo(His-Gly) 
and cyclo(His-Ala) stored at 4 C for one month and 45 C for one week. 
 
 
 
Figure 4.60: TEM imaged of folate-targeted liposomes encapsulating cyclo(His-Gly) and 
cyclo(His-Ala) after one week incubation at 45 C. Magnification is 12 000× and 
10 000× for cyclo(His-Gly) and cyclo(His-Ala) liposome images respectively. 
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4.4.4 Cytotoxicity of folic acid tethered liposomes 
The cytotoxicity of folate-targeted liposomes was assessed against MCF-7, HeLa and 
HeLa low folate cells and compared non-targeted liposome encapsulated cyclic 
dipeptides. Folate receptor targeting resulted in significant increase in inhibitory 
action of both cyclo(His-Gly) and cyclo(His-Ala) when tested against HeLa cells 
cultured in normal RPMI-1640 as well as folate free RPMI-1640 media as well as 
MCF-7 cells.  
 
IC50 values recorded for targeted liposomes against HeLa cells cultured in high folate 
media were reduced to 0.6153 mM (r2 = 0.9503) for cyclo(His-Gly) and 0.3775 mM (r2 
= 0.9604) for cyclo(His-Ala) when compared to non-targeted liposomes (1.029 mM 
and 0.6194 mM for cyclo(His-Gly) and cyclo(His-Ala) respectively (Figure 4.61). The 
decrease in IC50 was more pronounced in low folate HeLa cells with IC50 values of 
0.1807 mM (r2 = 0.9673) and 0.09617 mM (r2 = 0.9797) for cyclo(His-Gly) and 
cyclo(His-Ala) when compared to 0.3692 mM and 0.1680 mM respectively (Figure 
4.63). The increase in activity of folate-targeted liposomes was most likely due to 
greater internalization of encapsulated drug as a result of folate-receptor mediated 
endocytosis, increasing the intracellular concentrations of the drug as has been 
shown previously with folate-ligand liposomes (Lee and Low, 1995). Increased 
receptor numbers also played a role in the enhanced activity of liposomal activity 
with the greatest activity being recorded for cyclo(His-Ala) targeted liposomes 
against HeLa cells cultured in folic acid free medium. The overall inhibitory action of 
the two cyclic dipeptides was more pronounced in these HeLa cells, whether 
targeted or non-targeted and further highlights the problems with using high folic 
acid concentrations in cytotoxicity assays as outlined above. Although the 
cytotoxicity assays were all performed in low folate medium, residual folic acid left 
on the cell surface during the culturing process could have resulted in competitive 
binding to folate receptors, preventing cell interactions with targeted liposomes. 
Despite this potential competition and low folate receptors as illustrate above 
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(Section 4.4.1), increased activity for targeted liposomes was still observed in all cell 
lines.  
-1.5 -1.0 -0.5 0.0 0.5
0
20
40
60
80
Cyclo(His-Gly) Non-targeted
Cyclo(His-Gly) Targeted
Cyclo(His-Ala) Non-targeted
Cyclo(His-Ala) Targeted
Log Concentration (mM)
%
 I
n
h
ib
it
io
n
 
Figure 4.61:  Influence of folate receptor targeting on the cytotoxicity of cyclo(His-Gly) and 
cyclo(His-Ala) on HeLa cells cultured in normal RPMI-1640 medium expressing 
low folate receptor levels (n = 4 for each point). 
 
An increase in the cytotoxic activity of targeted liposomes was also observed for both 
cyclic dipeptides against MCF-7 cells. Cyclo(His-Gly) displayed a 42% reduction in IC50 
decreasing to 0.2094 mM (r2 = 0.9674) from 0.3584 (r2 = 0.9483) for the non-targeted 
liposomes. Cyclo(His-Ala) displayed a substantial decrease of 63% in recorded IC50, 
decreasing from 0.4987 mM (r2 = 0.9811) for non-targeted liposomes to 0.1856 mM 
(r2 = 0.9818) (Figure 4.62). Table 4.12 shows a summary the results. 
 
Table 4.12: IC50 data for targeted and non-targeted liposomal cyclo(His-Gly) and cyclo(His-
Ala). Values calculated using non-linear dose-response regression analysis. NF 
= normal folic acid media, LF = low folic acid media, FR = Folate receptor. 
Cell line 
cyclo(His-Gly) cyclo(His-Ala) 
Non-targeted FR Targeted Non-targeted FR Targeted 
HeLa NF 1.029 mM 0.6153 mM 0.6194 mM 0.3775 mM 
HeLa LF 0.3695 mM 0.1807 mM 0.1680 mM 0.0962 mM 
MCF-7 0.3584 mM 0.2094 mM 0.4987 mM 0.1856 mM 
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Figure 4.62:  Influence of folate receptor targeting on the cytotoxicity of cyclo(His-Gly) and 
cyclo(His-Ala) on HeLa cells cultured in folic acid free RPMI-1640 medium 
expressing high folate receptor levels (n = 4 for each point). 
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Figure 4.63:  Influence of folate receptor targeting on the cytotoxicity of cyclo(His-Gly) and 
cyclo(His-Ala) on MCF-7 cells cultured in normal RPMI-1640 medium 
expressing low folate receptor levels (n = 4 for each point). 
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Encapsulation of cyclo(His-Gly) and cyclo(His-Ala) into folate receptor targeted 
liposomes has therefore been shown to increase the cytotoxic activity of the cyclic 
dipeptides. These are promising results for many other marginally permeable drugs 
with low Log P and highlight the importance of targeted drug delivery. Problems 
experienced with long term stability of the folic acid-tethered liposomes should be 
addressed and reasons for the instability be elucidated.  
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
The cyclic dipeptides, cyclo(His-Gly) and cyclo(His-Ala) were identified from the 
literature as being the most promising agents with respect to their anticancer 
potential, but poor predicted lipophilicity of these agents prevented adequate cell 
permeability to fully realize the clinical potential as anticancer drugs.  
 
Physicochemical characteristics of Log P, topological polar surface area and stability 
at physiological pH were assessed. The log P for both compounds were found to be 
extremely low (-1.490 and -1.517 for cyclo(His-Gly) and cyclo(His-Ala) respectively) 
and topological polar surface area measured was also found to be inadequate for 
effective permeability. The kinetics of degradation at physiological pH followed first 
order kinetics for both compounds and stability of cyclo(His-Gly) was found to be 
lower than that of cyclo(His-Ala), but was still adequate for short term storage in 
liposome formulations. Lyophilisation is, however, an option should storage life of 
preparations be inadequate (Chen et al., 2010). 
 
Formulation of liposome formulations encapsulating cyclo(His-Gly) and cyclo(His-Ala) 
was assisted by the use of statistical experimental design and these tools were found 
to provide better insight into the formulation factors that affect the measured 
responses. It was found that increasing levels of stearylamine decreases the 
encapsulation efficiency of both cyclo(His-Gly) and cyclo(His-Ala). However, the 
decreased levels of stearylamine as determined during the optimization phase, may 
have resulted in sub-optimal zeta potentials in folic acid-tethered liposomes that may 
have resulted in their instability at accelerated conditions. Cholesterol content was 
found to increase the rate at which the fluorescent dye, 5(6)-carboxyfluorescein 
escaped from liposomes in both cyclo(His-Ala) and cyclo(His-Gly) formulations. While 
this is preferred to facilitate faster drug delivery in vivo, rapid escape of liposome 
190 
 
contents during storage may result in poor clinical performance. The optimized 
formulations were then chosen using the desirability factor calculated using the 
Design-Expert software, and the final liposome formulations prepared corresponded 
reasonably well with those predicted for most responses. 
 
The anticancer potential of liposomal cyclo(His-Gly) and cyclo(His-Ala) showed no 
significant improvement against HeLa cells, but reduced the IC50 values calculated for 
both drugs against MCF-7 cells. Improvement in the IC50 for non-targeted, 
encapsulated drugs is not common, particularly for poorly permeable drugs, as 
escape from the liposome vesicle is slower than immediate exposure to free drug. 
However, encapsulation in folate receptor targeted liposomes by incorporating F-
PEG-CHEMS into the phospholipid bilayer as a ligand showed a significant 
improvement for all drugs and in all cell lines tested, particularly for HeLa cells grown 
in low folate media. This indicates that cyclic dipeptides, particularly poorly lipophilic 
molecules, are ideal candidates for inclusion into targeted drug delivery systems such 
as liposomes. 
 
What was also a notable finding is that reduction in the folic acid levels used to 
culture HeLa cells was found to upregulate folate receptors, which is well known, 
however, the effectiveness of a known cytotoxic drug, 5-fluorouracil, was found to 
be increased as folate receptors were increased. This finding may prompt more 
laboratories to use folic acid free medium when screening for potential anticancer 
agents, particularly those that play a role in folate metabolism, as current trends to 
use folate concentrations in excess of 1000-fold of those found physiologically and 
could mask the cytotoxic potential of a particularly clinically useful drug. 
 
Recommendations for this study would be to further investigate the encapsulation of 
other cyclic dipeptides that have shown reasonable cytotoxic potential. Also, the 
stability issues identified with regards to folate-tethered liposomes at accelerated 
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conditions need further investigation in order to elucidate the exact mechanism of 
interaction that resulted in profound increase in mean particle size. It is also 
recommended that cell cultures be developed at varying concentrations of folate, 
including excess folate (>1 mg/L) to fully characterize the influence these increases 
have on the viability of the cell culture model as a screening system for anticancer 
drugs. 
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Abstract 
Various studies have shown the potentially beneficial biological activities of cyclic dipeptides 
and in particular, cyclo(L-tyrosyl-L-prolyl) (cyclo(Tyr-Pro)) has shown fair antibacterial activity 
in vitro. This study aimed to determine if liposome encapsulation would have any significant 
effects on the antibacterial activity of this compound. The thin-film hydration method with 
extrusion was used to produced small unilamellar vesicles containing cyclo(Tyr-Pro) that 
were shown to have an average encapsulation of 9.4% with a mean particle size of 160.4 
nm. Minimum inhibitory concentrations tested against Staphylococcus aureus, Escherichia 
coli, Klebsiella pneumoniae and Bacillus subtillis were shown to be lower in liposome 
encapsulated cyclo(Tyr-Pro) than for the free form, while no antimicrobial activity was noted 
for either encapsulated nor non-encapsulated drug against the fungus Candida albicans or 
two methicillin-resistant strains of Staphylococcus aureus (MRSA). A positive control of 
liposome encapsulated amoxicillin was shown to be extremely active against both MRSA 
strains. The results confirm that liposome encapsulation has the potential to enhance activity 
as well as overcome bacterial resistance towards current antibacterial agents. 
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1. Introduction 
The potential biological activity of diketopiperazines have been reported extensively with a 
wide range of activities being identified (Prasad, 1995). Recently, however, more intensive 
investigations have been conducted that explore this group of compounds’ antimicrobial 
activity, where cyclic dipeptides such as cyclo(Tyr-Pro), cyclo(Phe-Pro), and cyclo(Leu-Pro) 
have shown promising benefits in the treatment of infections with a wide variety of bacteria 
(Graz et al., 1999, Rhee, 2004).  Apart from this, some studies have isolated this group of 
compounds from bacterial supernatants of pseudomonas spp and have concluded that these 
molecules in quorum sensing, being able to inhibit  or promote bacterial functions such as 
swarming and overgrowth (Holden et al., 1999). 
 
Apart from its effects in bacteria, cyclo(L-tyrosyl-L-prolyl), also known as maculosin, has also 
been found to exhibit phytotoxic actions, being produced by the fungus Alternaria alternata 
(Park and Strobel, 1994). This makes this molecule of particular interest in terms of its 
biological activity, however, limitations in terms of permeability may result in therapeutically 
limited potential (van der Merwe et al., 2008). 
 
Efforts to improve cell entry through modification to enhance its physicochemical properties 
is not the only means to improve cell entry and hence its biological activity. Encapsulation of 
compounds into liposomes has been an established method of improving cellular entry, 
enhancing pharmacological activity while reducing systemic side effects and apart from 
these properties, the fact that liposomes are taken up by the body’s reticuloendothelial 
system and concentrate in inflamed tissues makes them ideal drug delivery systems for 
antibacterials (Smith, 2005, Hillery, 1997, Allen and Moase, 1996). 
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Apart from being ideal drug delivery systems for antibacterial agents as they improve entry 
into bacteria by membrane fusion (Rukholm et al., 2006), liposomes may also play an 
important role in the treatment of infection by resistant strains of bacteria. Recent reports 
suggest a vast increase in resistant strains of Staphylococcus aureus known as methicillin 
resistant Staphylococcus aureus (MRSA) with the number of isolates in the United States 
rising from 35.9% in 1992 to 64.4% in 2003 (Klevens et al., 2006). Besides MRSA, several 
other bacteria with pathogenic potential, such as Pseudomonas aeruginosa, have also  
shown resistance to antibacterial agents, whether it be inherent or by mutation (Rukholm et 
al., 2006) or through the development of biofilms which inhibit antibacterial penetration 
(Smith, 2005). The application of liposome technology in the treatment of infection by 
resistant strains of bacteria has shown positive outcomes (Smith, 2005, Rukholm et al., 
2006, Huang et al.) which justifies the use of liposomes in improving the antibacterial activity 
of cyclic dipeptides such as cyclo(Tyr-Pro). The aim of this study was, therefore, to 
determine the minimum inhibitory concentrations (MIC) of liposome encapsulated cyclo(Tyr-
Pro) against several Gram positive and Gram negative bacteria, as well as clinical isolates of 
MRSA.  
 
2. Results and Discussion 
2.1 Liposome characterization 
Particle size for liposomes was found to be 160.4 ± 9.8 nm which is within normal limits for 
extruded liposomes (Berger et al., 2001). Encapsulation efficiency varied from batch to batch 
but on average was shown to be 9.44%. All batches produced were physically stable and 
showed no signs of coagulation. 
 
2.2 Minimum inhibitory concentration 
Minimum inhibitory concentrations (MIC) for free and encapsulated cyclo(Tyr-Pro) and 
amoxicillin is shown in Table 2 below. The activity reported by Milne and colleagues (Milne 
et al., 1998) as well as Graz and colleagues (Graz et al., 1999) previously was calculated as 
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a percentage inhibition as compared to a positive control or determined using the Kirby-
Bauer disk diffusion assay. Percentage inhibition as compared to a negative control may not 
be the most effective means of determining whether an agent may be clinically useful as it 
simply states that growth was slower than the negative control but does not clearly indicate 
at what concentration bacterial growth was stopped (or inhibited). The Kirby-Bauer disk 
diffusion assay is also considered to provide a mostly qualitative assessment of antibacterial 
activity as it relies on the extent to which a drug diffuses through the agar to form a 
logarithmic concentration gradient radiating from the disk (Kiska, 1998). It is possible that 
this may be the reason why the results presented by these authors were not congruent with 
those obtained in this study. The MIC results indicated growth at all concentrations tested for 
free cyclo(Tyr-Pro), which may indicate that this agent, on its own, may not show benefit in 
the treatment of infection by the organisms tests. However, once encapsulated into the 
liposome formulation, significant differences in inhibition were noted with inhibition being as 
low as 0.3125 mg/ml for B. subtillis and S. aureus, while still showing improved activity 
against E. coli and K. pneumoniae. As was reported in the previous studies, no activity was 
noted for cyclo(Tyr-Pro) against the fungus C. albicans, in either the free or liposomal forms. 
 
With the rise in the incidence in bacterial resistance being well known (Gould, 2007), it was 
also valuable to assess the influence of liposomal encapsulation on clinical isolates of 
resistant forms of S. aureus (MRSA 1 and 2). No difference in the activity was noted (in the 
concentration range tested) for free or liposomal cyclo(Tyr-Pro) on either of the two clinical 
isolates of MRSA. It was extremely interesting to note, however, that although some limited 
activity of amoxicillin against these strains was noted (MIC = 2 mg/ml for both strains), 
encapsulation of amoxicillin in the liposome formulation resulted in a surprising increase in 
the activity, reducing the MIC against MRSA 1 to 0.0625 mg/ml while no growth was 
detected within the concentration range tested for liposomal amoxicillin against MRSA 2. 
This result further justifies the need to investigate alternative drug delivery strategies for 
known antibiotics against resistant strains of bacteria, particularly with the increase in 
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resistance noted for bacteria such as S. aureus and particularly the mycobacterium M. 
tuberculosis as the increasing incidence of extensively drug resistant tuberculosis (XDR TB) 
(Shah et al., 2007).  
 
3. Conclusion 
Rising bacterial resistance is a growing concern and with very few new antimicrobial agents 
having emerged in the last decade and even fewer in the pipeline (Gould, 2007) it may be 
necessary to re-look at the current agents available from a different drug delivery 
perspective. As has been shown in this study, agents that had shown limited activity against 
a range of bacteria, proved to be significantly more effective when encapsulated in a 
liposome vesicle. Reasons for the increase in activity could be as a result of improved cell 
entry or even protection of the antimicrobial agent from enzymatic degradation. Further 
investigations are necessary to evaluate the reasons for improved activity as well as to 
evaluate how the liposome formulation can be optimized for improved activity. 
 
4. Experimental 
4.1 Chemicals 
1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) was purchased from Avanti Polar 
Lipids (Alabaster, AL, USA) while cholesterol was purchased from Northern Lipids (Barnaby, 
BC, Canada). Protamine sulphate was purchased from Sigma (St Louis, MO, USA). The 
cyclic dipeptide, cyclo(L-tyrosyl-L-prolyl) or cyclo(Tyr-Pro) was synthesized according to the 
method of Milne et al. (1998) (Milne et al., 1998). Structural elucidation of the cyclic dipeptide 
was achieved through standard methods and included NMR spectroscopy, mass 
spectrometry and infrared spectroscopy. All other chemicals and reagents were obtained 
from local suppliers and were of analytical grade. 
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4.2 Preparation of liposomes 
Liposomes containing cyclo(Tyr-Pro) were prepared by the thin-film hydration method with 
extrusion through polycarbonate membranes. Briefly, DPPC and cholesterol in a molar ratio 
of 2:1 (90 mol total lipid) were dissolved in 5 ml of a 4:1 mixture of chloroform and methanol 
in a 50 mL round-bottom flask and dried to a lipid film with a rotary evaporator (BÜCHI 
Labortechnik AG, Flawil, Switzerland) at 60 C under controlled vacuum for 3 hours.  The 
lipid film was flushed with nitrogen to remove traces of chloroform and hydrated with 5 mL of 
a 20 mg/mL solution of either cyclo(Tyr-Pro), chloramphenicol or amoxicillin dissolved in 5 % 
DMSO in normal saline.  The drug-lipid suspension was shaken in a water bath at 60 C for 
3 hours to allow for full hydration of the lipid film. The multilamellar liposomes formed were 
then extruded 15 times through a 0.1 μm polycarbonate filter (Millipore, Billerica, USA) in a 
stainless steel pressure extrusion device (Avanti Polar Lipids, Alabaster, USA) in order to 
homogenize the size and size distribution of the liposomes.  The lipid content of the final 
suspensions were measured using the Stewart assay. Just prior to use, encapsulated drug 
was separated from free drug through centrifugation (19500 xg for 3 hours). 
 
4.3 Liposome characterization 
Encapsulation efficiency was determined indirectly through separation of free drug using 
protamine to aggregate liposome vesicles. To 50 l of suspension was added 50 l of 
protamine solution (10 mg/ml) and incubated for 10 minutes at 37 C. The mixture was made 
to 1 ml with saline and centrifuged at 5000 ×g for 20 minutes. Total drug was established by 
lysing of liposomes by adding 50 l of 10% Triton X-100 to 50 l of suspension and making 
to 1 ml with saline. Concentration of cyclo(Tyr-Pro) in either the protamine aggregated 
supernatant (free drug) or Triton X-100-lysed solution (total drug) was determined using 
HPLC on a C18 column (Waters Symmetry C18, 4.6 × 150 mm) and a mobile phase of 20% 
methanol in water utilizing an LC2020 HPLC system incorporating a binary pump and 
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photodiode array detector and chromatograms recorded on the software Package, LC 
Solutions (Shimadzu, Tokyo, Japan).  
Particle size was determined using transmission electron microscopy (TEM). Samples were 
prepared on Formvar®-coated 300-mesh copper grids (SPI Supplies, West Chester, USA) 
where one drop of liposome suspension diluted 1:100 with de-ionised water was dropped 
onto the grid and blotted with Whatman No. 1 filter paper. The grids were then transferred to 
the surface of a freshly poured, 1% agarose gel plate to facilitate de-salting and drying of the 
sample (Wei and Smith, 1994). TEM images were then recorded on a JEOL JEM 1210 
transmission electron microscope (Tokyo, Japan) and the average particle size of 20 
liposomes measured to determine mean particle size. 
 
 
4.4 Bacterial Strains and culture 
The following ATCC strains were utilized in this study: Staphylococcus aureus, Escherichia 
coli, Klebsiella pneumonia, Bacillus subtillis and Candida albicans. Two clinical isolates of 
MRSA were also used (MRSA 984444 and MRSA 985531) and their resistance profiles are 
shown in relation to ATCC Staphylococcus auereus in Table 1. All bacterial strains were 
received as a donation from the Department of Biomedical Technology at the Nelson 
Mandela Metropolitan University. Bacteria were cultured at 37 C in Mueller Hinton broth 
while the fungus was cultured in Sabouraud broth at 30 C. Bacteria and fungi were all 
standardized to the 0.5 McFarland standard at 540 nm prior to inoculation into test solutions. 
 
4.5 Minimum Inhibitory Concentration 
Minimum inhibitory concentrations were determined according to the broth microdilution 
method. All equipment and media were sterilized by autoclaving at 121 C for 15 minutes 
while drug solutions and liposome suspensions were filter sterilized through sterile 0.20 m 
cellulose acetate filters (GEMA Medical S.L, Barcelona, Spain).   
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Into each well of a sterile 96-well microtiter plate (Sarstedt, Nümbrecht, Germany) was 
added 100 l sterile Mueller Hinton broth for bacteria or Sabouraud broth for fungi. 100 l of 
liposome suspensions or free drug was then added and serially diluted such that the 
concentration of drug tested ranged from 6.25 g/ml to 10 mg/ml. 10 l of bacterial culture 
containing 5 × 104 CFU were then added to each well and incubated at 37 C (for bacteria) 
or 30 C (for fungi) for 24 hours. Free and liposome encapsulated amoxicillin and 
chloramphenicol were used as positive controls while sterile saline was used as a negative 
control. 
 
As a result of liposome suspensions being turbid, standard methods of optically evaluating 
wells for growth was not possible. For this reason, MTT was used as an indicator of bacterial 
viability. To each well, 50 l of MTT solution (5 mg/ml) was added and incubated for a further 
six hours. After incubation, the plates were centrifuged at 3000 rpm for 15 minutes and the 
supernatants aspirated and replaced with 150 l DMSO to solubilise the formazan 
precipitate formed. The MIC was defined as the lowest concentration at which no purple 
colour was visible. Each concentration was tested in quadruplicate and the average 
concentration at which no growth was present was reported. 
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 Table 1: Resistance patterns for MRSA strains in relation to Staphylococcus aureus. ‘R’ 
denotes resistant while ‘S’ denotes sensitive. 
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ATCC S. aureus S S S S S S 
MRSA 984444 R R R R S S 
MRSA 985531 R R S S R S 
 
 
Table 2: Minimum Inhibitory Concentrations (MIC) of free and liposomal cyclo(Tyr-Pro) and 
amoxicillin against several bacterial strains (n=4 for each value) 
 cyclo(Tyr-Pro) Lip. cyclo(Tyr-
Pro) 
Amoxicillin Lip. Amoxicillin 
E. coli  >10 mg/ml 5 mg/ml - - 
K. 
pneumoniae 
>10 mg/ml 0.625 mg/ml - - 
B. subtillis >10 mg/ml 0.3125 mg/ml - - 
C. albicans  >10 mg/ml >10 mg/ml - - 
S. aureus >10 mg/ml 0.3125 mg/ml 0.0625 mg/ml 0.0625 mg/ml 
MRSA 1 >10 mg/ml >10 mg /ml 2 mg/ml 0.0625 mg/ml 
MRSA 2 >10 mg/ml >10 mg/ml 2 mg/ml < 0.008 mg/ml 
Lip. = Liposome encapsulated 
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Abstract: 
Background: Cyclic dipeptides have been well characterized for their biological activity, 
including antimicrobial and anticancer activities. Cyclo(His-Gly) and cyclo(His-Ala) have also 
recently demonstrated significant anticancer activity against a range of cell lines, despite 
limitations with respect to their physicochemical properties, making them ideal candidates 
for liposome drug delivery. Materials and methods: Liposomes were composed of 
phosphatidylcholine, HSPC, stearylamine, α-tocopherol and PEG-DSPE or F-PEG-CHEMS using 
the thin-film hydration method and characterized for size and encapsulation. Results: The 
cytotoxic activity of the encapsulated cyclic dipeptides against HeLa, Low folate HeLa and 
MCF-7 cells and found to have limited improvement in activity. However, modification of the 
polyethylene glycol (PEG) with folic acid to target folate receptors significantly decreased the 
IC50 values recorded in all cells lines tested, particularly low folate HeLa cells with the lowest 
IC50 being recorded as 0.0962 mM for folate targeted cyclo(His-Ala). Conclusions: Hydrophilic 
cyclic dipeptides are ideal candidates for inclusion into targeted drug delivery systems such 
as liposomes. 
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Introduction 
Of late, much interest has been placed on the biological activity of selective cyclic dipeptides 
(CDPs). In a study by Milne and colleagues (1), it was noted that some of these compounds 
containing a tryptophan moiety showed significant tumour inhibition. Subsequent studies 
(2, 3) have confirmed these results, identifying cyclic dipeptides as potential 
chemotherapeutic agents. Other studies (4, 5) have also outlined the potential therapeutic 
usefulness of these compounds, exhibiting effects such as ion channel modulation, 
antibacterial and even antifungal properties. In a more recent study (6), selected cyclic 
dipeptides were evaluated against a number of cell lines, namely MCF-7 (breast carcinoma), 
HeLa (cervical carcinoma) and HT-29 (colon carcinoma), indicating that one of the 
compounds tested, cyclo(Phe-Pro), showed inhibition of more than 50% in some cell lines, 
and in addition induced apoptosis in the HT-29 cell line. More recently, significant inhibition 
of the same cell lines was demonstrated with the histidine-containing cyclic dipeptides, 
cyclo(His-Gly) and cyclo(His-Ala) (2). 
 
Physicochemical properties of these molecules indicate limitations with respect to their 
solubility in biological solutions as well as limited cell permeation (7). The potential tumour 
suppressive properties as well as the physicochemical limitations of this group of molecules 
make them ideal test candidates in the development of a targeted liposomal drug delivery 
system. 
 
Liposomes can be characterized as colloidal particles comprising mainly of phospholipids 
and cholesterol. They form spherical vesicles consisting of a phospholipid bilayer, much like 
that of normal cell membranes (8). These particles have a myriad of possibilities with 
respect to pharmaceutical applications due to their variation in composition, size and 
structure (9). Incorporation of many different types of therapeutic molecules such as simple 
organic drug compounds as well as protein-based and gene therapeutics aim to enhance 
their actions through the attainment of a number of goals, including the enhancement of 
their pharmacokinetics, decreased metabolic degradation and improved targeting, thereby 
enhancing their efficacy and decreasing potential side effects (10). 
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Besides tethering antibodies to liposomes, any molecule that can target proteins that are 
over expressed in tumour cells could prove beneficial. One such molecule is folic acid, as 
folate receptors are often found to be over expressed in tumours and this approach has 
been used in assisting with the targeting of liposomes (11-13). 
The aim of this study was therefore to formulate and evaluate liposome-encapsulated cyclic 
dipeptides that increase the tumour-suppressive actions of the cyclic dipeptides, while 
showing a high degree of specificity for tumour cells. 
 
Materials and methods 
Materials 
Folic acid, PEG-bis-amine, dicylcohexylcarbodiimide (DCC), pyridine, cholesteryl 
hemisuccinate (CHEMS), N-hydroxysuccinimide (NHS), α-tocopherol, stearylamine and 
trypsin were purchased from Sigma-Aldrich (St Louis, USA). L-α-phosphatidylcholine (PC), 
hydrogenated soy phosphatidylcholine (HSPC) and cholesterol were purchased from Avanti 
Polar Lipids (Alabaster, USA). Gibco® RPMI-1640 (standard and folic acid free) were 
purchased from Celtic Molecular Diagnostics (Mowbray, South Africa). All other reagents 
and chemicals were of analytical grade. 
 
Synthesis of Folate-PEG-cholesteryl hemisuccinate 
Folate-PEG-cholesteryl hemisuccinate (F-PEG-CHEMS) was used as the targeting molecule in 
liposome formulations and was synthesized by initial synthesis of its component parts, 
folate-PEG-amine (F-PEG-NH2) and N-hydroxysuccinimide-cholesteryl hemisuccinate (NHS-
CHEMS). F-PEG-NH2 was synthesized according to the method as adapted from Lee and Low 
(12). 40 mg folic acid, 250 mg PEG-bis-amine, 23.1 mg dicylcohexylcarbodiimide and 5 l 
pyridine were dissolved in 2.5 ml DMSO and stirred overnight, protected from light, at room 
temperature.  NHS-CHEMS was synthesized according to a method adapted from Xiang and 
colleagues (14) . 1 g of CHEMS was dissolved in 10 ml tetrahydrofuran (Saarchem, Midrand, 
South Africa) with 475 mg N-hydroxysuccinimide (NHS) and 1.25 g of DCC and reacted at 
room temperature overnight. Tetrahydrofuan was removed under vacuum in a rotary 
evaporator until dry. For the synthesis of F-PEG-CHEMS, F-PEG-NH2 (274 mg, 80 mol) and 
NHS-CHEMS (58.4 mg, 100 mol) were dissolved in 100 ml chloroform (CHCl3) and reacted 
overnight. The product was dried under vacuum in a rotary evaporator and re-hydrated with 
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20 ml 50 mM sodium carbonate buffer (pH 7.0) for 1 hour at 40 C to form F-PEG-CHEMS 
micelles. Low molecular weight contaminants were removed by dialysis of the micelle 
suspension with reverse osmosis water through a 14 000 MWCO dialysis tube (Snakeskin®, 
Thermo Fisher Scientific Inc., Rockford, USA). Micelles of F-PEG-CHEMS were lyophilized to a 
dry powder. Purity and structure were confirmed using TLC and 1H-NMR in deuterated-
DMSO (14).  
 
 
Preparation of liposomes 
Liposomes were manufactured using the thin-film hydration method extensively described 
by others (15-17). Lipid films comprising (in mg) HSPC 13.7, PC 13.5, Cholesterol 5.6, 
stearylamine 0.07, α-tocopherol 1, and either PEG-DSPE or F-PEG-CHEMS 0.7, were 
dissolved in 10 ml of a 9:1 mixture of chloroform and methanol and transferred to a 50 ml 
round bottomed flask. The solvent was then evaporated on a rotary evaporator under 
vacuum at 50 °C for at least 3 hours and remaining solvent was removed by flushing the film 
with nitrogen. Lipid films were hydrated at 60 °C with a solution containing cyclic dipeptide 
in phosphate buffered saline at pH 7.4 in a shaking water bath for three hours. Once 
hydrated, the multilamellar liposomes formed were extruded 13 times through a 100 nm 
pore polycarbonate membrane filter (Nuclepore) using an extruder (Avanti Polar Lipids, 
Alabaster, USA). 
 
Just prior to use, liposomes were separated from free drug by size exclusion 
chromatography using Sephadex G50 loaded mini spin columns that were equilibrated with 
PBS. Columns were centrifuged at 5000 rpm for 5 minutes and the elute, containing only 
liposomes, was retained for use in experiments. 
 
Liposome characterization 
cyclo(His-Gly) and cyclo(His-Ala) were quantified by HPLC with Luna NH2 column (with 
dimensions of 250 mm × 4.6 mm) with 5 m diameter packing (Phenomenex, Torrance, 
USA). The mobile phase comprised of acetonitrile (65%) in 50 mM phosphate buffer (pH 
3.0). A flow rate of 1.5 ml/min was used for analysis with an injection volume of 20 l. 
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liposome encapsulated drug was separated from free drug as described above and the 
liposomes lysed with a 10% Triton X-100 solution before analyzing for cyclic dipeptide 
content. Phospholipid was quantified according to Stewart (18) by dispersing 100 l of 
liposome suspension in 2 ml chloroform and adding 2 ml ammonium ferrothiocyanate 
solution. The absorbance of the chloroform phase was measured at 485 nm and related to 
phospholipid content using an external standard. The quantity of cyclic dipeptide 
encapsulated was therefore calculated as a proportion (in mg) encapsulated per mg 
phospholipid. 
 
Cell Culture 
HeLa cells were maintained in either standard RPMI-1640 medium or folic acid free RPMI-
1640 medium (in order to induce folate receptor upregulation). Cells were conditioned to 
low folate conditions over a period of three months, by slowly reducing the quantity of folic 
acid in the media by 5% each time the cells were passaged. Once at the target concentration 
of folic acid, cells were conditioned to grow in the reduced folic acid content until the 
doubling time was the same or similar to that of the standard folic acid culture.  Reduction 
of folic acid in growth medium was achieved by a stepwise reduction in the amount of folic 
acid solution (0.1 mg/ml) in PBS (Ph 7.4) that was added to folic acid free RPMI-1640 
medium (Gibco® brand, Celtic Molecular Diagnostics, Mowbray, South Africa).  
 
Cytotoxicity assay  
Cytotoxicity assays were conducted as described previously (Zhang et al., 2004). Cells were 
lifted by the addition of 1 ml 0.25% trypsin in 0.1% EDTA  solution and incubated for 5 min 
at 37 °C. Cell concentration was determined under a light microscope with a 
haemocytometer and adjusted to 6 × 104 cells/ml by dilution with culture medium. Wells of 
a 96-well microtitre tissue culture plate were seeded with 6 × 103 cells per well and 
incubated at 37 C with CO2 humidification for 24 hours prior to being exposed to liposome 
preparations or drug solutions. After incubation, medium was removed by careful aspiration 
and replaced with 180 l fresh culture medium. 20 l of drug solution in PBS, sterilized 
through 0.2  cellulose acetate filters, was then added to each well and the cells incubated 
for 48 hours at 37 C with CO2 humidification. Methotrexate and 5-fluorouracil, at 
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concentrations of 100 M were used as positive controls. Cell viability was determined after 
incubation for 48 hours using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) (19, 20). After drug exposure, cell medium was aspirated, washed with 200 l PBS and 
replaced with 180 l fresh culture medium. 20 l of MTT (5 mg/ml in PBS), was added to 
each well and incubated for a further 5 hours at 37 C. Plates were centrifuged at 3000 rpm 
for 10 minutes an culture medium aspirated and replaced with 100 l DMSO in order to 
solubilise the formazan crystals. Absorbance was read at a wavelength of 570 nm. Cell 
viability was calculated as a percentage of the negative control. All assays were performed 
in quadruplicate and the assay repeated on separate occasions at least three times. 
 
Statistical methods 
All assays were performed in quadruplicate on three separate occasions. Data was 
normalized to represent % inhibition relative to a negative control and the dose-response 
relationship analysed using non-linear regression analysis with GraphPad Prism version 5.03 
(GraphPad Software Inc., San Diego, USA). 
 
Results and discussion 
Liposome characterization  
The measured encapsulation of the non-targeted liposomes for cyclo(His-Gly) and cyclo(His-
Ala) was 0.115 +/- 0.012 mg/mg lipid and 0.105 +/- 0.005 mg/mg lipid respectively while 
folate-targeted liposomes had an encapsulation of 0.1354 +/- 0.00739 mg/mg lipid and  
0.090623 +/- 0.0141 mg/mg lipid for cyclo(His-Gly) and cyclo(His-Ala) respectively.  
 
The mean particle diameter for non-targeted cyclo(His-Gly) and cyclo(His-Ala) liposomes 
was 134.5 +/- 1.082 nm and 145.3 +/- 0.20 nm respectively while folate targeted liposomes 
had a meand particle diameter of of 150.0 +/- 1.021 nm and 152.5 +/- 6.780 nm for 
cyclo(His-Gly) and cyclo(His-Ala) liposomes respectively.  
 
Cytotoxicity of free and non-targeted cyclo(His-Gly) and cyclo(His-Ala)  
Lucietto and colleagues (2) reported that 100 M of both cyclo(His-Gly) and cyclo(His-Gly) 
exhibited significant inhibition of, in some cases, greater than 80%. Despite this report, the 
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inhibitory actions of both cyclic dipeptides was found to be relatively limited and IC50 values 
for cyclo(His-Gly) and cyclo(His-Ala) were 1.103 mM and 0.3244 mM respectively for HeLa 
cells (Figure 4.46) and 0.630 mM and 1.258 mM respectively for MCF-7 cells.  
 
Encapsulation of cyclo(His-Gly) into liposomes showed a slight apparent increase in activity 
against HeLa cells, although not significant within the concentration range tested. The IC50 
value for cyclo(His-Gly) liposomes was slightly higher than free drug (1.699 mM as opposed 
to 1.103 mM) (Table 1). Slower inhibitory response of liposome encapsulated drug may have 
been as a result of slower release of the drug from the liposomes, and thus lower levels of 
free drug available for inhibition. As the liposomes were not targeted to the cells, cellular 
uptake may have been slower than anticipated. Many studies have shown that drugs 
encapsulated into non-targeted liposomes display an increase in IC50 when compared to the 
free drug (12, 21, 22) and the benefits should not been viewed in the light of a decrease in 
IC50, but rather the decreased non-specific cytotoxic effects on free cytotoxic agents that 
leads to high side effect profiles. A similar trend was noted for cyclo(His-Ala) liposomes 
against HeLa cells with an IC50 value of 0.3532 mM was calculated for liposomal cyclo(His-
Ala) as opposed to 0.3244 mM for free cyclo(His-Ala). 
 
The effects of encapsulation were more notable in MCF-7 cells where both encapsulated 
drugs showed a marked decrease in calculated IC50. IC50 for cyclo(His-Gly) liposomes 
decreased to 0.3584 mM from 0.6296 mM for the free drug, while the IC50 for cyclo(His-Ala) 
liposomes reduced to 0.4978 mM from 1.258 mM of free cyclo(His-Ala). Therefore, for MCF-
7 cells, cellular entry of liposome encapsulated drug is and could result in poor cellular 
uptake of the drugs. Encapsulation would therefore enhance cellular entry and promote 
cytotoxicity. A summary of the results is given in Table 1 
 
Despite showing no improvement over the inhibitory effect of the cyclic dipeptides against 
HeLa cells, improvement was noted against MCF-7 cells. The difference in the IC50 
parameter for liposome cyclic dipeptides was not large for HeLa cells. In their study, Lee and 
Low (12) showed that the IC50 of free doxorubicin was 0.43 M as opposed to non-targeted 
liposomal doxorubicin with an IC50 of 25.3 M. As free doxorubicin shows good permeation 
into cells, it was concluded by the authors that a reduction in the cytotoxic activity was due 
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to slower release of doxorubicin in liposome formulations. The results obtained in this study 
are therefore promising as the difference between encapsulated and non-encapsulated 
drug for HeLa cells was marginal, while an improvement in activity was noted for 
encapsulated cyclic dipeptides on MCF-7 cells. This further emphasizes the problems faced 
with drugs exhibiting low permeation due to poorly lipophilic properties. Lee and Low (12) 
as well as others (11, 14, 22-25) have proposed that, while non-targeted liposomes reduce 
the side effect profile of cytotoxic drugs, incorporation into liposomes targeted to a 
particular receptor that over express in tumour cells, such as the folate receptor, would 
enhance cellular uptake of the liposome contents through receptor mediated endocytosis. 
This strategy was therefore used to improve the cytotoxic actions of cyclo(His-Gly) and 
cyclo(His-Ala). 
 
Cytotoxicity of folic acid tethered liposomes 
The cytotoxicity of folate-targeted liposomes was assessed against MCF-7, HeLa and HeLa 
low folate cells and compared non-targeted liposome encapsulated cyclic dipeptides. Folate 
receptor targeting resulted in significant increase in inhibitory action of both cyclo(His-Gly) 
and cyclo(His-Ala) when tested against HeLa cells cultured in normal RPMI-1640 as well as 
folate free RPMI-1640 media as well as MCF-7 cells.  
 
IC50 values recorded for targeted liposomes against HeLa cells cultured in high folate media 
were reduced to 0.6153 mM (r2 = 0.9503) for cyclo(His-Gly) and 0.3775 mM (r2 = 0.9604) for 
cyclo(His-Ala) when compared to non-targeted liposomes (1.029 mM and 0.6194 mM for 
cyclo(His-Gly) and cyclo(His-Ala) respectively (Figure 1). The decrease in IC50 was more 
pronounced in low folate HeLa cells with IC50 values of 0.1807 mM (r
2 = 0.9673) and 0.09617 
mM (r2 = 0.9797) for cyclo(His-Gly) and cyclo(His-Ala) when compared to 0.3692 mM and 
0.1680 mM respectively (Figure 2). The increase in activity of folate-targeted liposomes was 
most likely due to greater internalization of encapsulated drug as a result of folate-receptor 
mediated endocytosis, increasing the intracellular concentrations of the drug as has been 
shown previously with folate-ligand liposomes (12). Increased receptor numbers also played 
a role in the enhanced activity of liposomal activity with the greatest activity being recorded 
for cyclo(His-Ala) targeted liposomes against HeLa cells cultured in folic acid free medium. 
The overall inhibitory action of the two cyclic dipeptides was more pronounced in these 
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HeLa cells, whether targeted or non-targeted and further highlights the problems with using 
high folic acid concentrations in cytotoxicity assays as outlined above. Although the 
cytotoxicity assays were all performed in low folate medium, residual folic acid left on the 
cell surface during the culturing process could have resulted in competitive binding to folate 
receptors, preventing cell interactions with targeted liposomes. Despite this potential 
competition and low folate receptors, increased activity for targeted liposomes was still 
observed in all cell lines.  
 
An increase in the cytotoxic activity of targeted liposomes was also observed for both cyclic 
dipeptides against MCF-7 cells. Cyclo(His-Gly) displayed a 42% reduction in IC50 decreasing 
to 0.2094 mM (r2 = 0.9674) from 0.3584 (r2 = 0.9483) for the non-targeted liposomes. 
Cyclo(His-Ala) displayed a substantial decrease of 63% in recorded IC50, decreasing from 
0.4987 mM (r2 = 0.9811) for non-targeted liposomes to 0.1856 mM (r2 = 0.9818) (Figure 3). 
Table 2 shows a summary the results. 
 
 
Encapsulation of cyclo(His-Gly) and cyclo(His-Ala) into folate receptor targeted liposomes 
has therefore been shown to increase the cytotoxic activity of the cyclic dipeptides. These 
are promising results for many other marginally permeable drugs with low Log P and 
highlight the importance of targeted drug delivery. Problems experienced with long term 
stability of the folic acid-tethered liposomes should be addressed and reasons for the 
instability be elucidated.  
 
Conclusions  
The anticancer potential of liposomal cyclo(His-Gly) and cyclo(His-Ala) showed no significant 
improvement against HeLa cells, but reduced the IC50 values calculated for both drugs 
against MCF-7 cells. Improvement in the IC50 for non-targeted, encapsulated drugs is not 
common, particularly for poorly permeable drugs, as escape from the liposome vesicle is 
slower than immediate exposure to free drug. However, encapsulation in to folate receptor 
targeted liposomes by incorporating F-PEG-CHEMS into the phospholipid bilayer as a ligand 
showed a significant improvement for all drugs and in all cell lines tested, particularly for 
HeLa cells grown in low folate media. This indicates that cyclic dipeptides, particularly poorly 
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lipophilic molecules, are ideal candidates for inclusion into targeted drug delivery systems 
such as liposomes. 
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Table 1:  Summary of IC50 cytotoxicity results for free and liposome encapsulated cyclic 
dipeptides. Figures represent IC50 values calculated from dose-response analysis and are in 
mM. The positive controls, methotrexate and 5-fluorouracil were tested at concentrations 
of 100 M to validate the assays and all resulted in inhibitions above 80%. 
Cell Line 
Liposome encapsulated Free 
cyclo(His-Gly) cyclo(His-Ala) cyclo(His-Gly) cyclo(His-Ala) 
HeLa 1.699 mM 0.353 mM 1.103 mM 0.324 mM 
MCF-7 0.358 mM 0.498 mM 0.630 mM 1.258 mM 
 
Table 2: IC50 data for targeted and non-targeted liposomal cyclo(His-Gly) and 
cyclo(His-Ala). Values calculated using non-linear dose-response regression analysis. NF = 
normal folic acid media, LF = low folic acid media, FR = Folate receptor. 
Cell line 
cyclo(His-Gly) cyclo(His-Ala) 
Non-targeted FR Targeted Non-targeted FR Targeted 
HeLa NF 1.029 mM 0.6153 mM 0.6194 mM 0.3775 mM 
HeLa LF 0.3695 mM 0.1807 mM 0.1680 mM 0.0962 mM 
MCF-7 0.3584 mM 0.2094 mM 0.4987 mM 0.1856 mM 
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Figure 1:  Influence of folate receptor targeting on the cytotoxicity of cyclo(His-Gly) and 
cyclo(His-Ala) on HeLa cells cultured in normal RPMI-1640 medium expressing low folate 
receptor levels (n = 4 for each point). 
236 
 
-1.5 -1.0 -0.5 0.0 0.5
0
20
40
60
80
100
Cyclo(His-Gly) Non-targeted
Cyclo(His-Gly) Targeted
Cyclo(His-Ala) Non-targeted
Cyclo(His-Ala) Targeted
Log Concentration (mM)
%
 I
n
h
ib
it
io
n
 
 
Figure 2:  Influence of folate receptor targeting on the cytotoxicity of cyclo(His-Gly) and 
cyclo(His-Ala) on HeLa cells cultured in folic acid free RPMI-1640 medium expressing high 
folate receptor levels (n=4 for each point). 
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Figure 3:  Influence of folate receptor targeting on the cytotoxicity off cyclo(His-Gly) 
and cyclo(His-Ala) on MCF-7 cells cultured in normal RPMI-1640 medium expressing low 
folate receptor levels (n=4 for each point). 
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APPENDIX B: LIST OF REAGENTS AND SOLUTIONS 
 
Acetate buffer (pH 4.5) 
Sodium Acetate (Saarchem, Krugersdorp, RSA)    4.10 g 
Sodium chloride (Saarchem, Krugersdorp, RSA)    8.77 g 
HCl 1 M         qs 
RO water         to 1000 ml  
The sodium acetate and sodium chloride were dissolved in 950 ml water and adjusted to pH 4.5 with 
HCl. The solution was then made to volume with water. 
 
Agarose gel (1%) 
Agarose (Sigma-Aldrich, St Louis, USA)     1 g 
RO water         to 100 ml 
The agarose was dispersed in cold water and heated over a water bath for 15 minutes to facilitate 
dissolution. 10 ml of the mixture was poured into polystyrene petri dishes and allowed to cool. 
 
Ammonium ferrothiocyanate solution (Stewart assay) 
Ferric chloride (Minema, Johannesburg, RSA)    27.03 g 
Ammonium thiocyanate (ACE, Glenvista, RSA)    30.4 g 
RO water         to 100 ml 
 
Carboxyfluorescein 100 mM 
Carboxyfluorescein (Sigma-Aldrich, St Louis, USA)    188 mg 
1 M NaOH         qs 
PBS (pH 7.4)         to 100 ml 
The carboxyfluorescein was dissolved in PBS and the pH adjusted to 7.4 with the drop wise addition 
of 1 M NaOH solution. 
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Heat deactivated foetal calf serum 
Foetal calf serum (Celtic, Mowbray, RSA) was defrosted at 4 C for 8 hours and then heated to 65 C 
for 45 minutes to deactivate the serum. The serum was stored at 4 C prior to use.  
 
Hypochlorite solution 
NaOCl          1.44 mM 
NaCl          145 mM 
RO water         to 100 ml 
 
Liposome stock solutions 
Phosphatidylcholine 10 mg/ml: 
L-α-phosphatidylcholine (Avanti Polar Lipids, Alabaster, USA)  1 g 
Chloroform         to 100 ml 
Stored at -20 C prior to use.  
 
Cholesterol 10 mg/ml 
Cholesterol (Avanti Polar Lipids, Alabaster, USA)   1 g 
Chloroform         to 100 ml 
Stored at 4 C prior to use. 
 
PEG-DSPE 1 mg/ml 
PEG-DSPE (Avanti Polar Lipids, Alabaster, USA)    10 mg 
Chloroform         to 10 ml 
Stored at -20 C prior to use. 
 
α-tocopherol solution 2 mg/ml 
α-tocopherol (Sigma-Aldrich, St Louis, USA)    250 mg 
Chloroform         250 ml 
Stored at -20 C prior to use. 
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Stearylamine 0.2 mg/ml  
Stearylamine (Sigma-Aldrich, St Louis, USA)    20 mg 
Chloroform         100 ml 
Stored at -20 C prior to use. 
 
Mild cell lysis buffer 
Triton X-100         5 ml 
NaOH          0.1 g 
Ethanol         10 ml 
RO water          to 100 ml 
 
MTT solution 5 mg/ml 
MTT (Sigma-Aldrich, St Louis, USA)     50 mg  
PBS (pH 7.4)         10 ml 
The MTT was dissolved in the PBS and filtered through a 0.22  sterile cellulose acetate filter. The 
solution was stored at 4 C and protected from light prior to use. 
 
NaOH solution 1 M 
NaOH (Saarchem, Krugersdorp, RSA)     4 g  
RO water         to 100 ml 
 
Phosphate-buffered saline (PBS) (pH 7.4) 
NaCl (Saarchem, Krugersdorp, RSA)      8 g 
KH2PO4 (Protea Laboratory Services, Jhb, RSA)    0.2 g 
Na2HPO4.12H2O (Saarchem, Krugersdorp, RSA)   1.44 g 
KCl (Saarchem, Krugersdorp, RSA)      0.2 g  
EDTA (Sigma-Aldrich, St Louis, USA)     0.2 g 
HCl 1 M         qs 
RO water         to 1000 ml 
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The components were dissolved in 950 ml water and the pH adjusted to 7.4 with 1 M HCl and made 
to volume with water. 
 
Phosphate buffer 50 mM (pH 3.0) for HPLC mobile phase 
Na2HPO4.12H2O        17.9 g 
HCl 1M solution        qs 
RO water         to 1000 ml 
The Na2HPO4.12H2O was dissolved in approximately 950 ml water and the pH adjusted to 3.0 with 
HCl. The solution was filtered through a 0.45  PVDF filter. 
 
Phosphatidylcholine standard solution 0.1 mg/ml (Stewart assay) 
L-α-phosphatidylcholine (Avanti Polar Lipids, Alabaster, USA)  10 mg 
Chloroform (Saarchem, Krugersdorp, RSA)    to 100 ml 
 
Phosphoric acid/EDTA solution (Lipid peroxidation) 
Phosphoric acid (85%) (Saarchem, Krugersdorp, RSA)   1.176 ml 
EDTA (Sigma-Aldrich, St Louis, USA)     14.62 mg 
RO water         to 100 ml  
 
Protamine solution 
Protamine (from salmon) (Sigma-Aldrich, St Louis, USA)  10 mg 
PBS (pH 7.4)         to 10 ml  
 
Sephadex G50 
2 g Sepahadex G50 (Sigma-Aldrich, St Louis, USA) was hydrated for 24 hours at 25 C 
with 100 ml PBS (pH 7.4) 
 
Rhodamine B TLC stain 
Rhodamine B (Sigma-Aldrich, St Louis, USA)    100 mg 
Ethanol 95% (NMMU, RSA)       to 100 ml 
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Trypan blue solution 
Trypan blue stock solution 
Trypan blue (BDH Chemicals, Poole, England)     400 mg 
PBS          to 100 ml 
Working trypan blue solution 
1 ml trypan blue stock solution was diluted with 4 ml PBS. 
 
Triton X-100 10% 
Triton X-100 (Sigma-Aldrich, St Louis, USA)    10 ml 
RO water         to 100 ml 
 
Thiobarbituric acid 0.5 % solution     
Thiobarbituric acid (Sigma-Aldrich, St Louis, USA)   0.5 g 
RO water         to 100 ml 
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APPENDIX C: 25-1 FACTORIAL DESIGN AND RSM DATA 
Table C.1:  25-1 factorial design data for screening study. 
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14 1 100 0 3 50 0 0.0791 1.86 0.143 
10 2 100 0 0 50 2 0.0514 16.41 0.115 
1 3 0 0 0 20 2 0.04863 21.57 0.203 
5 4 0 0 3 20 0 0.05312 8.36 0.184 
12 5 100 5 0 50 0 0.1105 19.35 0.141 
8 6 100 5 3 20 0 0.0674 2.12 0.148 
17 7 50 2.5 1.5 35 1 0.08462 8.16 0.163 
21 8 50 2.5 1.5 35 1 0.07485 8.47 0.171 
2 9 100 0 0 20 0 0.09874 17.23 0.138 
20 10 50 2.5 1.5 35 1 0.09123 9.13 0.121 
7 11 0 5 3 20 2 0.0524 6.41 0.231 
13 12 0 0 3 50 2 0.0813 8.74 0.164 
15 13 0 5 3 50 0 0.121 9.12 0.169 
16 14 100 5 3 50 2 0.06896 1.23 0.084 
3 15 0 5 0 20 0 0.04264 23.47 0.181 
19 16 50 2.5 1.5 35 1 0.08745 9.11 0.148 
4 17 100 5 0 20 2 0.0712 17.25 0.122 
18 18 50 2.5 1.5 35 1 0.07124 9.32 0.161 
9 19 0 0 0 50 0 0.0891 24.86 0.157 
6 20 100 0 3 20 2 0.0714 2.41 0.079 
11 21 0 2.5 0 50 2 0.0614 27.36 0.174 
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Table C.2:  RSM data for cyclo(His-Gly) liposomes.  
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12 1 2 57.5 0.044827 126.606 0.204 46.5 0.495958 
2 2 1 20 0.109266 114.5684 0.088 39.6 31.37836 
10 3 3.5 35 0.098644 148.024 0.076 46.9 34.32 
16 4 2 35 0.081975 102.0359 0.132 50.7 2.296907 
5 5 1 50 0.091821 104.1118 0.13 44.2 3.204325 
14 6 2 35 0.093154 99.72547 0.111 44.1 10.60121 
9 7 0.5 35 0.114374 106.1428 0.097 37.3 15.16172 
1 8 1 20 0.087664 211.4652 0.073 41.4 41.0841 
7 9 3 50 0.058764 201.0171 0.142 46.6 2.471385 
6 10 1 50 0.114254 102.088 0.14 41.9 7.91766 
3 11 3 20 0.067213 106.248 0.1 46.5 42.32242 
13 12 2 35 0.081649 102.5 0.103 47.5 16.8158 
17 13 2 35 0.07381 87.90513 0.077 44.8 18.32372 
15 14 2 35 0.081319 99.98991 0.097 47.7 12.72681 
8 15 3 50 0.054492 150.1041 0.143 48.5 4.777994 
11 16 2 12.5 0.047844 160.4061 0.068 48.9 32.79024 
4 17 3 20 0.052599 195.6731 0.115 51.7 33.07064 
18 18 2 35 0.081347 71.79367 0.14 47.9 14.42084 
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Table C.3: RSM data for cyclo(His-Ala) liposomes. 
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11 1 2 57.5 0.038745 126.606 0.229092 38.38389 0.495958 
2 2 1 20 0.104321 114.5684 0.10412 32.68822 31.37836 
15 3 3.5 35 0.095243 148.024 0.084231 38.71407 34.32 
14 4 2 35 0.081425 102.0359 0.13268 41.85082 2.296907 
3 5 1 50 0.081563 104.1118 0.15324 36.48533 3.204325 
9 6 2 35 0.084251 99.72547 0.124653 36.40279 10.60121 
18 7 0.5 35 0.102165 106.1428 0.09124 28.131 15.16172 
8 8 1 20 0.088415 211.4652 0.0742 34.17404 41.0841 
17 9 3 50 0.031251 201.0171 0.159466 38.46644 2.471385 
1 10 1 50 0.102014 102.088 0.15722 34.58677 7.91766 
4 11 3 20 0.058413 106.248 0.1231 38.38389 42.32242 
7 12 2 35 0.069656 102.5 0.1054 39.20935 16.8158 
10 13 2 35 0.062542 87.90513 0.086471 36.98061 18.32372 
5 14 2 35 0.067845 99.98991 0.108931 39.37444 12.72681 
13 15 3 50 0.053214 150.1041 0.160589 36.4123 4.777994 
12 16 2 12.5 0.041452 160.4061 0.076364 40.36499 32.79024 
6 17 3 20 0.052314 195.6731 0.129145 38.414 33.07064 
16 18 2 35 0.06253 71.79367 0.15722 32.141 14.42084 
 
